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Abstract  
Altered Hemodynamic Control in the Skeletal Muscle Microcirculation in the Metabolic Syndrome: 
The Emergence of a new Attractor  
Joshua T. Butcher  
 
 Peripheral vascular disease is a pathological disease state whereby the peripheral vascular 
system becomes progressively limited in its ability to adequately perfuse extremities despite increases in 
metabolic demand. One of the primary risk factors for development of peripheral disease is the 
Metabolic Syndrome. It is the presentation of three simultaneous comorbidities, with obesity being the 
most common denominator in most metabolic syndrome patients, but also including a pro-
inflammatory state, pro-oxidant state, pro-thrombotic state, increased blood pressure, atherogenic 
dyslipidemia, or insulin resistance.  Currently, the population of the United States is approximately 75% 
overweight, obese, or extremely obese and the prevalence of obesity related consequences is rising, 
including but not limited to diabetes, cardiovascular disease, and peripheral vascular disease.  
 Our laboratory has demonstrated that a defining characteristic of metabolic syndrome is 
microvascular dysfunction. Increasing evidence has indicated that the mechanisms responsible for 
microvascular dysfunction in metabolic syndrome are oxidant stress-based alterations to arachidonic 
acid metabolism and increased sensitivity to adrenergic stimulation. However, it remains unclear if the 
altered microvascular reactivity that presents with metabolic syndrome plays a role in the perfusion: 
demand mismatch that accompanies and defines peripheral vascular disease. This dissertation seeks to 
understand the altered hemodynamic control found in metabolic syndrome. It set out to examine:  
1.  The effect of altered microvascular reactivity in metabolic syndrome on vascular tone and 
performance outcomes.  
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2.  Identify the spatial and temporal alterations to perfusion distribution in metabolic syndrome.   
3. Determine the effect of metabolic syndrome on erythrocyte distribution in the microvasculature 
and capillaries.  
The results of these studies determined that a key contributor to the development, maintenance, and 
progression of peripheral vascular disease is microvascular dysfunction. This dysfunction increases the 
microvascular perfusion distribution by spatially distinct mechanisms, with adrenergic dysfunction 
dominating in larger microvessels and oxidant stress-based increases in thromboxane A2 dominating in 
smaller microvessels. Additionally, metabolic syndrome blunts the temporal compensation that would 
serve to attenuate the increased perfusion distribution. Combined, the spatial and temporal 
impairments to microvasculature serve to alter erythrocyte distribution on a network level in skeletal 
muscle. These data shed light on how metabolic syndrome insidiously alters microvascular control of 
blood flow, leading to a perfusion: demand mismatch, and ultimately contributing to pathological 
disease states like peripheral vascular disease.   
iv 
 
Dedication  
 
To all the people who convinced me that giving up was never an option. 
To Mom, Dad, Kiah, Justin, and Mark.  
  
v 
 
Acknowledgments  
Much like my predecessor before me, I dislike this section. So many people to mention and thank, but I 
won’t be able to remember where I parked my car in the garage this morning, so I’m certainly going to 
overlook someone and hurt their feelings. So I will start with an apology to those I neglect to mention.  
I will start by thanking Kiah, my lovely and brilliant wife. This degree belongs to her as much as it does 
to me. She brought me here, she pushed me through, and she never stopped supporting me 
unconditionally. Although challenging, this graduate school adventure has been so much easier with a 
woman like her behind me. This degree most likely cost her far more than it ever cost me, and there is 
nothing I will ever be able to do to repay that debt. I pray the day never comes that you realize how 
completely unworthy I am of you. I have no doubt that without you, I wouldn’t be here.  
Special thanks to the Frisbee laboratory, past and present. Adam, you got me through a large chunk of my 
graduate school career. Thank you for the time you invested in me, both as a person and a scientist. It has 
taken me a long time to realize how utterly worthless I was when I worked with you. Sweet Jesus, I must 
have tortured you. And yet you never said anything, and you still take my phone calls. Your absence is 
still missed…..one could almost say the “passion” of research lessened with your graduation. Phoebe, 
thank you for always having an open door, and yes, you still scare me sometimes. Milinda, you were 
patient and always willing to help me, even long after it was your job. Shyla and Steve, thank you for all 
of your help and for putting up with me these last couple of months. I know it has been rough and for that, 
I am sorry. I will leave you with the same excellent advice Adam left me. “You have tremendous 
potential and, if you listen to Jeff, you’ll go far. Keep in mind, most of the things that he says will make 
little to no sense at the time. Just roll with it.” I guess the little one deserves mention. Paulina, you were a 
source of frequent amusement and often speechlessness. You handled the work load and my company on 
a daily basis with far more grace and aplomb than I expected. Well done and thank you. Please don’t 
forget about research; you are quite exceptional at it. There is no doubt in my mind that you will be 
vi 
 
successful at whatever you set your mind to and I wish you all the best. To Jefferson, I know there is a 
good chance you will never read this. A few years ago you asked me to trust you. You assured me that 
you would get me through, and that it would be worth it. You were right. Thank you for being my mentor, 
for pushing, pulling, and occasionally dragging me along. You made me a better scientist and a better 
person.  There is really not much else I can say, not without being called a wus by your son, anyway.  To 
Natty Cake, (there it is, printed forever) you are the man. While the title of “deviant uncle” still stings a 
little, I will miss you. And not just because I won’t be able to reach the stuff on the top shelf.  
To my Mom, Dad, Justin, Sara, Matt, Mark, my family, my friends, and frequent drinking buddies. Thank 
you for shaping me into what I am. Thank you for being there for me, both the good and the bad times. I 
hope I am not a complete disappointment. To each and every one of you who got me where I am today, 
thank you from the bottom of my heart.  
 
  
vii 
 
Table of Contents  
Altered Hemodynamic Control in the Skeletal Muscle Microcirculation in the Metabolic Syndrome: The 
Emergence of a new Attractor  i  
Abstract  ii  
Dedication  iv  
Acknowledgements  v  
Table of Contents vii 
Abbreviations viii 
Introduction  1 
Chapter 1 Differential Impact of Dilator Stimuli on Increased Myogenic Activation of Cerebral and 
Skeletal Muscle Resistance Arterioles in Obese Zucker Rats  15 
Chapter 2 Divergence Between Arterial Perfusion and Fatigue Resistance in Skeletal Muscle in the 
Metabolic Syndrome  43 
Chapter 3 Spatial Heterogeneity in Skeletal Muscle Microvascular Blood Flow Distribution is Increased in 
the Metabolic Syndrome  81 
Chapter 4 Blunted Temporal Activity of Microvascular Perfusion Heterogeneity in Metabolic Syndrome: 
A New Attractor for Peripheral Vascular Disease?  127 
Chapter 5 Altered Hemodynamics within the Skeletal Muscle Microvasculature in the Obese Zucker Rat 
 166 
Discussion  182 
   
viii 
 
Abbreviations  
4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-
15
N-oxyl  
17-octadecynoic acid  
Acetylcholine  
Arachidonic acid  
Bod y Mass Index  
Cyclooxygenase  
Lean Zucker Rat  
Lipoxygenase  
L-N
G
-nitroarginine methyl ester  
Metabolic Syndrome  
Nitric Oxide  
Nitric oxide synthase  
Obese Zucker Rat  
Peripheral Vascular Disease  
Prostacyclin  
Prostaglandin H2  
Thromboxane A2  
 
 
 
(TEMPOL) 
(17-ODYA) 
(ACH) 
(AA) 
(BMI)  
(COX) 
(LZR) 
(LOX) 
(LNAME) 
(MetSyn) 
(NO) 
(NOS) 
(OZR) 
(PVD) 
(PGI2)  
(PGH2) 
(TxA2)  
 
1 
 
Introduction 
Peripheral Vascular Disease 
Peripheral vascular disease (PVD) is an insidious pathological disease state that deprives lower 
extremities and organs of adequate blood flow due to a narrowing of the supply arteries. Currently within 
the United States PVD afflicts between 8-13 million people, but is estimated to be significantly under 
diagnosed. PVD patients frequently present with intermittent claudication that occurs during low levels of 
exercise (walking, climbing stairs, etc.) but discontinues upon cessation of movement. Patients with a 
history of smoking, diabetes, increased blood pressure, obesity, physical inactivity, or high cholesterol 
greatly increase their risk of developing PVD, in addition to very high correlations with aging
1
. The 
interventions for PVD are focused upon alleviating the areas with restricted blood flow, and involve 
major life alterations to remove risk factors, exercise, drugs, angioplasty, stents, or bypass surgery. Once 
diagnosed PVD is largely irreversible barring surgery and possesses a high direct and indirect cost burden 
to society
2, 3
. It becomes clear when position statements are integrated from the American Heart 
Association (AHA), Centers for Disease Control (CDC), and American Diabetes Association (ADA) that 
one of the major contributing factors to 
the development of PVD is structural 
and functional alterations to 
vasculature
4, 5
. These alterations 
decrease the capacity of the peripheral 
vascular system to adequately regulate 
blood flow within the skeletal muscle. 
The impact of impaired regulation of 
blood flow becomes especially evident 
in the presence of increased metabolic demand. PVD results in an inability of the system to effectively 
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match blood flow with an increase in metabolic demand, which is illustrated in Figure 1. The functional 
outcome of PVD in humans is a progressive acceleration toward decreasing tolerance to exercise, 
ultimately leading to disability.   
Classically, the perfusion: demand mismatch present in PVD has been characterized by structural 
alterations to larger conduit vasculature (e.g., atherosclerotic plaques and lesions)
6, 7
. However, there is a 
growing subset of human subjects that suffer from the symptoms of PVD, but do not exhibit the structural 
modifications to larger vasculature.  These emerging observations suggest that the underlying perfusion: 
demand mismatch seen with development of PVD may be caused by alterations localized to the 
microvasculature. Given that structural abnormalities within the microcirculation generally focus on 
altered mechanics of the arteriolar wall (which we have demonstrated only impact perfusion at the highest 
levels of metabolic demand), or on the density of terminal arterioles and capillaries within the 
microvascular network (which also exert their influence primarily with elevated metabolic demand) the 
manifestations of PVD at low-moderate metabolic demand may reflect dysfunction within the regulation 
of and perfusion distribution in the resistance arterioles
8, 9
.  Obviously, any alteration to normal processes 
of vascular reactivity within the resistance arterioles will exert a powerful effect on bulk blood flow and 
perfusion distribution and can result in local ischemia and impaired mass transport and exchange. This 
would likely be manifested by a variation in the distribution of erythrocytes in the distal microcirculation 
and capillary networks.  
Purpose  
 The purpose of this dissertation is to investigate network control of blood flow to determine the 
extent to which Metabolic Syndrome-induced microvascular dysfunction alters hemodynamics within 
skeletal muscle. It will also endeavor to identify those relevant mechanisms within the microcirculation 
that serve as contributors to the negative functional outcomes associated with Metabolic Syndrome 
(MetSyn). The obese Zucker rat (OZR) is a model of MetSyn that possesses a recessive leptin receptor 
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mutation that leads to chronic hyperphagia. Subsequently, the OZR develops rapid onset obesity, insulin 
resistance, dyslipidemia, and moderate hypertension. As the OZR ages, it develops an increasingly severe 
myriad of vascular impairments, serves as an appropriate model of MetSyn and development of non-
atherosclerotic peripheral vascular disease, and it mimics the leptin resistance induced hyperphagia 
observed within the human population. The hypothesis tested in this dissertation is that there is an altered 
intramuscular perfusion distribution throughout the skeletal muscle microcirculation in the MetSyn. 
Within each chapter of this dissertation is a sub-hypothesis that will address individual aspects of this 
hypothesis.  
Chapter one hypothesized that oxidant stress-based increases in vascular thromboxane A2 
contribute to enhanced myogenic activation and blunted endothelial dependent dilation in both cerebral 
and skeletal muscle microvasculature in the OZR. It was designed to examine if vascular tone was 
affected when vessels integrated dilator stimuli and pressure induced constriction simultaneously and 
whether interventions targeting elevated oxidant stress or elevated TxA2 production would be effective at 
restoring normal patterns of reactivity in the OZR. The data from Chapter 1 indicates that MetSyn 
induced microvascular dysfunction in the skeletal muscle is heavily dependent on altered arachidonic acid 
metabolism. In contrast, MetSyn induced cerebral microvascular dysfunction appears more dependent on 
nitric oxide bioavailability. The remainder of this dissertation will focus predominantly on skeletal muscle 
microvascular dysfunction.  
Chapter two was designed to investigate constrained functional hyperemia in the skeletal muscle 
of the OZR. It was hypothesized that the increased resistance to skeletal muscle blood flow was due to a 
combined adrenergic constraint and endothelial dysfunction. These data would further support the 
relevant mechanisms identified in skeletal muscle in Chapter one, and direct the following two chapters to 
focus on high resolution microvascular dysfunction. Chapter three hypothesized that the increased 
perfusion heterogeneity observed at bifurcations in the OZR skeletal muscle microvasculature will result 
in severe impairments to distal arteriolar blood flow distribution. Further, it identified spatially distinct 
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mechanisms within the microvasculature contributing to the increased perfusion heterogeneity, with alpha 
adrenergic dysfunction dominating at the proximal microcirculation and oxidant stress based increases in 
TxA2 dominating at the distal microcirculation. It would suggest to us that increased microvascular 
perfusion heterogeneity could be a major contributor to the poor muscle performance outcomes described 
in Chapter two.  
Chapter four hypothesized that the natural compensation for the increased perfusion 
heterogeneity at bifurcations in the OZR would be temporal switching. Increased temporal switching 
would maintain skeletal muscle performance by serving as a compensatory mechanism to cope with the 
increased perfusion heterogeneity. Additionally, this study allowed for the generation of an attractor for 
peripheral vascular disease. Chapter 5 hypothesized that the result of the spatial and temporal 
impairments iterated across the microcirculatory network would be a negatively impacted erythrocyte 
distribution localized to microcirculation and gas exchange vessels.  To briefly summarize the 
information found in the document below: The MetSyn alters spatial and temporal control of 
microvascular hemodynamics, specifically resulting in an altered perfusion distribution throughout the 
microvascular network, and serves to embed vascular impairments that contribute to the inability of the 
peripheral vascular system to adequately match blood flow with increases in metabolic demand.  
Metabolic Syndrome  
 MetSyn is comprised of many comorbidities that significantly increase the risk for developing 
diabetes, stroke, cardiovascular disease (CVD), kidney disease, and PVD. The primary risk factors from 
the International Diabetes Federation (IDF), AHA, and CDC are summarized in Table 1
10
. An individual 
who is diagnosed with three of the 
primary risk factors meets the criteria 
for MetSyn. Other measureable factors 
considered are a pro-inflammatory state 
Table 1: Risk Factors Men  Women 
Central Obesity 
(ethnicity dependent) 
>40 inches >35 inches  
Triglycerides  >150mg/dL >150mg/dL 
HDL Cholesterol  <40mg/dL <50mg/dL  
Fasting plasma glucose  >100mg/dL >100mg/dL 
Blood pressure  >130/85 >130/85 
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(as measured by elevated high sensitivity C-reactive protein, elevated cytokines such as TNF-alpha or IL-
6, or decreased adiponectin plasma levels) and a pro-thrombotic state (as measured by fibrinolytic factors 
like PAI-1 or clotting factors like fibrinogen). Other common contributors include aging, genetics, and an 
inactive lifestyle. MetSyn has received a steady increase in interest throughout popular culture as well as 
scientific research. This interest is mimicked as the incidence of MetSyn rises throughout the world, 
specifically developed countries
11
.  
 It is generally associated that obesity is the condition that initiates the development of not only 
MetSyn, but also many of the relevant risk factors. There is no universally accepted definition of obesity, 
but the frequently referenced standard is body mass index (BMI). Table 2 illustrates the differences in 
BMI between the overweight, obese, and extremely obese classifications of individuals. The National 
Health and Nutrition Examination Surveys (NHANES), a 
representative sample of the United States, examined the 
prevalence of obese and overweight individuals by gender, 
age, and ethnicity from 1999-2010. The percentages of BMI within the adult population of the U.S. in 
2010 are shown in Figure 2. It illustrates that two-thirds of the adult population is obese or overweight.  
Data analyzed from the last five decades 
showed that although overweight 
individuals held fairly constant (≈34%), 
there was a significant increase in obese 
and extremely obese individuals (Figure 
3)
12
. There has been a significant 
increase in obesity in the last decade in 
children age 2-19, ending with 17% of 
children in 2010 being considered 
overweight
13
. Obesity in adult men 
Table 2: Classification BMI 
Normal 18-25 
Overweight >25 
Obese  >30 
Extremely Obese  >40 
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significantly increased over the 10 year span, and in 2010 ≈35% were considered obese14. Obesity in adult 
women held constant across the ten years at ≈35%. A startling statistic was that obesity within the non-
Hispanic black adults and Hispanic adults stood at ≈49% and ≈39% respectively, significantly higher than 
their Caucasian counterparts. Trends suggest that body weight is continuing to rise in children and men, 
while women have 
leveled off. The rate 
of obesity for 
children, adolescents, 
and adults has 
continued to rise. As 
of 2010, the 
combined 
percentages of 
overweight, obese, 
and extremely obese 
individuals for the U.S. adult population is just over 75%
15
. Of particular importance is that this trend of 
obesity appears to be occurring within a younger population, combined with the increasing life span of 
adults, it would suggest that an alarming amount of the population within the U.S. will have a significant 
risk for developing PVD, particularly at a much younger age. The obesity epidemic, MetSyn, and its 
associated risks for cardiovascular disease have only just begun, and this is further reinforced by the 
National Institutes of Health (NIH) 2011 Strategic Plan. It includes obesity research targeting the 
biological processes and factors that regulate and contribute to body weight control, as well as evaluate 
promising strategies and tools for obesity prevention and treatment.  
MetSyn cumulatively increases risk for succumbing to a cardiovascular event. One of the many 
challenges that understanding MetSyn, and the pathologies it induces, is the broad variety of 
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comorbidities it can contain. While many individuals can be identified clinically as MetSyn patients, it is 
not a diagnostic tool. Physicians will target the specific indices of disease as they present. As such, public 
health professionals can identify many strong correlations for predicting further progression of MetSyn 
pathologies, but identifying causation is difficult. One concrete fact remains, the developed world as a 
whole is increasing in weight at a younger age and living longer. If this path is continues unabated, then 
an alarming amount of the American population will be significantly predisposed to many cardiovascular 
diseases and create an increased economic burden to society.  
Vascular Impact of Development of Metabolic Syndrome  
The multifaceted components of MetSyn have a varied impact upon the vasculature itself. This 
includes decreased endothelial function, increased thrombotic cardiovascular events, plaque 
destabilization, increased intima-media wall thickness, and increased vascular stiffness
16, 17
. It is 
becoming apparent that the risk factors involved in MetSyn act synergistically with each other to amplify 
alterations to vascular reactivity and structure. The combined outcome is an inability of the peripheral 
vascular system to adequately match perfusion with demand.  
Vascular tone is the basal level of smooth muscle constriction that a blood vessel experiences at 
rest compared to its passive diameter and can vary depending on the tissue bed or organ that the blood 
vessel innervates.  It is influenced by many factors, including the autonomic nervous system, vasoactive 
circulating factors, myogenic activation, shear stress, locally produced vasodilators/constrictors as well as 
tissue metabolic demand
18
. A vessel will integrate each of these influences and alter the blood flow 
accordingly. The microvasculature has a large impact on directing blood flow due to it being the primary 
site of resistance in the vasculature. The largest portion of resistance throughout the vasculature arises 
from arterioles (diameter ≈100 m), the vessels located between the large conduit arteries and capillaries. 
The relationship between flow, pressure, and radius is described in equation 1 below:  
  
  
 
       (Equation 1) 
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where Q is flow, R is resistance, and ΔP is change in pressure. Resistance is defined by equation 2: 
   
  
  
       (Equation 2)  
where R is resistance, η is viscosity, and r4 is radius to the fourth power. The combination of Equation 1 
and 2 is known as Poiseuille’s Law (Equation 3), and is used to approximate steady laminar flow of a 
Newtonian fluid through a tube of fixed length.  
   
     
   
      (Equation 3) 
 In the vasculature, the viscosity of blood and the length of blood vessels can be considered 
constants, thus the primary director of blood flow is 
through altering the diameter of a vessel, and the 
influence diameter changes is magnified due to being 
raised to the fourth power. The microvasculature 
controls blood flow (and thus resistance) by altering 
the diameters of blood vessels. The above equation 
illustrates the importance of basal vascular tone, and 
in general how the microvasculature controls blood 
delivery by changing diameter. This dissertation has 
focused increased attention on the observation that the 
cumulative outcome of spatial and temporal 
alterations to the regulation of vascular tone in 
MetSyn results in the inability of skeletal muscle 
microvasculature to adequately match perfusion: 
demand, thus compromising tissue oxygenation. The 
imbalance in perfusion:demand matching results in 
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ischemia, compromised tissue function, and diminished tissue viability.  
 Myogenic activity is an intrinsic property of smooth muscle found within blood vessels and is 
part of autoregulaton within organ systems that seeks to maintain blood flow despite changes in perfusion 
pressure. Specifically, myogenic activity causes smooth muscle cells to contract when pressure is 
increased and relax when pressure is decreased. It has been identified as a potent regulator of vascular 
tone in several vascular beds, including splanchnic, renal, cardiac, and skeletal muscle, and as such is 
important in regulating basal peripheral vascular resistance. It is currently unclear whether the 
mechanisms for myogenic activation lie within a mechanical stimulus like a stretch receptor, ion channel, 
or cytoskeletal tension, but what is known is that it causes mobilization of calcium and that there is 
general agreement that voltage gated calcium channels play an important role
18, 19
. It has been 
demonstrated that the myogenic activity of blood vessels becomes especially relevant in vessels of a 
diameter lower than 100 m and that it is endothelial independent, although certainly modulated by 
neural, humoral, and tissue factors
20, 21
.  
This dissertation will focus on the types of mechanisms by which MetSyn alters vascular tone 
including altered sympathetic activity, increased oxidant stress, and increased production of vascular 
thromboxane A2. The first mechanism of altered vascular tone lies within the sympathetic nervous 
system. Although the alterations to sympathetic activity in MetSyn are not universally agreed upon, it is 
documented in animal models that sympathetic activity is increased in the presence of metabolic 
syndrome
22
. The sympathetic nervous system (SNS) is understood to innervate all of skeletal muscle 
vasculature but the primary effect of SNS stimulation appears to constrict the larger blood vessels. It 
potentially may be the result of lessening innervation in smaller vessels as smooth muscle lessens toward 
capillaries, or perhaps the greater influence of other factors, such as tissue metabolic rate
23
. The data from 
isolated skeletal muscle microvessels and the in situ cremaster preparation have shown an increase in 
constriction in the OZR to phenylephrine compared to the lean Zucker rat (LZR) (Figure 4). This 
constriction is not mimicked with other potent constrictors, such as angiotensin 2 (Ang 2) or endothelin
24
. 
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The increased sensitivity to alpha adrenergic stimulation shows comparable results in an in vivo skeletal 
muscle artery preparation.  This corresponds well with evidence within the human population that 
MetSyn increases muscle sympathetic nerve activity (MSNA), although the specific alterations to the 
pathway remain unclear
25
. SNS over-activity is frequently seen in individuals with hypertension, and it 
contributes significantly to the initiation, progression, and maintenance of the pathology. A recent study 
concluded that deregulation of the SNS is a powerful predictor of the development of MetSyn
26
.   
Another frequently described alteration to vascular tone within the confines of MetSyn is based 
on increases in oxidant stress. Reactive oxygen species (ROS) are highly reactive derivatives of oxygen 
metabolism that include the superoxide radical, hydroxyl radical, hydrogen peroxide, and include nitric 
oxide (NO) and the peroxynitrite radical. ROS are linked to many biochemical processes, including 
signaling, growth, and apoptosis. However, in MetSyn the balance of ROS and antioxidants is often 
upset, leading to a pro-inflammatory state within the body. In excess, the highly reactive oxidative 
products can lead to cellular damage. Research from the Frisbee laboratory, and others, has indicated that 
there is an increase in oxidative stress in the OZR, mirroring the human population of MetSyn
27
. 
Classically, this increase in oxidant stress is indicated to be responsible for the decrease in endothelium 
derived NO bioavailability. The powerful, yet transient, dilator is scavenged by ROS and is indicated to 
be responsible for a significant portion of the impaired dilator capacity of the OZR skeletal muscle 
arterioles.  
Additionally, there is a growing body of evidence that suggests that the impact of oxidative stress 
is two-fold, as alterations to arachidonic acid (AA) metabolism increases the production of vascular TxA2. 
Arachidonic acid is a membrane bound phospholipid found within most mammalian cells.  It is freed 
from the membrane by the enzymes phospholipase A (PLA2), phospholipase C, or phospholipase D. Once 
cleaved, the AA can diffuse into the cytoplasmic space and be metabolized. The three primary enzymatic 
pathways are through cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome P450 (CYP450). The 
prostaglandins are derived via the COX pathway and are the focus of the subsequent research. Once AA 
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is metabolized into PGH2 by COX, it can produce multiple vasoactive compounds that generally will be 
classified under two families, the prostacyclins and the thromboxanes (Figure 5). 
  
In health, a balance of constrictors and dilators will be produced, with a functional outcome on 
vascular tone being appropriate regulation of blood flow. Research has shown in mice with genetic 
dyslipidemia that AA induced dilation is blunted in skeletal muscle arterioles and that vascular TxA2 end 
products are increased. However, treatment with an antioxidant or a TxA2 receptor antagonist improved 
the altered reactivity and the antioxidant additionally improved the altered AA metabolism
28
. Additional 
research using the OZR, a model of metabolic syndrome, suggested that the impaired dilator response to 
reduced oxygen tension could be a result of not only a decrease in prostacyclin production, but also an 
increase in vascular TxA2. This data suggests that the increase in oxidant stress goes beyond the inhibition 
of a vasodilator. By simultaneously scavenging NO and shifting AA metabolism from prostacyclin to 
TxA2, the microvasculature predominantly experiences a greater tonic vasoconstrictor force as well as 
counteracting the effect of vasodilators.  
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Clinical Significance and Miscellaneous  
The significance of this research has far reaching albeit indirect clinical implications. The most 
obvious is that treatment of PVD should not just address bulk blood flow impairments, which is 
classically what physicians address upon a diagnosis of PVD, but also microvascular dysfunction for real 
improvement to performance outcomes. The most difficult aspect of this, at the moment, would be 
proving microvascular dysfunction directly in human beings, given that the level of resolution for in vivo 
human blood flow is limited by technology. Additionally, while altered AA metabolism has long been 
suspected in many pathological states, and has long been a target for therapeutics, an effective target for 
the altered production of TxA2 has not been demonstrated. Importantly, while the first chapter of this 
dissertation includes cerebral microvasculature but for the remainder focused on skeletal muscle 
microvasculature, the impact of altered cerebral blow flow on stroke, dementia, Alzheimer’s, and other 
brain pathologies cannot be underestimated. One of the effective and frequently prescribed treatments for 
PVD is anticoagulants. Our experiments utilize a heparinized carotid catheter for the prevention of blood 
clots with the monitoring of mean arterial pressure. While this could potentially serve as a confounding 
variable in our experimental design, the concentration of heparin the animal is exposed to is well below 
the treatment limits. This is further verified by blood clotting during animal experimentation, of which no 
impairment is observed. It is worth noting that the vessels being studied in the in vivo and in situ studies 
have survived the progressive loss of microvessel density frequency observed in OZR of this age, and it is 
estimated that approximately 20-30% of vessels have undergone rarefaction.    
13 
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ABSTRACT  
Objective:  To use the obese Zucker rat (OZR) model of the metabolic syndrome to determine the impact 
of dilator stimuli on myogenic activation (MA) of gracilis arterioles (GA) and middle cerebral arteries 
(MCA).  We tested the hypothesis that increased oxidant stress and thromboxane A2 (TxA2) exacerbate 
MA, and prevent its blunting with dilator stimuli, in OZR.  Methods:  GA/MCA from OZR and lean 
Zucker rats (LZR) were pressurized ex vivo.  MA was determined under control conditions and following 
challenge with acetylcholine, hypoxia and adenosine.  Responses were also evaluated after pre-treatment 
with TEMPOL (antioxidant) and SQ-29548 (PGH2/TxA2 receptor antagonist).  Results: MA was 
increased (and dilator responses decreased) in GA/MCA from OZR, dependent on the endothelium and 
ROS.  In GA, the impact of ROS on MA and dilator effects was largely via TxA2, while in MCA, this 
appeared was more dependent on NO bioavailability.  Intrinsic responses of GA/MCA to carbacyclin, 
U46619, and NO donors were similar between strains. Conclusions: A developing ROS-based 
endothelial dysfunction in MCA and GA of OZR contributes to an enhanced MA of these vessels.  While 
treatment of GA/MCA with TEMPOL attenuates MA in OZR, the mechanistic contributors to altered 
MA, distal to ROS, differ between the two resistance vessels.     
 
Key Words: regulation of vascular tone, rodent models of metabolic syndrome, peripheral resistance, 
microcirculation  
 
List of Abbreviations: Gracilis Arteriole (GA), Middle Cerebral Artery (MCA), Thromboxane A2 (TxA2), 
Reactive Oxygen Species (ROS) 
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INTRODUCTION  
The metabolic syndrome, also referred to as insulin resistance syndrome or cardiometabolic syndrome, 
was fully articulated by Reaven in 1988 (25) but has since been more stringently defined with its 
continual increases in both incidence and prevalence (1, 4, 6, 7).  According to the International Diabetes 
Federation (IDF), a clinical diagnosis of metabolic syndrome is made in patients that have central 
(abdominal) obesity, and two of the following co-morbidities: dyslipidemia, hypertension and impaired 
glycemic control (1).  With these systemic pathologies, a companion pro-inflammatory and pro-
thrombotic state is also commonly present (16, 20, 22).   The most significant health outcome of these 
states is that they severely increase the risk for developing peripheral vascular disease (PVD) (4, 16, 20), 
a condition characterized by an inability of the vasculature to effectively match blood perfusion with local 
tissue/organ metabolic demand.  As the regulation of vascular tone and the ability to effectively integrate 
multiple vasoactive processes is a critical component of blood flow regulation, alterations to the normal 
patterns of vascular reactivity could severely compromise perfusion:demand matching.   
The obese Zucker rat (OZR: fa/fa) is an excellent model for the development of the metabolic syndrome 
and the associated negative vascular outcomes in humans.  It possesses a recessive mutation leading to 
leptin receptor dysfunction (3, 29), causing a chronic hyperphagic state (17), which results in rapid-onset 
obesity.  By 17 weeks of age, the OZR is severely obese, with the combined presentation of profound 
insulin resistance, dyslipidemia, and moderate hypertension (17, 26); a combination of pathologies that 
parallels metabolic syndrome in humans.   
Full manifestation of the metabolic syndrome in OZR has been well documented to be associated with 
significant alterations to vascular reactivity (8, 15, 28).  It has previously been shown that myogenic 
activation of both cerebral (24) and skeletal muscle (10) resistance vessels is enhanced, although there is 
no consistent understanding of the mechanistic underpinnings of this elevated responsiveness to 
intralumenal pressure.  However, in ex vivo skeletal muscle and cerebral resistance arteries/arterioles from 
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OZR, there is an impaired response to multiple endothelium-dependent dilator stimuli (8, 9, 24, 28), and 
elevated levels of vascular oxidant stress can cause an increased production of the potent vasoconstrictor 
metabolite thromboxane A2 (TxA2; refs: 15, 21, 28).  The extent to which impaired dilator responses and 
elevated production of constrictor metabolites can impact myogenic activation remains unclear.  
Our previous work has suggested that the enhanced myogenic activation of skeletal muscle and cerebral 
resistance vessels in OZR may not reflect a common mechanistic basis (10, 24).  Further, it is entirely 
unclear how myogenic activation in these critically important sites of vascular resistance integrates 
stimuli from intralumenal pressure and dilator influences to produce a change in diameter.  As such, the 
general purpose of the present study is to determine the fundamental mechanisms of altered myogenic 
activation between these vascular beds, how this may be impacted by challenge with dilator stimuli, and if 
identified alterations are due to a consistent, system-wide effect.   The general hypothesis is that oxidant 
stress-based increases in generation of vascular thromboxane A2 will contribute to enhanced myogenic 
activation and blunted endothelium-dependent dilation in both cerebral and skeletal muscle resistance 
vessels. 
MATERIALS AND METHODS  
Animals: Male lean Zucker (LZR; n=32) and obese (OZR; n=35) rats (Harlan, Indianapolis, IN) of ~17 
weeks age were used for all experiments.  Animals were housed and fed standard chow and tap water ad 
libitum at the West Virginia University HSC and all protocols received prior approval from the 
Institutional Animal Care and Use Committee.   Table 1 summarizes the baseline characteristics of 
animals used in the present study and clearly demonstrates the systemic pathologies associated with the 
metabolic syndrome.   Following an overnight fast, all animals were anesthetized with pentobarbital 
sodium (50 mg/kg; i.p.) and received tracheal intubation to facilitate maintenance of a patent airway.  All 
animals also received cannulation of both a carotid artery for blood pressure recording and a jugular vein 
for infusion of supplemental anesthetic (as needed) and the collection of blood samples.  Venous blood 
19 
 
samples were analyzed for glucose (Freestyle Lite, Abbott, Alameda, CA), while the plasma components 
were analyzed for insulin concentrations (Millipore; Billerica, MA) as well as cholesterol/triglyceride levels 
(Wako Diagnostics; Richmond, VA), and nitrotyrosine (Oxis International; Foster City, CA).  Unless 
otherwise noted, all drugs and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Preparation of Isolated Microvessels: After the initial surgery (above), a gracilis muscle resistance 
arteriole (GA) was surgically removed from the anesthetized animal and prepared for video microscopy, 
as described previously (5).   Briefly, the arteriole was placed in a heated (37
o
C) bath, doubly-cannulated 
with glass micropipettes and secured with silk suture.  The vessel was then perfused and superfused with 
a physiological salt solution (PSS) equilibrated with 21% O2, 5% CO2, balance N2.    Immediately 
following removal of the GA from the animal, the rat was humanely euthanized and the brain was rapidly 
removed from the skull case, placed in chilled PSS (~4
o
C), and the middle cerebral artery (MCA) was 
surgically removed from the base of the brain.  The MCA was then doubly-cannulated and prepared in an 
identical manner as described for the GA.  Both the MCA and the GA were allowed to equilibrate for at 
least 45 minutes at an intralumenal pressure of ~80% of the individual animal’s mean arterial pressure 
(equilibration pressure).   Vessel dimensions under control conditions and in response to imposed 
challenge were obtained under pressurized, zero flow conditions using video microscopy and an on-
screen video-micrometer (5).    
Changes in vessel diameter (myogenic activation) were measured following random changes in 
intralumenal pressure between 60 mmHg and 140 mmHg in 20 mmHg increments.   After the initial 
assessment of myogenic responses, dilator reactivity was assessed at each level of intralumenal pressure 
following challenge with hypoxia (20 minutes), acetylcholine (10
-6
 M), and adenosine (10
-6
 M).  For the 
purposes of the present study, hypoxia was defined as a change in PO2 of the superfusate/perfusate PSS 
from ~135 mmHg [21% O2, 5% CO2, balance N2 in the equilibration gas] to ~45 mmHg [0% O2, 5% CO2, 
balance N2 in the equilibration gas]).  These oxygen pressures have been previously validated with O2 
microelectrodes in the vessel chamber (19).   Upon completion of data collection under untreated control 
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conditions (above), both MCA and GA were treated with either the antioxidant TEMPOL (10
-4
 M) or the 
PGH2/TxA2 receptor antagonist SQ-29548 (10
-5
M) and at least 30 minutes was allowed for incubation.   
Following the incubation period, myogenic activation and dilator reactivity to the three stimuli at each 
level of intralumenal pressure was determined as described above.   In an additional series of experiments, 
following the determination of responses under control conditions, the endothelium of both MCA and GA 
was denuded by passage of air boli through the vessel lumen (19) and the mechanical responses to 
intralumenal pressure and dilator stimuli were repeated.     
A final series of experiments was performed to determine the responses of isolated GA and MCA 
from both LZR and OZR, at the equilibration pressures, in response to increasing concentrations of 
carbacyclin (10
-12
 – 10-8 M; a stable PGI2 analog; Enzo Life Sciences, Farmingdale, NY), U46619 (10
-12
 – 
10
-8 
M; a stable TxA2 analog; Enzo Life Sciences, Farmingdale, NY), and sodium nitroprusside (10
-10
 – 
10
-6 
M).  These experiments were performed to determine if the development of the metabolic syndrome 
had a significant impact on the intrinsic responses of the GA or MCA in response to the major relevant 
vasoactive metabolites under interrogation in the present study.   
Data and Statistical Analysis: All data are presented as mean±SE.  Active tone of individual vessels at 
the equilibration pressure was calculated as (D/Dmax)100, where D is the diameter increase from rest 
in response to Ca
2+
-free PSS, and Dmax is the maximum diameter measured at the equilibration pressure in 
Ca
2+
-free PSS.  Curves describing myogenic activation under any of the imposed conditions were fit with 
linear regression equations:        ; where   =intralumenal pressure 
(mmHg),   =y-intercept, and  =the slope of myogenic activation of the vessel.  All other statistical 
analyses utilized Student’s t-test or analysis of variance (ANOVA) with Student-Newman-Keuls test 
post-hoc.  Statistical significance is represented by p< 0.05.  
RESULTS  
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The baseline characteristics of LZR and OZR used in the present study are summarized in Table 1.  At 17 
weeks of age, OZR demonstrate significant increases in body mass, moderately elevated blood pressure, 
increased insulin resistance, and systemic oxidant stress.  Table 2 summarizes the diameters of the vessels 
in this study from both LZR and OZR, at the equilibration pressures, under the different treatment groups 
in the present study.    In GA, there were few differences between LZR and OZR, although the passive 
diameter of the vessel at the equilibration pressure was reduced in the obese animals.  In contrast, MCAs 
manifested a significant increase in basal tone at the equilibration pressure, but exhibited no reduction in 
passive diameter. 
Figure 1 summarizes myogenic activation of isolated GA (Panel A) and MCA (Panel B) from LZR and 
OZR in response to elevated intralumenal pressure.  In both GA and MCA, the pressure-induced 
vasoconstriction was significantly elevated in vessels from OZR as compared to responses in LZR.  The 
impact of endothelium denudation is presented in Panels C (for GA) and D (for MCA).  Removal of the 
vascular endothelium abolished almost all of the differences in myogenic activation of either GA or MCA 
between LZR and OZR.   
The impact of pre-treatment of vessels with the antioxidant TEMPOL or the PGH2/TxA2 receptor 
antagonist SQ-29548 on myogenic activation is presented in Figure 2.  In GA from OZR, pretreatment 
with either TEMPOL (Panel A) or SQ-29548 (Panel B) significantly reduced the slope of the myogenic 
activation curve as compared to responses in untreated control conditions.  In contrast, while TEMPOL 
exerted a similar effect on myogenic activation in MCA of OZR as compared to that in GA (Panel C), 
treatment with SQ-29548 did not significantly impact myogenic activation (Panel D).   Combined 
treatment with both TEMPOL and SQ-29548 did not significantly reduce the slope of myogenic 
activation beyond that determined for either agent alone (data not shown).   
The impact of hypoxia on myogenic activation of GA and MCA is summarized in Figure 3.  In GA from 
LZR, imposition of hypoxia increased arteriolar diameter at the equilibration pressure and blunted 
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myogenic activation.  In contrast, challenge with hypoxia had no significant impact on myogenic 
activation of GA from OZR (Panel A).  Pre-treatment with either TEMPOL (Panel B) or SQ-29548 
(Panel C) altered this response in GA from OZR, causing not only an increased diameter at the 
the pressure-induced constrictor response.  Combined treatment with both TEMPOL and SQ-29548 did 
not result in any significant additive effect beyond that determined for either application alone (data not 
shown).    The impact of hypoxia alone (Panel D) and hypoxia following pre-treatment with TEMPOL 
(Panel E) on myogenic activation of MCA were similar to that for GA from OZR.  Hypoxia alone did not 
significantly impact the enhanced pressure-induced constriction from MCA in OZR, although pre-
treatment with TEMPOL not only increased the vessel diameter at the equilibration pressure, it also 
blunted to slope of the myogenic activation curve to levels that were comparable to that in LZR.  In 
contrast, pre-treatment with SQ-29548 did not significantly impact the relationship of myogenic 
activation and hypoxia in MCA from OZR (Panel F). As with GA, treatment of MCA with both 
TEMPOL and SQ-29548 did not alter the response as compared to the maximum improvement following 
single treatment (data not shown). 
The impact of acetylcholine on myogenic activation of GA and MCA from LZR and OZR is presented in 
Figure 4.  In GA from OZR, treatment with acetylcholine resulted in a modest dilation at the equilibration 
pressure, but did not significantly impact the slope of the myogenic activation curve (Panel A).  While 
pre-treatment of GA from OZR with TEMPOL resulted in both an increased dilation at the equilibration 
pressure and a shifted slope coefficient for myogenic activation to levels that were not different from that 
in LZR (Panel B), treatment with SQ-29548 (Panel C) demonstrated no identifiable improvements to 
either the diameter at the equilibration pressure or the slope of myogenic activation.  In MCA, 
acetylcholine increased the vessel diameter at the equilibration pressure in LZR, while also causing a 
significant shift in slope.  In contrast, challenge with acetylcholine resulted in directionally similar, 
although less striking effect on myogenic activation of MCA from OZR (Panel D).  Pre-treatment of 
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MCA from OZR with TEMPOL (+acetylcholine) reduced the severity of myogenic activation to a slope 
coefficient that was actually more positive than that determined under control conditions in LZR (Panel 
E).   Treatment of MCA from OZR with SQ-29548 (Panel F) did not elicit a significant impact on 
myogenic activation following treatment with acetylcholine beyond that identified in for acetylcholine 
treatment alone (Panel D).  
The mechanical responses of GA and MCA from LZR and OZR to increasing concentration of 
carbacyclin (Panel A), U46619 (Panel B) and sodium nitroprusside (Panel C) are summarized in Figure 5.  
For carbacyclin and sodium nitroprusside, dilator responses of GA and MCA in response to increasing 
concentrations of the agonist were brisk throughout the concentration range, with no significant 
differences between vessels from LZR and OZR.  Similarly, constrictor responses to U46619, while brisk 
and extensive for both GA and MCA were not significantly different between LZR and OZR.     
Figure 6 presents myogenic activation of GA and MCA from LZR and OZR in response to the presence 
of elevated adenosine (10
-6
M).  In both GA (Panel A) and MCA (Panel B), the presence of adenosine 
significantly increased vessel diameter at the respective equilibration pressures and blunted the severity of 
the enhanced myogenic activation.  
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DISCUSSION  
Systemic PVD is an insidious disease that is characterized by an inability of the tissue/organ vasculature 
to adequately match local metabolic demand with perfusion.  While there can be several contributors to 
this outcome, alterations to the control of vascular tone within resistance vessels represents a dominant 
factor.  The OZR has proven to be an excellent model for the human progression to non-atherosclerotic 
PVD as the metabolic syndrome can alter vascular reactivity in the absence of plaque/lesion development 
(2).  However, one of the challenges of studying any disease with a functional outcome on the regulation 
of blood flow and its intra-organ distribution is an understanding of how resistance arteries/arterioles 
integrate multiple inputs to produce an appropriate response.  It has been established that OZR possess an 
enhanced myogenic activation in response to intralumenal pressure in both the skeletal muscle (10) and 
cerebral circulation (24).  It has also been demonstrated that the chronic increase in vascular oxidant 
stress in OZR results in a shift in arachidonic acid metabolism, increasing production of vascular TxA2 
over levels determined in LZR (15).  Further, it has been demonstrated that this this process can have a 
marked deleterious impact on intra-organ distribution of perfusion via alterations to the integrated 
regulation of vascular tone in skeletal muscle (11).   From this, the question arises as to how vascular 
myogenic activation within the metabolic syndrome is impacted by changes in dilator stimuli and whether 
interventions targeting elevated oxidant stress or elevated TxA2 production are effective at restoring 
normal patterns of reactivity between myogenic activation and interactions with dilator influences.   
The initial observation from this study is that pressure-induced constriction is increased in both GA and 
MCA from OZR as compared to LZR, supporting previous observations (10, 24).  Removal of the 
vascular endothelium largely abolished differences in myogenic activation between OZR and LZR, 
suggesting that the endothelium may represent the primary contributor to differences between the strains.  
Previous evidence using OZR (9, 10, 15, 28) and similar models (2) suggests that two endothelium-
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dependent mechanisms, both of which stem from a chronically elevated vascular oxidant stress, may be 
responsible for the endothelial influence on myogenic activation: a reduction to vascular NO 
bioavailability via increased ROS scavenging and a shift in arachidonic acid metabolism toward 
production of the vasoconstrictor TxA2.  This interpretation is supported by data presented in Figure 2, 
where pre-treatment of GA or MCA of OZR with the TEMPOL shifted myogenic activation to levels that 
were comparable to those determined in LZR.  However, while is it clear that ROS plays a role in 
myogenic activation of both GA and MCA, the role for TxA2 is less consistent.  In GA, pre-treatment 
with SQ-29548 resulted in a similar effect to that for TEMPOL, a restoration of pressure-induced 
constriction to levels in LZR.  However, this treatment was largely without effect in MCA from OZR 
(Figure 2, Panel D).  These data suggest that the contribution of ROS to increased myogenic activation 
may not be consistent across vascular beds; being more dependent on TxA2 in skeletal muscle arterioles, 
and more dependent on NO bioavailability in the cerebral circulation. 
To further explore the potential contribution of altered arachidonic acid metabolism to the main 
observations, the myogenic activation of ex vivo GA and MCA was evaluated under conditions of 
hypoxia. While other contributors to this response have been identified, including NO (8, 13, 24) and 
-hydroxlases and epoxygenases (8, 12, 13), in both GA 
and MCA, this has been demonstrated to be a dilator response that is largely-dependent on the production 
of PGI2 from arachidonic acid (15, 19, 21).  As shown in Figure 3, imposition of hypoxia alone had only 
mild effects on myogenic activation in either GA or MCA from OZR.   This was not surprising, as 
hypoxic dilation of resistance vessels is impaired in OZR, in large measure due to a reduction in mediator 
bioavailability and an increased production of TxA2 (8, 15, 24). However, when pre-treated with 
TEMPOL, the impact of hypoxia became much more pronounced, significantly blunting the slope of 
myogenic activation in vessels from OZR.  This observation clearly suggests that the increased vascular 
oxidant stress is contributing to not just the enhanced myogenic activation of GA and MCA, but also to 
the inability of hypoxia to blunt the enhanced pressure-induced constriction in vessels from OZR.   An 
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intriguing disparity exists when this is extended to the potential role for TxA2, as pre-treatment with SQ-
29548 resulted in an identical outcome as that for TEMPOL pre-treatment in GA from OZR (Figure 3, 
Panel C), while having a very limited effect in MCA (Figure 3, Panel F).  These data clearly suggest that 
the impact of ROS on myogenic activation in GA from OZR, and the relative inability of hypoxia to blunt 
the pressure-induced constriction in these vessels, may be mediated predominantly through the production 
and actions of TxA2.  In contrast, while the effects of ROS and the impact of hypoxia on myogenic 
activation of MCA from OZR are qualitatively similar in MCA, the contribution of TxA2 to this process 
may be considerably lower.   
Pursuant to this, we switched to a mechanistically different dilator, acetylcholine, which is largely NO-
dependent in the rat vasculature (27).  While the impact of acetylcholine on myogenic activation of GA 
and MCA from OZR was comparable to that for hypoxia, and pre-treatment with TEMPOL increased the 
impact of the stimulus on myogenic activation of both GA and MCA, pre-treatment with SQ-29548 had 
no identifiable impact on myogenic activation of either vessel (+ acetylcholine; Figure 4, Panels C and F).   
Based on previous data regarding the mechanistic pathways for acetylcholine and the results presented 
above, these data provide additional support for the concept of a divergence in ROS-dependent 
contributors to the enhanced myogenic activation of GA and MCA from OZR. 
One question that arises from the results of the present study is the intrinsic sensitivity of GA and MCA 
from LZR and OZR in response to PGI2 (carbacyclin), TxA2 (U46619) and nitric oxide, and whether this 
changes with the evolution of the metabolic syndrome.  However, the data presented in Figure 5 indicate 
that vascular responsiveness to these three metabolites remains robust and does not demonstrate any 
consistent alteration in this model.  As such, it is plausible at this time to ascribe differences in vascular 
responses to myogenic stimulation and dilator influences as an issue of mediator bioavailability, rather 
than one of vascular responsiveness. 
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Used as a proxy variable for elevated metabolic demand, the impact of elevated adenosine (10
-6
 M) on 
myogenic activation of GA and MCA from OZR reveals an intriguing relationship.  In skeletal muscle 
arteriole of OZR, elevated adenosine attenuated the severity of the pressure-induced vasoconstriction, 
resulting in a response that was similar to that determined in GA from LZR.  One would predict that this 
would be an appropriate response of the resistance vasculature in response to elevated metabolic demand 
– a shift in the overall setting of myogenic activation, such that flow regulation can still be maintained, 
although at a lower overall resistance.  However, given that this ‘adenosine-treated’ response remains 
blunted below that in GA from LZR treated with adenosine, altered myogenic activation in GA of OZR 
may still represent a contributor to reduced bulk perfusion and altered perfusion distribution with elevated 
metabolic demand (14).  In contrast, application of adenosine to MCA resulted in a very comparable 
blunting of myogenic activation in vessels from both LZR and OZR.  Speculatively, these observations 
suggest that the ability of local metabolic demand in the brain may be more able to override the increased 
pressure-induced constriction in the cerebral resistance vessels of OZR than in the skeletal muscle 
microcirculation.  However, the extent to which this may serve as a protective mechanism under 
conditions of cerebral ischemia or hypoxia in OZR, where stroke severity may be enhanced (22) remains 
unknown at this time.  
PERSPECTIVES 
With the development of the metabolic syndrome in this model, an increased pressure-induced 
constriction of resistance vessels develops in both the skeletal muscle and cerebral circulation.  While the 
genesis of this increased myogenic activation for both vessels appears to lie within an elevation in 
vascular oxidant stress, the increased response in skeletal muscle vessels appears to reflect an increased 
contribution from the production of TxA2, while responses in the cerebral circulation appear to reflect a 
loss of dilator metabolite bioavailability.  Importantly, the ability of local metabolic demand to override 
myogenic activation appears to still be present in both tissues, and may be fully intact in the brain.  While 
this may reflect a protective mechanism in the brain versus skeletal muscle, further interrogation into the 
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functional impact of these differences on organ perfusion as well as therapeutic interventions against the 
increased myogenic activation should keep this in mind. 
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Table 1. Baseline characteristics of 17 week-old LZR and OZR used in the present study.  * p<0.05 
versus LZR.  
 LZR (n=30) OZR (n=34) 
Mass (g) 34411 66912* 
MAP (mmHg) 106±6 126±5* 
[Glucose]plasma (mg/dl) 105±11 181±10* 
[Insulin]plasma (ng/ml) 1.4±0.2 8.5±1.2* 
[Nitrotyrosine]plasma (ng/ml) 15±5 45±8* 
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Table 2. Inner diameter (at the equilibration pressure) of gracilis arterioles (GA) and middle cerebral 
arteries (MCA) of LZR and OZR used in the present study.  Data in parentheses represents % active tone.  
* p<0.05 versus LZR.  
 
 Gracilis Arteriole Middle Cerebral Artery 
 LZR OZR LZR OZR 
Control 1045 (44±4%) 965 (43±3%) 121±4 (43±4%) 105±5 (46±4%)* 
-Endothelium 101±4 100±5 118±5 114±4 
+Hypoxia 118±4 100±5 138±4 115±5* 
+SQ-29548 107±4 102±4 120±5 109±4 
+TEMPOL 104±5 105±4 116±5 113±5 
+Acetylcholine 115±5 101±5 133±5 112±4 
+Adenosine 118±4 109±5 129±4 119±5 
Ca
2+
-free PSS (Passive) 184±5 169±5* 204±4 194±5 
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FIGURE LEGENDS 
Figure 1: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A and C; n=5 
for both) and middle cerebral arteries (Panels B and D; n=5-6 for both) from LZR and OZR in response to 
increased intralumenal pressure.  Data, presented as mean±SE, are presented for vessels under control 
conditions (Panels A and B) and following removal of the endothelium (Panels 
coefficients describing the curve of myogenic activation are presented in the inset legend.   * p<0.05 vs. 
LZR-Control; † p<0.05 vs.OZR-Control. 
Figure 2: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A and B; 
n=5-7 for both) and middle cerebral arteries (Panels C and D; n=6 for both) from LZR and OZR in 
response to increased intralumenal pressure.  Data, presented as mean±SE, are presented for vessels under 
control conditions and following pre-treatment of the vessels with either TEMPOL (10
-4
M) or the 
PGH2/TxA2 receptor antagonist SQ-29548 (10
-5
myogenic activation are presented in the inset legend.   * p<0.05 vs. LZR-Control; † p<0.05 vs.OZR-
Control. 
Figure 3: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A-C; n=5-6 
for all) and middle cerebral arteries (Panels D-F; n=5 for all) from LZR and OZR in response to increased 
intralumenal pressure.  Data, presented as mean±SE, are presented for vessels under control conditions, 
following imposition of hypoxia and following pre-treatment of the hypoxic vessels with either TEMPOL 
(10
-4
M) or the PGH2/TxA2 receptor antagonist SQ-29548 (10
-5
curve of myogenic activation are presented in the inset legend.   * p<0.05 vs. LZR-Control; † p<0.05 
vs.OZR-Control; ‡ p<0.05 vs. OZR-Hypoxia. 
Figure 4: Data describing myogenic activation of isolated gracilis muscle arterioles (Panels A-C; n=5 for 
all) and middle cerebral arteries (Panels D-F; n=5-6 for all) from LZR and OZR in response to increased 
intralumenal pressure.  Data, presented as mean±SE, are presented for vessels under control conditions, 
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following challenge with acetylcholine (10
-6
 M) and following pre-treatment of the acetylcholine-
challenged vessels with either TEMPOL (10
-4
M) or the PGH2/TxA2 receptor antagonist SQ-29548 (10
-
5
* p<0.05 vs. LZR-Control; † p<0.05 vs.OZR-Control; ‡ p<0.05 vs. OZR-Hypoxia. 
Figure 5:  Data describing the mechanical responses of isolated gracilis muscle arterioles and middle 
cerebral arteries from LZR and OZR in response to increased concentrations of carbacyclin (Panel A; n=5 
for all), U46619 (Panel B; n=5 for all) and sodium nitroprusside (Panel C; n=5 for all).  Data, presented as 
mean±SE, are presented for vessels under control conditions, at their equilibrium pressure.  There were no 
significant differences in the mechanical responses of GA or MCA between LZR and OZR for the three 
agonists. 
Figure 6: Data describing myogenic activation of isolated gracilis muscle arterioles (Panel A; n=5) and 
middle cerebral arteries (Panel B; n=5) from LZR and OZR in response to increased intralumenal 
pressure.  Data, presented as mean±SE, are presented for vessels under control conditions and following 
challenge with adenosine (10
-6
 M). * p<0.05 vs. LZR-Control; † p<0.05 vs.OZR-Control. 
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Conceptual Framework:  
The first chapter of this dissertation is entitled “Differential Impact of Dilator Stimuli on 
Increased Myogenic activation of Cerebral and Skeletal Muscle Resistance Arterioles in Obese Zucker 
Rats”. This paper is part of the foundational work that illustrates the potent impact of MetSyn on vascular 
tone. Myogenic activation is a dominant factor controlling vascular tone because it is part of the intrinsic 
vascular control within vessels that maintains a constant blood supply despite changes in perfusion 
pressure. It has been previously shown that myogenic activation is increased in vascular beds in the OZR 
compared to the LZR, although the mechanism for this increase had not been elucidated. This paper 
sought to examine if the increase in oxidant stress and/or altered AA metabolism were appropriate 
interventions to treat the increased myogenic activation and how this will integrate with other dilator 
stimuli. The data confirmed the increased myogenic activation seen previously in the OZR in both 
skeletal muscle and cerebral vasculature, and that the changes in myogenic activation appear to largely be 
endothelial dependent. It also revealed that the impact of ROS was primarily through the action of TxA2. 
In the isolated microvessel preparation the skeletal muscle gracilis arteriole showed a restoration of 
myogenic activation with treatment of TEMPOL, a ROS scavenger, and a similar response to SQ-29548, 
a TxA2 receptor antagonist. Further experiments integrating dilator conditions (hypoxia, acetylcholine, 
and adenosine) with myogenic activation revealed an attenuated dilator response compared to the LZR. In 
skeletal muscle, a large portion of the impaired dilator response is oxidant stress-induced as well as 
mediated through the production and action of TxA2. A key part of these data showed that the increased 
myogenic activation seen in the OZR was capable of blunting the adenosine response. Adenosine is often 
used as a mimic for an increase in metabolic demand, and this indicates that increased myogenic 
activation contributes to altered vascular responses even during increased levels of metabolic demand. 
This chapter lays the groundwork for suggesting that the microvasculature in the OZR is compromised in 
its ability to integrate vasoactive compounds and adequately regulate blood flow.  
43 
 
Chapter 2 
DIVERGENCE BETWEEN ARTERIAL PERFUSION AND FATIGUE RESISTANCE IN SKELETAL 
MUSCLE IN THE METABOLIC SYNDROME 
Jefferson C. Frisbee
1
, Adam G. Goodwill
1
, Joshua T. Butcher
1
, and I. Mark Olfert
2 
Department of Physiology and Pharmacology
1
 and Division of Exercise Physiology
2
 and Center for 
Cardiovascular and Respiratory Sciences, West Virginia University HSC, Morgantown, WV  
 
Address for Correspondence: 
Jefferson C. Frisbee, Ph.D. 
Center for Cardiovascular and Respiratory Sciences 
Department of Physiology and Pharmacology 
West Virginia University Health Sciences Center; 3152 HSN 
1 Medical Center Drive 
Morgantown, WV 26506 
Phone: (304) 293-6527 
Fax: (304) 293-5513 
Email: jfrisbee@hsc.wvu.edu 
 
44 
 
ABSTRACT 
The metabolic syndrome is associated with elevated peripheral vascular disease risk, characterized by 
mismatched blood flow delivery/distribution and local metabolism.  The obese Zucker rat (OZR) model 
of the metabolic syndrome exhibits myriad vascular impairments, although their integrated impact on 
functional hyperemia remains unclear.  In this study, arterial pressor responses and skeletal muscle 
perfusion were assessed in lean Zucker rats (LZR) and OZR during adrenergic stimulation 
(phenylephrine), challenge with thromboxane (U46619) and endothelium-dependent dilation 
(methacholine).  OZR were hypertensive versus LZR, but this was abolished by adrenoreceptor blockade 
(phentolamine); pressor responses to U46619 were similar between strains and were abolished by 
blockade with the PGH2/TxA2 receptor antagonist, SQ-29548.  Depressor reactivity to methacholine was 
impaired in OZR, but was improved by antioxidant treatment (TEMPOL).  Across levels of metabolic 
demand, blood flow to in situ gastrocnemius muscle was restrained by adrenergic constriction in OZR, 
although this diminished with increased demand.  O2 extraction, reduced in OZR vs. LZR across levels of 
metabolic demand, was improved by TEMPOL or SQ-29548; treatment with phentolamine did not impact 
extraction and neither TEMPOL nor SQ-29548 improved muscle blood flow in OZR.  While VO2 and 
muscle performance were consistently reduced in OZR vs. LZR, treatment with all three agents improved 
outcomes, while treatment with individual agents was less effective.  These results suggest that 
contributions of vascular dysfunction to perfusion, VO2 and muscle performance are spatially distinct, 
with adrenergic constriction impacting proximal resistance and endothelial dysfunction impacting distal 
microvessel-tissue exchange.  Further, these data suggest that increasing skeletal muscle blood flow in 
OZR is not sufficient to improve performance, unless distal perfusion inhomogeneities are rectified.  
 
Key Words: rodent models of obesity; skeletal muscle blood flow regulation; models of peripheral 
vascular disease; blood flow heterogeneity; vascular dysfunction 
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INTRODUCTION 
One of the hallmark characteristics in the development of the metabolic syndrome, with its 
constituent systemic pathologies of obesity, insulin resistance/type II diabetes mellitus, atherogenic 
dyslipidemia and hypertension, is the substantially increased risk for the progressive evolution of 
peripheral vascular disease (Cannon, 2008; Ford and Mokdad, 2008; Jones 2008; Obunai et al. 2007).  
While this can possess atherosclerotic or non-atherosclerotic elements in its constitution (with distinct 
etiological characteristics and outcomes), one of the defining elements of peripheral vascular disease 
(PVD) is an evolving inability to effectively match tissue perfusion with local metabolic demand, an 
observation routinely demonstrated in both humans and in multiple animal models of the metabolic 
syndrome (Baron, 2002; He et al. 1995; Nicholson et al. 1992; Ruiter et al. 2010; Wolfram et al. 2001).  
While this has been identified across numerous organs/tissues, we have demonstrated reduced bulk blood 
flow to in situ gastrocnemius muscle of the obese Zucker rat (OZR) across ranges of demand from rest to 
near maximum metabolic intensity (Frisbee et al. 2009; Frisbee 2005; 2004; 2003). 
In OZR, a model of the metabolic syndrome which derives its genesis through chronic 
hyperphagia as a result of a severe receptor-based leptin resistance (Guerre-Millo, 1997; Williams et al. 
2001), the basic contributing mechanisms underlying the compromised perfusion and hyperemic 
responses may include: 1) enhanced adrenergic constrictor reactivity and signaling of skeletal muscle 
arterioles (Frisbee, 2004; Naik et al. 2006; Stepp and Frisbee, 2002), 2) a widespread impairment to 
arteriolar dilator reactivity, primarily centered around compromised endothelial function (Bouvet et al. 
2007; Frisbee et al. 2009; Goodwill et al. 2008; Katakam et al. 2009; Lu et al. 2010), and 3) structural 
remodeling of the microvasculature (Bovet et al. 2007; Goodwill et al. 2009; Lu et al. 2010; Stepp  et al. 
2004), including a reduced wall distensibility of the resistance arterioles (predominantly contributing to 
an elevated vascular resistance) and a rarefaction of the distal microvasculature (predominantly 
contributing to impairments to mass transport and exchange in the microenvironments).  With these 
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elements in place, a progressive deterioration in tissue perfusion develops which can, and ultimately does, 
negatively impact the ability of the skeletal muscle to resist fatigue (Frisbee, 2006; 2004). 
However, recent data suggests that a more complex relationship than has been previously 
understood may exist with regard to the linkages between skeletal muscle perfusion and fatigue resistance 
within the metabolic syndrome.  Specifically, we have recently provided initial evidence that multiple 
pathways which derange the normal patterns of skeletal muscle arteriolar reactivity integrate to impair not 
only vascular dilation in a metabolic demand-dependent fashion, but also that these can contribute to 
perfusion heterogeneity at microvascular bifurcations which could represent a significant contributor to 
the compromised ability of microvascular networks to match perfusion to local metabolic demand 
(Frisbee et al. 2009).     
As a result of these recent observations, there is an immediate need for a more accurate 
understanding of the relationships between the perfusion to, and the performance of, skeletal muscle 
within the setting of the metabolic syndrome.  Given that the metabolic syndrome represents a condition 
which strongly predisposes individuals to an elevated risk of PVD, which can be defined as a condition 
wherein the perfusion:metabolic demand matching can be substantially impaired, the translational 
importance of the thorough understanding of how perfusion and muscle performance are intertwined in 
this pathological setting is imperative.  The purpose of this study is to thoroughly evaluate functional 
outcomes (performance) in skeletal muscle and to provide a framework for future interrogation into the 
detailed relationships between vascular function, perfusion and skeletal muscle performance outcomes.  
This study was designed to provide a rigorous test of the hypothesis that functional hyperemia is 
constrained within skeletal muscle of OZR owing to the combined impact of adrenergic constraint and 
endothelial dysfunction, each of which acts to either inappropriately increase, or prevent reductions in, the 
resistance to skeletal muscle blood flow over a range of imposed metabolic demand. 
MATERIALS AND METHODS 
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 Animals: 15-17 week old male lean Zucker rats (LZR) and OZR fed standard chow and tap water ad libitum 
were used for all experiments.  Data describing the baseline characteristics of LZR and OZR in the present 
study are presented in Table 1.  At this age range, OZR were significantly heavier than age-matched LZR and 
also demonstrated fasting (overnight) hyperglycemia, hyperinsulinemia, elevated plasma triglyceride levels 
and moderate hypertension.  Rats were housed in animal care facility at either the Medical College of 
Wisconsin or at the West Virginia University Health Sciences Center, and all protocols received prior 
IACUC approval.  Rats were anesthetized with injections of sodium pentobarbital (50 mgkg-1 i.p.), and 
received tracheal intubation to facilitate maintenance of a patent airway.  In all rats a carotid artery and an 
external jugular vein were cannulated for determination of arterial pressure and for intravenous infusion of 
additional substances as necessary (e.g., anesthetic, heparin, etc.).      
Preparation of In Situ Blood-Perfused Skeletal Muscle: In all LZR and OZR, the left gastrocnemius 
muscle was isolated in situ (Frisbee, 2003).  Briefly, the left leg received a medial incision from the 
calcaneus to the femoral triangle, and all muscles, vessels and connective tissue overlaying gastrocnemius 
muscle were removed, thus exposing the gastrocnemius muscle, its vascular supply, and the sciatic nerve.  
The nerve was isolated and utilized for initiating muscle contraction via a stimulating electrode attached to an 
electrical stimulator (Grass SD9).  Branches from the femoral artery that did not perfuse the gastrocnemius 
muscle directly were ligated or cauterized, depending on size and location.  A microcirculation flow probe 
(Transonic) was placed around the femoral artery, immediately distal to its origin from the iliac artery, in 
order to measure blood flow to the gastrocnemius muscle.  As a final step, a 24 gauge angiocatheter was 
inserted into the femoral vein to allow for sampling of venous blood from the contracting muscle.  The entire 
preparation was covered in PSS-soaked gauze and plastic film to minimize evaporative water loss and was 
placed under a lamp to maintain temperature at 37C.  At this time, heparin (500 U/kg) was infused via the 
jugular vein to prevent blood coagulation.   
Section One:  Arterial Pressor and Hindlimb Perfusion Responses:  Following the complete surgical 
preparation of the rats, it was necessary to validate the effectiveness of the experimental conditions that were 
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to be utilized for the subsequent interrogations of skeletal muscle perfusion and fatigue resistance 
1 2 adrenoreceptor 
antagonist phentolamine (10 mg/kg; followed by 30 minutes of equilibration), the superoxide dismutase 
mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL; 50 mg/kg; followed by 45 minutes of 
equilibration), or the PGH2/TxA2 receptor antagonist SQ-29548 (10 mg/kg; followed by 30 minutes of 
equilibration) in order to remove the influences of adrenergic tone, vascular oxidant stress and influence of 
vascular sources of TxA2 from the system, respectively.  Following treatment of the individual rats with 
phentolamine, TEMPOL or SQ- -
-dependent nitric oxide donor 
2 ).  Alterations in mean arterial pressure and 
femoral artery perfusion were monitored following agonist infusion in order to determine peak responses and 
the time to restoration of baseline (pre-treatment) conditions.  All infused intravenous doses of drugs were 
corrected for differences in circulating blood volume between LZR and OZR at this age (Frisbee, 2006; 
Schreihofer et al. 2005). 
Section Two: Responses of Contracting In Situ Skeletal Muscle: Following validation of the actions of 
phentolamine, TEMPOL or SQ-29548 and restoration of baseline conditions, the gastrocnemius muscle was 
stimulated to perform (via the sciatic nerve) bouts of isometric twitch contractions (1, 3, or 5 Hz, 0.4 ms 
duration, 5V) for 3 minutes followed by 15 minutes of self-perfused recovery, with arterial pressure and 
femoral artery blood flow continuously monitored.   Data were collected under control conditions and 
following treatment of the rats with phentolamine, TEMPOL or SQ-29548, as described above.   
Data Calculations:  In 
cannula and femoral vein angiocatheter immediately prior to and following completion of, the muscle 
contraction periods.  Samples were stored on ice until they were processed for blood gas pressures, percent 
oxygen saturation and hemoglobin concentration using a Corning Rapidlab 248 blood gas analyzer.  Muscle 
perfusion, arterial pressure, and bulk blood flow through the femoral artery were monitored for one minute 
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prior to muscle contractions and throughout the contraction period using a Biopac MP150 with 
Acqknowledge data acquisition software at a 50Hz sampling frequency.  Muscle perfusion and performance 
data after three minutes of contraction were normalized to gastrocnemius mass, which was not different 
between LZR (2.180.09 g) and OZR (2.060.10 g).  Oxygen content within the blood samples was 
determined using the following standard equation:  
        (     [  ]        )  (          )    Eq. 1 
Where CxO2 and PxO2 represent the total content (ml/dL) or partial pressure of oxygen (mmHg), respectively, 
of arterial or venous blood (denoted simply as ‘x’). [Hb] represents hemoglobin concentration within the 
blood sample (g/dL); %O2Sat represents the percentage oxygen saturation of the hemoglobin and 1.39 and 
0.003 represent constants describing the amounts of bound and dissolved oxygen in blood.  Oxygen uptake 
across the gastrocnemius muscle was calculated using the Fick equation:  
      222 CvOCaOQOV 
     
 Eq. 2 
where 
2OV
  represents oxygen uptake by the gastrocnemius muscle, Q  represents femoral artery blood flow 
(ml/g/min), and 
2CaO  and 2CvO  represent arterial and venous oxygen content, respectively.  Perfusion 
resistance across gastrocnemius muscle was calculated as the quotient of mean arterial pressure and muscle 
blood flow.  Muscle O2 conductance (    ) was calculated using Fick’s law of diffusion as a simple 
model of O2 flux to the working muscle, 
    ̇        (            )    
 Eq. 3 
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where DmO2 is the diffusing capacity of O2 at the muscle (ml/min/mmHg/mg muscle),  P O2 is the mean 
capillary PO2 (mmHg), and PmitoO2 is average mitochondrial PO2 (mmHg) (Kurdak  et al. 1996; Roca et 
al. 1989).  Estimation of P O2 is based on a numerical (Bohr) integration procedure that uses a single 
parameter for tissue diffusing capacity-to-muscle blood flow ratio (DO2/QT), which is assumed to be 
constant along the capillary, where DO2/QT is varied iteratively until the calculated end-capillary PO2 
matches the measured venous PO2 to within 0.1 mmHg (Kurdak  et al. 1996; Roca et al. 1989).  Mean 
capillary PO2 (P O2) is then a time-weighted average of all computed PO2 values along the capillary 
based on the initial measured arterial and venous PO2 values. Explicit assumptions in making the DmO2 
calculation are that, 1) mitochondrial PO2 is negligibly small (i.e. PmitoO2=0 mmHg) at maximal or near 
maximal exercise, and that 2) the only explanation of O2 remaining in the femoral venous blood is 
diffusion limitation of O2 efflux from the muscle microcirculation (Wagner, 1992).  Accordingly, 
perfusional or diffusional shunts are considered negligible, and we only calculate DmO2 for data obtained 
at maximal or near maximal exercise (i.e. electrical stimulation at 5 Hz).  For all calculations we used 
hemoglobin of 15 gm/dL and p50 of 26.8 mmHg. 
Statistical Analyses:  Statistically significant differences in determined results were assessed using either 
Student’s t-test or analysis of variance (ANOVA), with Student-Newman-Keul’s post-hoc test as needed.  In 
all cases, p<0.05 was taken to reflect statistical significance.  All data are presented as mean±SE. 
RESULTS 
 Data describing the animals under investigation in the current study are summarized in Table 1.  At 
15-17 weeks of age, OZR were dramatically heavier than LZR, and demonstrated a significant impairment to 
glycemic control, dyslipidemia, and chronic elevations in vascular oxidant stress. 
 Figure 1 summarizes the impact of challenge of LZR and OZR with phenylephrine (with and without 
pre-treatment with phentolamine) on arterial pressure (Panel A), femoral artery blood flow (Panel B) and 
vascular resistance (Panel C) in LZR and OZR.  In response to intravenous infusion of the adrenoreceptor 
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agonist, mean arterial pressure was significantly increased in both strains, although the magnitude of this 
increase was similar between LZR (67±9 mmHg) and OZR (72±12 mmHg).  Pre-treatment of animals with 
phentolamine reduced arterial pressure in both strains to a similar level and abolished pressor responses to 
infused phenylephrine (Panel A).   Femoral artery blood flow in OZR was not significantly different as 
compared to LZR under control conditions, and challenge with phenylephrine infusion resulted in a mild, but 
variable, reduction in blood flow in both strains (Panel B).  Following treatment with phentolamine, femoral 
artery blood flow was mildly elevated to similar levels between LZR and OZR, and infusion of 
phenylephrine was without effect.  Vascular resistance, elevated in OZR versus LZR under control 
conditions, increased significantly in both strains following infusion of phenylephrine (Panel C), although 
this response was enhanced in OZR [347±42 mmHg/(ml/g/min)] as compared to LZR [187±30 
mmHg/(ml/g/min)].   Treatment of rats with phentolamine lowered resistance in both strains to a similar 
level, and blocked the overwhelming majority of the phenylephrine-induced increases in vascular resistance. 
 The impact of challenging the animal with the TxA2 analog U46619 and the effectiveness of 
blockade of the PGH2/TxA2 receptors with SQ-29548 is summarized in Figure 2.  Infusion of U46619 
increased arterial pressure in both strains, although the magnitude of this effect was very similar between 
LZR and OZR (Panel A).  While blockade of PGH2/TxA2 receptors had no discernible impact on arterial 
pressure, it abolished the pressor response to U46619 in both strains.  Infusion of U46619 (either with or 
without pre-treatment with SQ-29548) had no impact on bulk blood flow through the femoral artery in either 
LZR or OZR (Panel B).  Treatment of rats with U46619 resulted in a similar, significant increase in vascular 
resistance in both strains, and this response was abolished by pre-treatment with SQ-29548 (Panel C).  
 Figure 3 presents data describing the impact of both infusion of methacholine and the effects of pre-
treatment with TEMPOL on arterial pressure (Panel A), femoral artery blood flow (Panel B) and vascular 
resistance across the gastrocnemius muscle (Panel C) in LZR and OZR.  In LZR, challenge with 
methacholine caused a rapid, significant depressor response that was unaffected by pre-treatment with 
TEMPOL.  In contrast, infusion of methacholine in OZR did not significantly reduce arterial pressure, while 
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pre-treatment of rats with TEMPOL improved the depressor response (Panel A).  In preliminary studies, 
treatment of either LZR or OZR with the nitric oxide synthase inhibitor L-NAME (100 mg/kg) prevented the 
depressor effects of methacholine under any condition (MAP from control in LZR+L-NAME=-3.5±3.6 
mmHg; (MAP from control in OZR+L-NAME=+1.4±4.1 mmHg).   In LZR, infusion of methacholine 
resulted in an increased femoral artery blood flow, a response not identified in OZR.  This effect was not 
altered in LZR following pre-treatment with TEMPOL, although it was increased in OZR to the point of 
reaching statistical significance (Panel B).  Similarly, methacholine infusion resulted in a decreased vascular 
resistance in LZR only (with or without TEMPOL treatment), while methacholine-induced reductions in 
resistance in OZR were identified following pre-treatment with TEMPOL (Panel C). 
 The hemodynamic characteristics within gastrocnemius muscle of OZR and LZR under resting 
conditions in the present study are summarized in Figure 4.  The decreased femoral artery blood flow in OZR 
as compared to LZR at rest was eliminated following treatment with phentolamine, although treatment with 
either TEMPOL or SQ-29548 was without effect (Panel A).  Incorporating arterial pressure, the elevation in 
vascular resistance across the gastrocnemius in OZR was corrected following infusion of phentolamine, while 
treatment with TEMPOL or SQ-29548 provided no discernible benefit (Panel B).  Under resting conditions, 
the extraction of oxygen from arterial to venous blood was significantly reduced in OZR versus LZR and, in 
contrast to the previous panels, only treatment with TEMPOL or SQ-29548 increased extraction, while 
adrenoreceptor blockade was without effect (Panel C).  Integrating blood flow and extraction, oxygen uptake 
at the gastrocnemius muscle was reduced in OZR versus LZR, and only combined treatment of OZR with all 
three agents (phentolamine, TEMPOL and SQ-29548) resulted in a significant improvement to muscle VO2.  
In preliminary experiments, treatment of LZR with phentolamine, TEMPOL and/or SQ-29548 failed to elicit 
a consistent and/or significant change in the above parameters (data not shown). 
 In response to 1Hz twitch contractions (Figure 5), the general patterns of the measured outcomes 
in the present study were not strikingly different than that presented in Figure 4.  Femoral artery blood 
flow (Panel A) was reduced and vascular resistance (Panel B) was elevated in OZR versus LZR, and these 
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alterations were corrected by pre-treatment with phentolamine (TEMPOL and SQ-29548 having no 
consistent measureable impact).  In contrast, the reduction in oxygen extraction in OZR versus LZR 
(Panel C) was only ameliorated following treatment with either TEMPOL or SQ-29548, with only a 
trivial benefit provided by treatment with phentolamine.  However, the recovery in VO2 in contracting 
gastrocnemius of OZR to levels determined in LZR was only realized following treatment of the animal 
with all three agents (Panel D).  Muscle fatigue resistance mirrored the patterns in VO2, with a reduced 
tension development after three minutes of contraction in OZR as compared to LZR, and a significant 
improvement in contractile performance only occurring following combined treatment of OZR with 
phentolamine, TEMPOL and SQ-29548 (Panel E). 
 Figure 6 summarizes hemodynamic responses in gastrocnemius muscle of LZR and OZR in 
response to three minutes of contraction at 3Hz.    While femoral blood flow was lower (Panel A) and 
vascular resistance was higher (Panel B) in OZR versus LZR, the ability of phentolamine to restore these 
values was less robust than at lower levels of metabolic demand, with neither TEMPOL nor SQ-29548 
exerting a discernible impact on these outcomes.  In contrast, both TEMPOL and SQ-29548 improved 
oxygen extraction (Panel C) and VO2 (Panel D) across gastrocnemius muscle of OZR, while 
phentolamine exerted only minimal benefits.  Phentolamine was unable to improve skeletal muscle 
fatigue resistance in OZR at 3Hz, while both TEMPOL and SQ-29548 did result in a mild improvement 
to performance, and combined treatment with all three agents resulted in the greatest improvement in the 
ability of the gastrocnemius muscle to maintain developed tension (Panel E). 
 Data describing the perfusion responses of in situ gastrocnemius muscle of OZR and LZR in 
response to 5Hz contraction are summarized in Figure 7.  These data appear present a different conceptual 
framework, as no employed intervention was able to improve femoral artery blood flow in OZR above 
that identified under control conditions (Panel A), and this was paralleled by measures of vascular 
resistance, which were very consistent across OZR groups, regardless of intervention (Panel B).  
However, treatment with TEMPOL or SQ-29548 improved oxygen extraction (Panel C) to levels similar 
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to that in LZR, and VO2 as well (Panel D), although this improvement was constrained by the limits on 
normalized muscle O2 conductance (Panel E).  Finally, while treatment of OZR with phentolamine was 
without effect on muscle fatigue resistance at 5Hz, and both TEMPOL and SQ-29548 resulted in mild 
improvements, combined therapy with all agents significantly improved muscle performance in OZR over 
that determined under control conditions (Panel F). In preliminary experiments, treatment of LZR with 
phentolamine, TEMPOL and/or SQ-29548 failed to elicit a consistent and/or significant change in the above 
parameters across levels of metabolic demand (data not shown). 
 
 The robust correlative relationships between skeletal muscle O2 conductance and muscle 
performance at 5Hz contraction for LZR and OZR under the conditions of the present study are shown in 
Figure 8.   DmO2 was a strong correlate of muscle fatigue resistance across LZR and OZR, with an r-
squared value explaining nearly 60% of the variability in the data.     
DISCUSSION 
  One of the most vexing challenges to public health and the quality of life of afflicted individuals 
is the insidious progression of peripheral vascular disease (PVD), with its characteristic impairment to 
blood flow delivery and the accelerated development of fatigue in those muscles experiencing an 
increased metabolic demand (Baron, 2002; Hudlicka and Brown, 2009; Nicholson et al. 1992; Ruiter et 
al. 2010; Wolfram et al. 2001).  The OZR, with its inherent development of obesity, insulin resistance, 
moderate hypertension and hyperlipidemia represents an excellent model of non-atherosclerotic PVD risk, 
and while there have been numerous studies describing alterations to vascular reactivity, microvascular 
network structure and microvessel wall mechanics in OZR, the ability to extend these observations to an 
integrated system for the regulation of blood flow has been far more limited.  While several studies have 
indicated that functional dilation (Xiang et al. 2008; 2006) or hyperemia (Frisbee, 2004; 2003) are 
impaired in skeletal muscle of OZR as compared to LZR, these remain superficially described, and results 
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from recent study suggests that the integration across vascular structure/function relationships, the 
regulation of perfusion, functional hyperemia and skeletal muscle fatigue resistance may be more 
complicated than has previously been appreciated (Frisbee et al. 2009).    
 The initial observations from the first section of this study demonstrate that the increased 
resistance across the skeletal muscle microcirculation of OZR is multi-factorial in nature.  While the 
a 1 2 adrenoreceptor 
blockade (Figure 1), this is clearly a more complicated process, and one that appears to involve alterations 
to endothelial function.  While data in Figure 2 suggest that vascular responses to TxA2 are not altered in 
OZR, supporting earlier observations (Goodwill et al. 2008), previous studies provided compelling 
evidence that vascular production of TxA2, elevated in OZR (Xiang et al. 2008; 2006), can compromise 
functional dilation and hyperemic responses within the distal microcirculation (where contribution to 
overall resistance is lower; Greene et al.  1989) (Frisbee et al. 2009; Xiang et al. 2008; 2006).  
Additionally, the muted response to the endothelium-dependent agonist methacholine in OZR was 
partially ameliorated by pre-treatment with the antioxidant TEMPOL (and was consistently abolished by 
the nitric oxide synthase inhibitor L-NAME), clearly indicating the impairments to nitric oxide 
bioavailability through oxidant scavenging, an especially compelling issue for several reasons.  Not only 
does elevated systemic oxidant stress in OZR have the capacity to severely compromise nitric oxide 
bioavailability, it also has the capacity to alter arachidonic acid metabolism leading toward the increased 
generation of TxA2 (Goodwill et al. 2008; Zou, 2007; Zou et al. 2004).  While these can obviously have 
immediate impacts on vascular tone regulation themselves, alterations in NO and TxA2 bioavailability in 
the microcirculation of OZR have also been demonstrated to contribute to significant changes to the 
patterns and severity of adrenergic constriction (Stepp and Frisbee, 2002), myogenic activation (Frisbee et 
al.2002), and the integration of these parameters for the determination of net vascular tone (Frisbee et al. 
2009).   
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 The second portion of this study focused on relationships between vascular function, blood flow 
and muscle fatigue resistance in OZR under control conditions and in response to the imposed 
interventions of phentolamine, TEMPOL and SQ-29548.  As compared to LZR, OZR exhibited a blunted 
functional hyperemia and an elevated vascular resistance across gastrocnemius muscle across the 
continuum of metabolic demand.  Interestingly, this was also accompanied by a reduction in oxygen 
extraction and a compromised VO2 in OZR, which, not surprisingly, was strongly predictive of an 
impaired muscle performance.  This is a particularly intriguing outcome for multiple reasons.  The 
gastrocnemius muscle was driven to contract via electrical stimulation of the sciatic nerve, and not only 
were the stimulation parameters identical between strains, but gastrocnemius mass was also very similar, 
which should have minimized differences between metabolic demand and muscle performance between 
the two strains.  Further, at this age, daily physical activity is very similar between LZR and OZR (Stepp 
et al. 2004), fiber type profiles are similar (Adachi et al. 2007; Pujol et al. 1993), and the maximum 
developed tension was nearly identical between the two strains (Table 1).  As such, results from these 
experiments strongly suggest that impairments to muscle performance in OZR at this age appear to reflect 
an altered behavior within blood delivery/distribution in the microcirculation (i.e. O2 flux across the 
working muscle), rather than overt dysfunction within skeletal muscle myocyte and motor unit 
recruitment patterns.  However, it must be emphasized that these conclusions are relevant for OZR at this 
age only, as previous studies have clearly demonstrated significant, although variable, alterations to 
contractile and metabolic functions of skeletal muscle myocytes in OZR afflicted with the metabolic 
syndrome with increasing age (Campion et al. 1987; Farkas et al. 1994; He et al. 1995). 
 At the lower end of this continuum of metabolic demand, blood flow to gastrocnemius muscle of 
OZR was restrained by increased adrenergic tone, as infusion of phentolamine abolished the elevated 
vascular resistance (Figures 4 and 5).  However, adrenergic constraint appeared to play little role in terms 
of the poor oxygen extraction and VO2, as these were unaffected by phentolamine infusion.  In contrast, 
the endothelial dysfunction in OZR was not a significant contributor to perfusion resistance across the 
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gastrocnemius muscle, as neither TEMPOL nor SQ-29548 altered femoral artery blood flow.  What was 
most compelling was that TEMPOL and SQ-29548 improved oxygen extraction across the gastrocnemius 
of OZR as compared to LZR, although VO2 remained low owing to the lack of an impact on blood flow.  
These relationships were also evident in the gastrocnemius of OZR working at 3 Hz contractions (Figure 
6), wherein the influence of phentolamine, while decreased with elevated metabolic demand, was 
primarily via reduced blood flow resistance while TEMPOL and SQ-29548 improved oxygen extraction, 
and the combined influence of all three agents improving VO2 and muscle performance to the greatest 
extent.  The condition at 5 Hz (Figure 7) contractions was somewhat different owing to the structural 
remodeling of the microvessel wall and networks to impose an upper ‘ceiling’ on bulk blood flow to the 
muscle in OZR (Frisbee, 2005).  As such, phentolamine was without effect on resistance in OZR, 
although its restrictive effect was diminishing with increased contraction frequency owing to metabolic 
sympatholysis (Frisbee, 2004).  However, TEMPOL and SQ-29548 retained their ability to improve 
oxygen extraction and conductance such that an optimal muscle VO2 under these conditions in OZR was 
realized.  Not surprisingly, regardless of metabolic demand, optimization of bulk blood flow, muscle 
oxygen conductance in OZR, specifically following treatment with all three pharmacological agents, was 
associated with the greatest improvement to gastrocnemius muscle fatigue resistance.   
 Taken together, the results of the present study have three significant and novel implications.  The 
first of these is the altering blood flow alone cannot restore skeletal muscle performance within the OZR 
model of PVD.  This observation is in some contrast to the accepted interpretations of PVD, wherein a 
consistent assumption is that improving blood flow to active tissue, and certainly in proportion to the 
continuum of metabolic demand (i.e. O2 uptake), would improve functional outcomes.  That an 
intervention which enhanced functional hyperemia was ineffective at improving muscle oxygen 
conductance and performance emphasizes the complexity of the processes affecting the diffusional 
conductance of oxygen that is central to the poor outcomes identified in OZR and the strong relationship 
determined between muscle O2 conductance and the fatigue response (Figure 8).  
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 Importantly, treatment of OZR with TEMPOL or SQ-29548 improved oxygen flux across the 
microcirculation of the gastrocnemius muscle with minimal impact on aggregate vascular resistance.  This 
observation suggests that the beneficial impact of improving endothelial function with regard to 
enhancing the integrated outcome of muscle performance may be the result of optimizing hemodynamic 
behavior in the distal microcirculation (where localized mass transport and exchange phenomena are most 
relevant) than in the proximal microcirculation (where the regulation of perfusion resistance is most 
relevant).  This observation is be supported by the muscle performance data in the present study, wherein 
neither phentolamine nor TEMPOL/SQ-29548 alone improved muscle performance, while only combined 
treatment with all three agents reduced fatigue development.  This apparent spatial distinction of the 
major contributors to poor perfusion and muscle performance outcomes, with the beneficial impacts of 
adrenoreceptor blockade being primarily relevant in the proximal microcirculation and those for improved 
endothelial dysfunction being primarily relevant in the distal microcirculation represents the second major 
implication and novel observation of the results present study.   
 The concept involving the spatial relevance of interventions suggests the third major implication 
of the present study.  The results of the previous study indicated that one of the hallmark characteristics of 
the distal microcirculation within in situ cremaster muscle of OZR was that perfusion distribution at 
microvascular bifurcations was more heterogeneous than in LZR, with potential contributors to this 
derangement being elevated oxidant stress and increased TxA2 production (Frisbee et al. 2009).  
Speculatively, this may be the underlying physiological/hemodynamic mechanism for the impact of 
TEMPOL/SQ-29548 on improving oxygen flux in contracting muscle of OZR in the present study.  If 
development of PVD in OZR is characterized by an increasing perfusion heterogeneity at microvascular 
bifurcations, resulting in a poor pattern of oxygen extraction across the muscle through an increasing 
propensity for ‘high flow pathways’ with lower extraction and ‘low flow pathways’ which become flow-
limited, this could compromise net oxygen extraction and be reflective of a generalized impairment to 
mass transport and exchange across the skeletal muscle microcirculation.  Indeed, this process is akin to 
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matching of ventilation and perfusion in the lung, which is known to be an important determinant in 
transfer of O2 (i.e. O2 conductance) from alveolar gas into blood.  Further interrogation of the contributing 
physiological, biochemical and molecular signaling mechanisms, their spatio-temporal distribution, their 
interactions, and the potential for ameliorative intervention appears to be well justified. 
 While the results of this study provide for a compelling framework for the interrogation of the 
relationships between perfusion and fatigue in skeletal muscle under conditions of the metabolic 
syndrome, one inherent limitation that should be acknowledged is the preparation itself.  The combination 
of a barbiturate anesthetic, which can inhibit reflex sympathetic excitation as a result of the muscle 
contraction, clearly has the potential to impact the results of study in an unpredictable manner.  Further, 
the potential for electrical activation of sympathetic postganglionic fibers and group IV afferents as a 
result of the current applied to the sciatic nerve cannot fully be discounted.  Given these inherent 
limitations to the preparation, further effort into the verification and potential application of a decerebrate 
preparation without the necessity of anesthesia where the skeletal muscles in question can be activated via 
direct stimulation of ventral roots may be warranted.  
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Table 1.  Baseline characteristics of 15-17 week-old LZR and OZR used in the present study.  * p<0.05 
versus LZR. 
 
 LZR OZR 
Mass (g) 3668 68411* 
MAP (mmHg) 101±5 124±6* 
[Glucose]plasma (mg/dl) 111±10 184±14* 
[Insulin]plasma (ng/ml) 2.0±0.4 9.4±1.1* 
[Cholesterol]plasma (mg/dl) 78±9 138±12* 
[Triglycerides]plasma (mg/dl) 84±11 348±19* 
[Nitrotyrosine]plasma (ng/ml) 14±4 48±8* 
Maximum Tension Development (g/g) 384±28 369±27 
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Table 2.  Arterial and femoral venous blood oxygen content values (ml O2/dL blood) from LZR and OZR under the conditions of the present 
study.  Data are presented under resting conditions and across levels of increasing metabolic demand. 
 
   
 Rest 1Hz 3Hz 5Hz 
 CaO2 CvO2 CaO2 CvO2 CaO2 CvO2 CaO2 CvO2 
LZR 20.8±1.1 14.2±1.1 20.7±1.1 12.1±0.8 20.7±1.1 11.0±1.2 20.6±1.1 7.4±0.9 
OZR 21.0±0.9 15.9±1.0 20.6±1.0 13.9±1.4 20.6±1.1 13.2±1.6 20.8±1.1 9.9±1.4 
OZR+Phentolamine 20.7±0.9 15.2±0.9 20.1±0.9 14.1±1.2 19.9±1.1 13.1±0.9 20.7±1.2 10.1±1.6 
OZR+TEMPOL 20.7±1.0 14.3±1.0 20.6±1.0 11.8±1.5 20.8±1.0 10.8±1.3 20.2±1.2 6.9±1.5 
OZR+SQ-29548 20.9±0.8 13.9±1.0 19.9±1.4 12.0±1.2 20.8±1.2 10.9±1.6 19.9±1.1 7.1±1.2 
OZR+All 20.7±0.9 14.1±1.1 20.4±0.9 12.0±1.1 20.6±1.1 9.8±1.5 20.5±1.3 6.7±1.5 
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FIGURE LEGENDS 
Figure 1.  Arterial pressor responses and gastrocnemius muscle perfusion in LZR and OZR following 
intravenous infusion of the adrenoreceptor agonist phenylephrine ( ) under control conditions and 
in response to pre- 1 2 adrenoreceptor antagonist phentolamine (10 mg/kg).  Data 
(meanSE) are presented for changes in mean arterial pressure (Panel A), femoral artery blood flow 
(Panel B) and vascular resistance across the gastrocnemius muscle (Panel C). * p<0.05 vs. LZR; † p<0.05 
vs. OZR; n=6 animals under each condition. 
 
Figure 2.  Arterial pressor responses and gastrocnemius muscle perfusion in LZR and OZR following 
intravenous infusion of the TxA2 mimetic U46619 ( ) under control conditions and in response to 
pre-treatment with the PGH2/TxA2 receptor antagonist SQ-29548 (10 mg/kg).  Data (meanSE) are 
presented for changes in mean arterial pressure (Panel A), femoral artery blood flow (Panel B) and 
vascular resistance across the gastrocnemius muscle (Panel C). * p<0.05 vs. LZR; † p<0.05 vs. OZR; n=6 
animals under each condition. 
 
Figure 3.  Arterial pressor responses and gastrocnemius muscle perfusion in LZR and OZR following 
intravenous infusion of the endothelium-dependent dilator agonist methacholine ( ) under control 
conditions and in response to pre-treatment with the superoxide dismutase mimetic TEMPOL (50 mg/kg).  
Data (meanSE) are presented for changes in mean arterial pressure (Panel A), femoral artery blood flow 
(Panel B) and vascular resistance across the gastrocnemius muscle (Panel C). * p<0.05 vs. LZR; † p<0.05 
vs. OZR; n=6 animals under each condition. 
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Figure 4. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR 
under resting conditions.  Data (meanSE) are presented for femoral artery blood flow (Panel A), 
vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction (Panel C) and oxygen 
uptake (VO2) by the muscle (Panel D).  Values are presented under control conditions and following 
treatment of OZR with phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-29548 (10 mg/kg) or all three 
substances.  * p<0.05 vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for control; n=5 for each treatment 
group; all oxygen extraction and VO2 data are from n=5 animals).  The legend for all panels is presented 
in Panel A. 
 
Figure 5. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR in 
response to three minutes of 1 Hz muscle contraction.  Data (meanSE) are presented for femoral artery 
blood flow (Panel A), vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction 
(Panel C), oxygen uptake (VO2) by the muscle (Panel D) and developed tension by the gastrocnemius 
(Panel E).  Values are presented under control conditions and following treatment of OZR with 
phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-29548 (10 mg/kg) or all three substances.  * p<0.05 
vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for control; n=5 for each treatment group; all oxygen 
extraction and VO2 data are from n=5 animals).  The legend for all panels is presented in Panel A. 
 
Figure 6. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR in 
response to three minutes of 3 Hz muscle contraction.  Data (meanSE) are presented for femoral artery 
blood flow (Panel A), vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction 
(Panel C), oxygen uptake (VO2) by the muscle (Panel D) and developed tension by the gastrocnemius 
(Panel E).  Values are presented under control conditions and following treatment of OZR with 
phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-29548 (10 mg/kg) or all three substances.  * p<0.05 
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vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for control; n=5 for each treatment group; all oxygen 
extraction and VO2 data are from n=5 animals).  The legend for all panels is presented in Panel A. 
 
Figure 7. Hemodynamic and oxygen uptake responses across gastrocnemius muscle of LZR and OZR in 
response to three minutes of 5 Hz muscle contraction.  Data (meanSE) are presented for femoral artery 
blood flow (Panel A), vascular resistance across the gastrocnemius muscle (Panel B), oxygen extraction 
(Panel C), oxygen uptake (VO2) by the muscle (Panel D), normalized O2 conductance across the muscle 
(Panel E) and developed tension by the gastrocnemius (Panel F).  Values are presented under control 
conditions and following treatment of OZR with phentolamine (10 mg/kg), TEMPOL (50 mg/kg), SQ-
29548 (10 mg/kg) or all three substances.  * p<0.05 vs. LZR (n=5 animals); † p<0.05 vs. OZR (n=15 for 
control; n=5 for each treatment group; all oxygen extraction and VO2 data are from n=5 animals).  The 
legend for all panels is presented in Panel B. 
 
Figure 8.  Correlation between O2 conductance (DmO2) and muscle performance in LZR (n=5) and OZR 
(n=5-6) in response to three minutes of muscle contraction at a frequency of 5Hz.  Values are presented 
under control conditions and following treatment of OZR with phentolamine (10 mg/kg), TEMPOL (50 
mg/kg), SQ-29548 (10 mg/kg) or all three substances.  Data are presented for individual animals and the 
equation for the line of best fit is determined using a least squares analysis.  
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Conceptual Framework  
The second chapter is entitled “Divergence Between Arterial Perfusion and Fatigue Resistance in 
Skeletal Muscle in the Metabolic Syndrome”. This chapter takes the vascular impairments that render the 
OZR unable to adequately match perfusion and demand, and give it functional relevance. It utilized the in 
situ blood perfused gastrocnemius preparation and revealed that the increase in the OZR microvasculature 
resistance is multifactorial in nature. There exists an impairment to bulk blood flow and also an inability 
to extract oxygen in the OZR compared to the LZR. These impairments exist at rest as well as at low, 
moderate, and high levels of electrical stimulus. The intervention that proved effective at restoring bulk 
blood flow was phentolamine, an alpha-adrenoreceptor antagonist. The antioxidant TEMPOL or TxA2 
receptor antagonist SQ-29548 proved effective at restoring oxygen uptake. However, none of the three 
interventions alone were effective at restoring tension development in the OZR. It was only when the 
combination of interventions was utilized that a significant improvement in performance was observed. 
The importance of these findings is two-fold. The first is that alteration to structure-function relationships 
via alpha-adrenergic and endothelial dysfunction has the ability to compromise functional hyperemia in 
the OZR. The second is the observation that oxygen extraction and uptake is compromised in the OZR. At 
this age (17 weeks) the OZR has the same activity and similar maximal developed tension and fiber types 
compared to the LZR control. Thus one would expect a significantly higher oxygen extraction with the 
estimated 25% rarefaction and lower blood flow accompanying this age group. This suggests that the 
impairments to OZR skeletal muscle performance are being significantly influenced by alterations to 
erythrocyte perfusion distribution.   
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ABSTRACT 
Previous studies have demonstrated that the metabolic syndrome is associated with impaired skeletal 
muscle arteriolar function, although integrating observations into a conceptual framework for impaired 
perfusion in peripheral vascular disease (PVD) has been limited.  This study builds on previous work to 
evaluate in situ arteriolar hemodynamics in cremaster muscle of obese Zucker rats (OZR) to integrate 
existing knowledge into a greater understanding of impaired skeletal muscle perfusion.  In OZR cremaster 
than in controls.  However, while consistent, the underlying mechanistic contributors were spatially 
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divergent a
microvascular bifurcations, with a steady decay with distance, while endothelial dysfunction was a 
stronger contributor in distal bifurcations with no discernible role proximally.  Using measured values of 
distribution in distal arterioles than in controls; an effect that could only be rectified by combined 
adrenoreceptor blockade and improvements to endothelial dysfunction.  Intravascular 
125
I-albumin tracer 
washout from in situ gastrocnemius muscle of OZR provided independent support for these observations, 
indicating increased perfusion heterogeneity that was corrected only by combined adrenoreceptor 
blockade and improved endothelial function.  These results suggest that a defining element of PVD in the 
heterogeneous and spatially distinct, and that interventions to rectify this negative outcome must take a 
new conceptual framework into account. 
 
Key Words: rodent models of obesity; microcirculation; skeletal muscle blood flow regulation; models of 
peripheral vascular disease; blood flow heterogeneity; vascular dysfunction 
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INTRODUCTION 
 For myriad social, biological and behavioral reasons (14, 26), Western societies and economies 
are experiencing a robust growth in both the incidence and prevalence of obesity, impaired glycemic 
control (both from insulin resistance and the more severe type II diabetes mellitus).  While there are 
multiple venues through which these conditions can impact public health, patient quality of life and 
mortality (13, 26), one of the most common is via an elevated risk for the development of peripheral 
vascular disease (PVD), which can generally be considered as an evolving condition wherein the ability 
of the vasculature to effectively deliver and distribute blood perfusion relative to local metabolic demand 
becomes increasingly compromised.   While the presence of PVD based on structural alterations to larger 
conduit arteries, including atherosclerotic plaques/lesions and other structural abnormalities that intrude 
on the vascular lumen represents a major contributor to the overall prevalence of PVD (1, 9), the presence 
of an array of ‘microvasculopathies’ that are not a function of structural hindrances to perfusion can also 
represent a powerful contributor to a growing PVD under ‘non-atherosclerotic’ conditions (17, 34). 
 In the obese Zucker rat, classically considered as a model of the metabolic syndrome based on 
chronic hyperphagia subsequent to a disruption of leptin signaling at its receptor, we (16, 19) and others 
(40, 41) have demonstrated that basal perfusion and/or functional hyperemia can be compromised through 
adrenergic-based elevations in vascular resistance (19, 35) or increased adrenergic signaling (31), 
alterations to vascular endothelial function that can impact myogenic activation (21) and multiple 
parameters of dilator responses (7, 8, 16, 23, 25, 37). However, an understanding of how this array of 
contributors to an integrated vascular/perfusion-based outcome relevant for skeletal muscle performance 
or fatigue resistance has proven to be an exceptionally difficult process owing to difficulties in translating 
results in isolated tissues/ex vivo preparations to the functioning intact system, the inherent complexity of 
studying multiple processes simultaneously and the challenges of accurately integrating the concepts of 
space (location) and time into system behaviors and outcomes.   
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 In our recent studies, we have provided evidence that the ability of in situ skeletal muscle of OZR 
to resist fatigue under conditions of elevated metabolic demand is partially a function of the inability to 
reduce the aggregate vascular resistance through the microvascular network (which was largely dependent 
on reducing adrenergic constrictor tone) and elevate oxygen extraction and conductance within the distal 
microcirculation (which was predominantly related to elevated vascular oxidant stress and the effects of 
the increased vascular production of thromboxane A2; TxA2) (15, 16).  While alterations to skeletal 
muscle performance with either adrenoreceptor blockade or antioxidant treatment/PGH2/TxA2 receptor 
antagonism were trivial, the combination of these interventions effectively resulted in a maximal 
improvement to perfusion, O2 extraction, O2 conductance (a lumped parameter describing skeletal muscle 
oxygen flux that reflects all of the resistances for O2 in moving from red cell to muscle fiber 
mitochondria; Ref. 38),  resulting in significant improvements to muscle oxygen uptake (VO2) and 
contractile performance.  These observations, which help to identify the specific role of microvascular 
dysfunction in limiting VO2 and muscle performance at low, moderate and near maximal metabolic 
demand, are especially intriguing given the results from previous studies which suggested that one of the 
defining characteristics of PVD and a poor perfusion outcome in OZR is an increasingly heterogeneous 
blood flow distribution at microvascular bifurcations within skeletal muscle (16).  While that study 
provided an initial insight revealing the presence of increased perfusion heterogeneity at bifurcations, 
those results focused on only the distal microcirculation and provided no insight into either the presence 
of perfusion heterogeneity at different levels of the microcirculation or how contributing elements to this 
effect might vary with longitudinal position within the networks (16).  In addition, those previous data 
provided no information regarding the functional outcomes or implications that result from the increased 
perfusion heterogeneity.    
 The primary purpose of the present study was to interrogate the presence of the increased 
perfusion heterogeneity at four distinct levels of the skeletal muscle microcirculation of OZR, to 
determine the physiological mechanistic contributors to this process (and if they vary with position within 
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the microcirculation), and to predict the functional implications of this process for perfusion patterns 
within the distal levels of the microcirculation.  A secondary purpose of the present study was to utilize 
indicator dilution analyses in intact skeletal muscle to determine the presence and impact of increased 
microvascular perfusion heterogeneity in skeletal muscle of OZR and the role of the physiological 
mechanisms determined at the higher level of resolution (individual bifurcations) in contributing to these 
outcomes.  Specifically, these studies tested the hypothesis that the presence of increased heterogeneity of 
perfusion distribution at successive bifurcations within the skeletal muscle microcirculation results in 
severe impairments to distal arteriolar blood flow distribution, and is a major contributor to the impaired 
muscle performance outcomes that have been previously demonstrated in OZR (15, 20).   
MATERIALS AND METHODS 
Animals:  Male lean (total n=26) and obese Zucker rats (total n=102), purchased from Harlan, were fed 
standard chow and drinking water ad libitum and were housed in the animal care facility at the West Virginia 
University Health Sciences Center or the Medical College of Wisconsin.  All protocols received prior IACUC 
approval.  At ~17 weeks of age, rats were anesthetized with injections of sodium pentobarbital (50 mg/kg, 
i.p.), and received tracheal intubation to facilitate maintenance of a patent airway.  In all rats, a carotid artery 
and an external jugular vein were cannulated for determination of arterial pressure and for infusion of 
supplemental anesthetic and pharmacological agents, as necessary.  Any animal in which mean arterial 
pressure was found to be below 85 mmHg, or where MAP had decreased by more than 15% from that 
following equilibration (without any pharmacological intervention) was not used in the present study.  Blood 
samples were drawn from the venous cannula for determination of glucose and insulin concentrations 
(Millipore, Billerica, MA) as well as cholesterol/triglyceride levels (Wako Diagnostics, Richmond, VA), and 
nitrotyrosine (Oxis International. Foster City, CA).  Unless otherwise noted, all drugs and chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
  
87 
Preparation of In Situ Cremaster Muscle:  In each rat (LZR n=16; OZR n=74), an in situ cremaster 
muscle was prepared for study using intravital microscopy as described previously (16).  After 
completion of the in situ cremaster muscle preparation, the tissue was continuously superfused with 
physiological salt solution (PSS) equilibrated with a 5% CO2-95% N2 gas mixture, and maintained at 
35C as it flowed over the muscle.  Volume flow rate was ~3.0 ml/min.  The ionic composition of the 
PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 1.18, MgSO4 1.17, NaHCO3 24.0, 
and disodium EDTA 0.03. Arteriolar diameters were measured with a video-micrometer.   Following a 30 
minute period of equilibration following the surgical preparation, arterioles and bifurcations within five 
distinct di
- -3A), 3) ~60 
- -5A).  
Arterioles/bifurcations were selected based on the following criteria: 1) distance from any site of incision, 
2) presence of significant vascular tone (assessed by brisk dilator response to challenge with 10
-3
 M 
adenosine), 3) clearly discernible walls, 4) a rapid and stable level of erythrocyte perfusion, and 5) the 
presence of two clearly defined ‘daughter’ branches that also met criteria 1-4.  Please see Figure 1 for a 
schematic representation of these concepts. 
 The mechanical (using on-screen videomicroscopy) and perfusion (using optical Doppler 
velocimetry) responses of both the ‘parent’ and ‘daughter’ arterioles within a bifurcation class were 
assessed under resting conditions within the cremaster muscle of each rat.  All procedures were performed 
under control conditions in LZR and OZR, and following treatment of the in situ cremaster muscle with 
the anti-oxidant TEMPOL (10
-3
 M), the TxA2 receptor antagonist SQ-29548 (10
-4
 M), the nitric oxide 
synthase inhibitor L-NAME (10
-4
1 2 adrenergic receptor antagonist phentolamine (10
-5
 
M); within the superfusate solution.  All treatments to the cremaster were of a minimum of 40 minutes 
duration prior to any subsequent experimental manipulation. 
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Interrogation of Arteriolar Bifurcations:  Within each animal, the numbers of bifurcations of each order 
that were studied differed depending on longitudinal position in the arteriolar network.  Bifurcations 
spanning 1A-2A arterioles averaged 1-2/animal, while bifurcations spanning 3A-4A and 4A-5A arterioles 
averaged between 3-4/animal.  For an individual measurement, arteriolar diameter and erythrocyte 
velocity were sampled for 10 seconds. All arterioles and bifurcations were selected on the basis of the 
criteria outlined above and were placed into their categories by size rather than by strict branch number.  
This was done as our experience demonstrated that branch order classification limited data collection as 
frequently not all inclusion criteria could be satisfied.   
No cremaster muscle was exposed to all interventions as this would have compromised data 
quality owing to experiments of excessive duration.  In addition to the collection of responses under 
control conditions, individual cremaster preparations were exposed to a maximum of three interventions, 
each separated by ~30 minutes of washout.  Treatment or washout effectiveness was verified by 
determining abolition or recovery of mechanical responses following challenge with appropriate agonists 
1 adrenergic antagonist phenylephrine, the stable TxA2 mimetic U-46619, and the endothelium 
dependent dilator agonist acetylcholine).  Maximum experimental duration from preparation to 
termination was approximately five hours, after which time all animals were humanely euthanized by an 
intravenous overdose of anesthetic followed by a bilateral pneumothoracotomy.   
the proportion in the daughter arteriole with the higher perfusion.  Within an individual arteriolar 
bifurcation, the maximum disparity between parent arteriole blood flow and the summated daughter 
arteriolar perfusion did not exceed 15%.  If this error was consistent in terms of magnitude and direction, 
this could lead to a biased outcome on the distal arteriolar perfusion distributions.  However, there is no a 
priori reason to believe that this would be a consistent error in terms of artificially increasing or 
decreasing Q determination, and it is more likely that measurement errors would be randomly distributed.  
To the extent possible, all measurements within an experiment were taken at the same arteriolar 
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bifurcation sites within a specific animal.  However, this was not possible in every animal, owing to 
alterations to visibility that can develop with time and interventions in this experimental preparation.     
Preparation of In Situ Blood Perfused Hindlimb: In a separate set of age-matched LZR (n=10) and OZR 
(n=28), the left hindlimb of each animal was isolated in situ (20) with minor modifications.  Heparin (500 
IU/kg) was infused via the jugular vein to prevent blood coagulation.  Subsequently, an angiocatheter was 
inserted into the femoral artery, proximal to the origin of the gastrocnemius muscle to allow for bolus tracer 
injection.  Additionally, a small shunt was placed in the femoral vein draining the gastrocnemius muscle that 
allowed for diversion of flow into a port which facilitated sampling of the venous effluent.  Finally, a 
microcirculation flow probe (Transonic; 0.5/0.7 PS) was placed on the femoral artery to monitor muscle 
perfusion.  In indi 1 2 adrenoreceptor 
antagonist phentolamine (10 mg/kg), TEMPOL (50 mg/kg) and/or SQ-29548 (10 mg/kg).  Effectiveness of 
these interventions was assessed by monitoring the changes in arterial pressure in response to intravenous 
-
16).  
 Upon completion of the surgical preparation, the gastrocnemius muscle was allowed 30 minutes of 
self-perfused re
125
I- -Elmer, Shelton, CT) was injected as a 
spike bolus (injection time <0.5 s) into the arterial angiocatheter and venous effluent samples were collected 
at a rate of 1/s for the subsequent 35 seconds. Venous effluent samples were then immediately transferred 
into silicate tubes and placed into a gamma counter for activity determination.  Each rat received an 
intravenous infusion of homologous donor erythrocytes suspended in PSS at the individual animal’s 
hematocrit (~45%) to replace the lost volume, and this was allowed a minimum of 20 minutes for circulation 
prior to subsequent intervention.  In order to assess the potential for leakage of the labeled albumin from 
the intravascular space as a source for error, the gastrocnemius muscle was cleared by perfusion with 
physiological salt solution following euthanasia.  Subsequent to a determination of mass, the muscle was 
placed in the counter for determination of residual activity.  Residual activity within the gastrocnemius 
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muscle did not exceed 200 cpm/animal; a level that was far lower than those determined in the venous 
blood aliquots.  All protocols had received prior approval from the Radiation Safety Office at the WVU 
Health Science Center.   
Data and Statistical Analyses:  Arteriolar perfusion in both parent and daughter vessels within in situ 
cremaster muscle of LZR and OZR was calculated as: 
    (       )(   )(     )     Equation 1 
where, Q represents arteriolar perfusion (nl•s-1), V represents the measured red cell velocity from the 
optical Doppler velocimeter (mm•s-1; with V/1.6 representing an estimated average velocity; Ref. 11), and 
 perfusion in the daughters was determined as 
the sum of the individual perfusion rates, and the proportion of flow within each was determined as the 
in the daughter vessel to the total flow in the parent vessel.  As an example, if flow distribution was 
proportion of flow in one daughter arteriole was 60%, for that bifurcation would be 0.6, with flow distribution 
being 0.6 in the ‘high perfusion’ arteriole and 0.4 in the ‘low perfusion’ arteriole (5).  Please see Figure 1 for 
additional clarification. 
 erfusion distribution 
cremaster muscle were inserted into a simulation of a dichotomous branching network with each outflow 
(daughter) arteriole arising -
perfusion.  These respective values of daughter arteriolar perfusion then become in the inflow perfusion 
(parent) values for the next generation bifurcation.  The process was repeated over a total of eight 
bifurcations, resulting in 2
8
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the 1A-2A, the 2A- -
generations, and three 4A-  
 For the 
125
I-albumin washout, four standard parameters describing characteristics of tracer 
washout curves, including mean transit time ( t ), relative dispersion (RD), skewness ( 1 ), and kurtosis     
( 2 ), were computed as functions of the transport function h(t) (6). The tail of tracer washout curves are 
extrapolated in the form of single exponential time course to allow for computing the four parameters by 
the integration for sufficiently long time for Equation 3 to converge (24). In this study, experimentally-
measured time courses are extrapolated to 100 seconds, at which C(t) is estimated to be less than 10
-9
 of 
the maximum washout tracer activity.  The transport function h(t) is estimated from 
0
h( ) C( ) C( )t t t dt

        Equation 2 
where C(t) is the time course of activity of intravascular tracer in outlet flow exiting the collecting tube.  
The mean transit time t  is calculated from experimentally measured washout curves according to: 
0
h( )t t t dt

        Equation 3 
The RD of h(t) is a measure of the relative temporal spread of h(t) and computed as the ratio of standard 
deviation of h(t) to the mean transit time from: 
 
1/ 2
2
0
h( )d /RD t t t t t
 
   
 
     Equation 4 
The skewness ( 1 ) is a measure of asymmetry of h(t) and computed from: 
   
3/ 2
3 2
1
0 0
h( )d h( )dt t t t t t t t
  
     
 
    Equation 5 
Skewness is a measure of the asymmetry of the perfusion distribution.  In other words, it is a measure of 
the extent to which the perfusion distribution is skewed (as opposed to simply being shifted) to higher or 
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lower values of perfusion.  The kurtosis ( 2 ) is a measure of deviation of h(t) from a normal distribution 
and computed from: 
   
4 / 2
4 2
2
0 0
h( )d h( )d 3t t t t t t t t
  
      
 
   . Equation 6 
Kurtosis is a measure of the “sharpness of the peak” of the perfusion distribution. The familiar Gaussian 
bell- 2 2 indicate a sharper peak than a Gaussian.  The four 
parameters are estimated based on the above equations for each animal in each experimental group.  
 All data throughout the manuscript are presented as mean±SE.   Statistically significant differences in 
measured and calculated parameters were determined using a one sample t-test (differences from zero), 
Student’s t-test or analysis of variance (ANOVA) with Student-Newman-Keuls post-hoc test used as needed.  
Analyses of the simulation results for distal arteriolar perfusion distribution (Figure 6) utilized descriptive 
statistics (variance, skewness, kurtosis, range, maximum, minimum, quartiles (25%, 50% and 75%) and the 
75-25% interquartile difference).  Statistically significant differences between the frequency distributions for 
the simulations were evaluated using the Kruskal-Wallis test, although because indices of central tendency 
were not different between groups (due to the normalization procedures), multiple post-hoc comparisons 
were not possible.  In all cases, p<0.05 was taken to reflect statistical significance.   
RESULTS 
 Baseline characteristics describing the animals used in the present study are summarized in Table 
1.  At ~17 weeks of age, male OZR were significantly heavier than LZR and, in addition to a moderate 
hypertension, hypercholesterolemia and hyperglycemia, also exhibited a severe elevation in plasma levels 
of insulin, triglycerides and nitrotyrosine.  Data describing the perfusion characteristics of the individual 
cremasteric arteriolar segments (described above) under the experimental conditions of the present study 
are summarized in Table 2.  These data clearly demonstrate general differences between arteriolar 
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diameter and perfusion characteristics that are distributed longitudinally throughout the cremasteric 
microcirculation under the conditions of the present study.   
 Figure 2 presents the magnitude of the perfusion distribution coefficie
control conditions and in response to the interventions employed in the present study (Panel A) and the 
extent to which specific interventi
Specifically, the ordinate in Figure 2B is defined as:  
 
* *Recovery(%) 1 100% 100%OZR LZR OZR OZR
OZR LZR OZR LZR
   
   
 
    
       
    
  Equation 7 
where *OZR   represents one of the treatments indicated.  Full (100%) recovery indicates that the 
 
 In these proximal resistance arterioles,  was significantly elevated in OZR as compared to LZR, 
although this was restored by treatment of the cremaster muscle with the adrenoreceptor antagonist 
phentolamine (either alone or in combination with any other agent).  In contrast, treatment with 
TEMPOL, SQ-29548, or L-NAME, either alone or in any combination was without effect in terms of 
restoring the normal magnitude of  unless phentolamine was also present.   
 The magnitude of  (Panel A), and its recovery following intervention (Panel B), in arteriolar 
bifurcations spanning 2A (80 m) parent to 3A (60 m) daughter arterioles in cremaster muscle of LZR 
and OZR are summarized in Figure 3.  In contrast to the data presented in Figure 2, the ability of 
phentolamine to restore normal levels of  in OZR at this level of the cremasteric microcirculation, while 
still statistically significant, was blunted as compared to responses at the more proximal bifurcation.  
Neither TEMPOL nor SQ-
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microcirculation when applied individually.  Further, when either TEMPOL or SQ-29548 was co-
administered with phentolamine, these restorative effects appeared to be partially additive, as the 
-
mpacted by 
amelioration of vascular oxidant stress by co-administration with TEMPOL.   
 
s in cremaster muscle of LZR 
and OZR are presented in Figures 4 and 5 respectively.  At these levels of the cremasteric 
OZR to the levels determined in LZR.  However, improvements to endothelial function from TEMPOL 
and SQ-
microcirculation at these positions within the networks.  As with the data presented above, we were 
unable to determine an apparent role for nitric oxide bioavailability in terms of regulating  in the 
cremasteric microcirculation of OZR. 
 Using the data presented above for  distribution at the different levels of the cremasteric 
microcirculation of LZR and OZR under the employed experimental interventions, Figure 6 presents the 
predicted outcomes on perfusion distribution within the terminal arterioles, and Table 3 summarizes the 
results of the statistical analyses of the distribution outcomes presented in Figure 6.  These predictions are 
based on a dichotomous branching network of eight bifurcations between the major perfusing arteriole 
and the terminal arterioles, resulting in a total of 256 terminal arterioles.  These data clearly predict that 
the shifts in  identified through direct examination of the cremaster muscle result in profound alterations 
in the outcomes for distal arteriolar perfusion distribution.  While the distribution for volume flow in any 
single arteriole, relative to the mean flow across all 256 arterioles, was relatively tight in LZR as 
compared to OZR (Figure 6, Panel A versus Panel B), demonstrating much lower degrees of variability, 
skewness and kurtosis, with a much lower inter-quartile difference (Table 3), treatment with the 
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individual interventions of phentolamine, TEMPOL and SQ-29548 (Figure 6, Panels C-E, respectively) 
all results in moderate improvements to the variability, skewness, kurtosis and interquartile difference of 
the distributions (Table 3).  However, the greatest magnitude of improvement was identified under 
conditions of adrenoreceptor blockade combined with either TEMPOL or SQ-29548 (or both).  These 
perfusion outcome predictions and statistical analyses also suggest that vascular nitric oxide 
bioavailability, either under control conditions in OZR skeletal muscle at rest or following reductions to 
vascular oxidant stress that have been repeatedly demonstrated to increase NO bioavailability, may not 
 
 Figure 7 presents the mean tracer washout curves for 
125
I-albumin from the isolated 
gastrocnemius muscle of LZR and OZR following the pharmacological treatments described above.  
Figure 8 summarizes data describing the aggregate washout curves.  Mean transit time of the tracer across 
the gastrocnemius was very similar across all groups, suggesting that the relationship between bulk blood 
flow to the gastrocnemius muscle and vascular volume under the experimental conditions of the present 
study were very similar across groups (Panel A).  The relative dispersion of tracer across the muscle (RD; 
Panel B) was significantly elevated in OZR as compared to LZR under control conditions, indicative of 
an increased perfusion heterogeneity throughout the microcirculation of the gastrocnemius muscle.  
Treatment of OZR with phentolamine (with or without TEMPOL or SQ-29548) significantly improved 
RD, although treatment with TEMPOL and/or SQ-29548 in the absence of the adrenoreceptor blockade 
was generally less effective.  Both the skewness (Panel C) and the kurtosis (Panel D) of the tracer 
washout curves were reduced in OZR as compared to LZR, and these shifts in the washout patterns were 
improved toward the level in LZR as a result of the experimental interventions, with the greatest impact 
being determined in response to combined treatment with phentolamine and TEMPOL/SQ-29548.  Based 
on the data presented in Figures 2-6, this final group of experiments and analyses did not involve direct 
manipulations to vascular nitric oxide bioavailability. 
DISCUSSION 
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 A recent study has demonstrated that the increased rate of skeletal muscle fatigue in OZR, 
defined as the percent decline in developed tension over the duration of the imposed bout of contraction, 
is not necessarily improved subsequent to an improved functional hyperemic response (15).  However, 
one of the central observations of that study was that the vascular dysfunction in the skeletal muscle 
microcirculation of OZR impacted muscle performance outcomes through two distinct patterns, such that 
impairments within the proximal microcirculation restricted volume perfusion and responses in the distal 
microcirculation impaired normal patterns of perfusion:demand matching.  Further, that study also 
implicated the possibility that the physiological and cellular mechanisms underlying the vascular 
dysfunction within the skeletal muscle microcirculation may be spatially distinct, with alterations to 
adrenergic constraint on perfusion dominating with regard to the regulation of bulk perfusion, and the 
endothelial dysfunction playing a stronger role in terms of the higher resolution matching of blood flow 
distribution to metabolic demand (15).   When taken into account with our previous studies demonstrating 
the potential for increased perfusion heterogeneity at microvascular bifurcations as a defining 
characteristic of the metabolic syndrome in skeletal muscle of OZR (16), a greater understanding of the 
impact of the metabolic syndrome on integrated microvascular function represented a critical need.  As 
such, the present studies were designed to determine whether the initial observation of perfusion 
heterogeneity at arteriolar bifurcations is present throughout microvascular networks, what the 
contributing mechanisms to this effect are, if they are spatially distinct, and what the functional outcomes 
of the successive perfusion distribution events would be for blood flow at the level of the terminal 
arterioles. 
 The foremost observation from the present study was that the increased heterogeneity at 
microvascular bifurcations within skeletal muscle () of OZR was identified over four distinct bifurcation 
classes spanning five arteriolar diameter ranges.  While at bifurcations in LZR tended to be slightly 
lower than 0.54 across all levels of arteriolar/bifurcation ranges, this value was elevated toward 0.60 in 
OZR.  The axis limits on the ordinates in Figures 2-
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While on the absolute scale the observed differences in  are relatively small, these differences are 
significant statistically and their cumulative effects translate into physiologically significant differences in 
function.  The consistency of the elevated within the microcirculation of OZR afflicted with the 
metabolic syndrome suggests that this increased heterogeneity of perfusion at bifurcations may represent 
a defining characteristic of PVD in this animal model.  This observation suggests that, as blood flow 
enters into the microvascular networks of the skeletal muscle of OZR, there is an increased heterogeneity 
of distribution at bifurcations involving the larger resistance arterioles, where the result is the generation 
of ‘high flow’ and ‘low flow’ daughter arterioles arising at this bifurcation.  Essentially, this represents a 
source for increased variability as compared to perfusion distribution in LZR, and through a repetitive 
iteration at successive bifurcations will result in a striking increase to the heterogeneity of arteriolar 
perfusion within the distal microcirculation; predicted in Figure 6.   
 Our recent study that initially identified the presence of an altered  in the skeletal muscle 
microcirculation of OZR suggested that this effect was a function of combined alterations to adrenergic 
tone and the evolving endothelial dysfunction in the metabolic syndrome, as acute interventions against 
these negative outcomes changed  to levels that were similar to those determined in LZR (16).  While the 
microvascular network within OZR skeletal muscle, data from these experiments also demonstrated a 
significant heterogeneity in terms of the physiological/cellular mechanisms which contribute to the 
arterioles, the alteration 
microvessel, as treatment with the adrenoreceptor antagonist almost completely removed the change in 
 in the present results was that 
acute interventions designed to ameliorate microvascular dysfunction, the antioxidant TEMPOL and the 
PGH2/TxA2 receptor antagonist SQ-
arteriolar bifurcatio
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adrenoreceptor blockade was also evident.  This relationship gradually changed with longitudinal position 
in the microvascular networks, such that in smaller diameter bifurcations (2A-3A and 3A-4A), the impact 
TEMPOL and SQ-
to the most distal levels of the microcirculation (4A-5A), where adrenoreceptor blockade was entirely 
support our previous initial observations, combined treatment with an adrenoreceptor antagonist and 
either an antioxidant or the PGH2/TxA2 
throughout the microvascular network.   With the incorporation of the results from the present study, the 
amelioration of different contributing mechanisms of dysfunction, while varying in proportion across 
levels of the microcirculation, suggests that a multi-faceted approach against the microvasculopathy in 
OZR is required to significantly improve integrated perfusion outcomes.  
 One of the more intriguing results of the present study is the lack of demonstrated evidence for a 
treatment of OZR with L- networks in that strain was 
not surprising, as multiple previous studies have demonstrated that vascular NO bioavailability is 
dramatically reduced in OZR at this age and treatment and that further antagonism of nitric oxide 
synthase (NOS) is without effect (18).  However, as previous studies have demonstrated that antioxidant 
treatment with TEMPOL and L- elling 
in OZR.  The current study employed pharmacological interventions targeted at determining the role of 
NO bioavailability (L-NAME and TEMPOL) treatments.  As such, this study does not rule out the 
possibility that NO in other ‘stored’ forms, such as nitrosothiols could contribute, as any roles for these 
sources for NO were not directly interrogated. 
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 While there is considerable ongoing effort to identify the molecular signaling cascades that 
underlying specific identified sites of vascular dysfunction in the metabolic syndrome (2, 29, 30, 32), 
these efforts can suffer from a lack of contextual relevance as it becomes exceptionally difficult to 
integrate these myriad observations from highly reduced preparations into either a functioning tissue type 
(e.g., vascular smooth muscle cell, isolated microvessel) or into an integrated system (e.g., blood perfused 
skeletal muscle).  The present study incorp
tissue perfusion distribution at in the distal microcirculation.  Using a dichotomous branching network of 
re able to predict 
the perfusion distribution in a network consisting of 256 terminal arterioles (5A).   In these initial 
simulations, the resulting frequency distributions reveal that distal arteriolar perfusion in OZR was 
substantially more heterogeneous than in LZR, with a distribution characterized by an increased inter-
quartile difference that reflects the genesis of a large number of ischemic pathways and a small number of 
very high flow pathways that may represent functional thoroughfares.   While adrenoreceptor blockade 
and improving endothelial dysfunction with TEMPOL or SQ-29548 each resulted in some improvement 
to the perfusion distribution characteristics in the distal microcirculation, only combined interventions 
with both phentolamine and TEMPOL/SQ-29548 allowed for a maximal improvement (i.e., recovery) in 
the frequency distribution and its descriptive characteristics (Table 3) toward levels predicted in LZR.  
Obviously, distal arteriolar perfusion distribution within the skeletal muscle will be neither discrete nor 
clustered, and this is an artifact of the simulation employed. However, our simulation does illustrate both 
a real broadening of the distribution with the presence of PVD in OZR, and the capacity for ameliorating 
these negative outcomes with appropriately targeted interventions. 
 
microvascular bifurcations in resting muscle, they may provide a partial explanation for the results from 
our recent study that evaluated the fatigue resistance of in situ skeletal muscle of OZR across levels of 
elevated metabolic demand (15).  In that study, while the gastrocnemius muscle fatigue rate was elevated 
in OZR as compared to that in LZR, single pharmacological interventions were of extremely limited 
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effectiveness in improving the ultimate functional outcome of increased muscle performance.  While 
adrenoreceptor blockade with phentolamine improved bulk perfusion and active hyperemia, 
improvements to muscle oxygen extraction, uptake (VO2) and oxygen conductance (DmO2) were 
minimal.  Further, improving endothelial function with TEMPOL or SQ-29548 tended to improve 
extraction, VO2 and DmO2, although minimal impacts on bulk perfusion and muscle performance were 
identified.  A significant improvement in muscle fatigue resistance was identified only when combined 
interventions with phentolamine and TEMPOL/SQ-29548 were applied, and this was also associated with 
the improvements to bulk perfusion, O2 extraction, VO2 and DmO2 (15, please see ref. 37 for full review).  
When combined with the results of the present study, these data strongly suggest that the multi-faceted 
approach to reducing proximal resistance to bulk perfusion in combination with improving distal 
microvascular perfusion:demand matching represent a requisite condition to lessen the impact of PVD on 
muscle performance outcomes. 
 One of the main considerations that must be addressed in the present study is that of the level of 
resolution for the data.  The in situ cremaster muscle preparation allows for very high resolution 
measurements of multiple arterioles throughout the tissue for both their mechanical (dimension) and 
hemodynamic (RBC flux, volume blood flow) status.  However, this preparation does not lend itself well 
to the integrated study of the entire network at one time.  We have employed the in situ gastrocnemius 
muscle preparation for the integrated assessment of network function using tracer washout kinetics, as the 
anatomy and the range of blood flow volumes to the muscle allow for an effective tracer washout protocol 
physiological mechanistic contributors and its distribution with the results in the in situ gastrocnemius 
muscle in our previous study is compelling, the intravascular washout experiments summarized in Figures 
8 and 9 provide independent data that reflect the flow distributions throughout the gastrocnemius muscle 
circulation.  Since the washout of 
125
I-albumin (which is confined to the intravascular space) introduced 
into the femoral artery immediately proximal to the gastrocnemius muscle reflects the whole-network 
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flow distribution, any potential for a selection bias is eliminated.  As presented in Figures 7 and 8, striking 
differences in the washout kinetics were determined between LZR and OZR under the conditions of the 
present study.  In general, OZR manifested an earlier appearance time of tracer than in LZR as well as a 
longer retention in the microcirculation.  Speculatively, this change could reflect the combined influence 
of both the ‘high flow’ and ‘low flow’ pathways that are demonstrated at bifurcations, and is consistent 
with the frequency distributions of predicted distal arteriolar perfusion summarized in Figure 6.  While 
treatment of OZR with phentolamine, TEMPOL or SQ-29548 all exhibited the ability to partially restore 
the washout kinetics to levels determined in LZR, combined therapy, which would result in an improved 
ls of the networks, resulted in the greatest restoration of the 
tracer washout kinetics.  One particularly intriguing element of the present study was also revealed 
through the use of the tracer washout approach.  Given that the mean transit times for tracer washout was 
at least 15 seconds under all conditions, despite arteriolar perfusion velocities that would suggest a more 
rapid tracer appearance, this suggests that a significant dispersion of the tracer may have also occurred 
across the capillary beds and within the post-capillary venular networks.  While alterations to venular 
function have been unexplored in this model, interrogating how alterations to venular reactivity and 
hemodynamics can impact perfusion responses may represent an exciting area for future investigation.  
The reader is directed to our computational modeling manuscript (39), where these tracer washout 
kinetics are analyzed using a computational model for microvascular perfusion distributions in OZR 
versus LZR skeletal muscle, revealing additional insights into network flow distributions associated with 
these washout data. 
a substantially increased heterogeneity in blood flow distribution within the distal microcirculation of the 
skeletal muscle of OZR, is strikingly relevant to the concept of the ‘network Fahraeus effect’ described by 
Pries et al. in the late 1980s (33).   As a brief summary, the non-uniform distribution of perfusion at 
successive bifurcations within a microvascular network, contributes to a reduction in the mean 
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microvascular hematocrit (HMV) measured within the distal microcirculation and capillaries (12, 28).  This 
process is distinct from the classically described ‘vessel Fahraeus effect’, wherein the differential mean 
velocities of plasma and erythrocytes within individual microvessels causes a reduction in the 
instantaneous ‘tube’ hematocrit within a microvessel (4, 27).  However, the combined influence of the 
normal contributing mechanisms to hematocrit reduction within the microcirculation and the effects of an 
MV within 
OZR versus LZR that could contribute to the impaired muscle fatigue resistance demonstrated in our 
previous studies (15, 20).  It is important to state that the results from present study do not account for the 
effects of plasma skimming at bifurcations, inherent within the network Fahraeus effect (33), on our 
measurements of arteriolar blood flow and that this process may have impacted the washout kinetics of 
125
I-albumin in an uncontrolled fashion (as this is an intravascular tracer).  Bearing this in mind, further 
studies will be required to interrogate the speculative argument outlined above as well as the potential 
impact of targeted interventions in improving HMV in OZR.   
In keeping with this concept, the results from a several earlier studies resulted in a competing 
argument regarding the degree of heterogeneity in capillary perfusion.  While results from Tyml’s group 
suggested that capillary perfusion heterogeneity was reduced with elevated metabolic demand and the 
inherent vasodilation, suggesting a significant, yet unidentified, control mechanism (36), results from 
Duling’s group did not support this concept, suggesting that capillary perfusion heterogeneity was not a 
controlled variable in skeletal muscle (10).   The results of the present study may be conservatively 
interpreted as supporting the former argument, where treatment with phentolamine in OZR increased flow 
and narrowed the perfusion frequency distribution (Table 3).  Further, as an improvement to endothelial 
function in OZR following treatment with TEMPOL and/or SQ-29548 also decreased perfusion 
heterogeneity, this also suggests that the normal vascular and endothelial function may contribute to the 
regulation of capillary perfusion heterogeneity.  However, as these previous studies (10, 36) utilized a 
metabolic stimulus as the primary intervention where the current study was conducted in resting muscle, 
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additional experiments must be performed to provide for a stronger argument regarding the degree of 
control over capillary perfusion heterogeneity.  
 The results of the present study provide for a new conceptual framework with regard to the study 
of PVD in the metabolic syndrome.  Foremost, these results highlight the critical importance of 
integration across levels of resolution in efforts to interrogate complex disease states.  While previous 
work has identified multiple signaling pathways and elements that may contribute to specific indices of 
vascular dysfunction (2, 29, 30, 32), there has been a limited effort to determine how these actually 
impact perfusion responses in specific vessels (16, 41) and almost no study of how these integrate to 
produce an impaired perfusion response across an entire network. A description of network flow 
generation, can help to reveal specific mechanistic contributors to PVD, including alterations to 
adrenergic constriction, vascular oxidant stress and increased actions of TxA2.   This new conceptual 
framework is strongly predictive of the most translationally relevant outcomes associated with 
amelioration of PVD, and will be useful in designing and interpreting future studies of PVD in the 
metabolic syndrome.   
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Table 1.  Baseline characteristics of ~17 week-old LZR and OZR used in the present study.  * p<0.05 
versus LZR.  Data are presented as mean±SE. 
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 LZR (n=26) OZR (n=102) 
Mass (g) 3668 68411* 
MAP (mmHg) 101±5 124±6* 
[Glucose]plasma (mg/dl) 111±10 184±14* 
[Insulin]plasma (ng/ml) 2.0±0.4 9.4±1.1* 
[Cholesterol]plasma (mg/dl) 78±9 138±12* 
[Triglycerides]plasma (mg/dl) 84±11 348±19* 
[Nitrotyrosine]plasma (ng/ml) 14±4 48±8* 
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Table 2.  ity (VRBC; 
mm/s), and volume perfusion within the arteriole (Q; nl/s).  * p<0.05 versus LZR; † p<0.05 versus OZR.  Data are presented as mean±SE; -P 
represents treatment with phentolamine, -T represents treatment with TEMPOL, -SQ represents treatment with SQ-29548, -LN represents 
treatment with L-NAME; with combinations representing treatment with multiple agents. 
 
  LZR OZR O-P O-T O-SQ O-LN O-PT O-PSQ O-PLN O-TLN O-TSQ O-PTSQ 
 ID 94±4 85±6 92±3 87±6 88±5 84±6 93±3 93±4 90±4 86±3 86±4 93±3 
1A VRBC 56±5 46±6 48±5 45±6 49±7 38±6* 52±6 53±5 46±5 48±5 48±4 53±5 
 Q 245±14 165±20* 200±15 169±14* 186±9* 134±15* 219±6† 224±14† 183±13* 175±13* 176±14* 227±17† 
 ID 75±4 66±5 72±3 69±6 68±6 64±5 73±4 74±4 71±5 67±6 69±5 74±4 
2A VRBC 40±6 35±5 40±5 36±6 36±5 32±4 39±5 39±4 36±6 37±5 38±6 40±4 
 Q 112±10 74±12* 100±9 84±9* 82±5* 65±6* 102±5 105±8 89±9 82±11* 89±12 108±6† 
 ID 53±4 48±7 50±5 53±6 53±5 47±6 52±5 53±5 48±5 52±5 53±6 53±5 
3A VRBC 20±4 14±3 17±4 14±3 14±3 12±3 18±3 18±4 15±4 12±3 14±4 20±2 
 Q 28±4 16±4* 21±3 19±4 19±3 13±3* 24±5 25±5 17±3 16±3 19±4 28±4* 
 ID 36±4 30±3 31±3 33±5 32±4 28±3 34±5 34±4 29±4 32±5 35±4 35±3 
4A VRBC 12±3 8±2 12±3 9±2 10±3 8±2 11±2 12±2 8±2 9±2 9±2 12±2 
 Q 7.8±1.9 3.7±1.5 5.5±1.7 4.7±1.1 4.8±1.3 3.1±0.8* 6.1±1.6 6.6±1.3 3.5±0.9 4.3±1.2 5.5±1.4 7.2±1.6 
 ID 21±3 18±3 18±2 20±3 19±3 18±3 19±2 20±3 18±2 19±3 19±2 20±2 
5A VRBC 7±1 4±1 5±2 4±1 4±1 3±1 6±2 7±2 5±2 5±2 5±1 7±1 
 Q 1.5±0.3 0.7±0.2* 0.8±0.2 0.8±0.2 0.7±0.2* 0.5±0.2* 1.1±0.3 1.3±0.2 0.8±0.2 0.8±0.2 0.8±0.3 1.4±0.3 
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Table 3.  Statistical analysis of the individual frequency distributions of predicted distal arteriolar perfusion heterogeneity presented in Figure 6.  
Data are presented for variance, skewness, kurtosis and ranges of the individual distributions, as well as the quartiles and the inter-quartile 
difference (IQ Diff.).  Results from the Kruskal-Wallis test indicated that there are significant differences across the different distributions 
(p<0.001). -P represents treatment with phentolamine, -T represents treatment with TEMPOL, -SQ represents treatment with SQ-29548, -LN 
represents treatment with L-NAME; with combinations representing treatment with multiple agents. 
 
 
 
 
 LZR OZR O-P O-T O-
SQ 
O-
LN 
O-
PT 
O-
PSQ 
O-
PLN 
O-
TLN 
O-
TSQ 
O-
PTSQ 
Variance 0.015 0.384 0.195 0.086 0.106 0.298 0.026 0.024 0.204 0.070 0.070 0.013 
Skewness 0.319 1.678 1.131 0.673 0.744 1.470 0.422 0.407 1.175 0.631 0.555 0.302 
Kurtosis -
0.083 
4.193 1.625 0.171 0.311 3.168 0.033 0.009 1.829 0.184 
-
0.183 
-0.104 
Range 0.690 4.210 2.590 1.525 1.705 3.590 0.918 0.888 2.716 1.427 1.280 0.653 
Minimum 0.706 0.166 0.291 0.469 0.430 0.206 0.632 .6418 0.278 0.495 0.526 0.722 
Maximum 1.397 4.376 2.881 1.994 2.135 3.795 1.551 1.530 2.994 1.921 1.806 1.375 
Percentiles 25 0.914 0.571 0.687 0.783 0.755 0.617 0.878 0.895 0.697 0.800 0.795 0.918 
50 0.994 0.853 0.916 0.967 0.959 0.883 0.990 0.991 0.912 0.975 0.975 0.996 
75 1.081 1.275 1.223 1.194 1.216 1.263 1.117 1.098 1.194 1.187 1.195 1.082 
IQ Diff.  (75-25) 0.167 0.704 0.536 0.411 0.461 0.646 0.239 0.203 0.497 0.387 0.400 0.164 
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FIGURE LEGENDS 
Figure 1.  Schematic representation of the in situ cremasteric arteriolar bifurcation used for assessing ‘parent’ 
and ‘daughter’ arteriolar mechanical and hemodynamic/perfusion responses to pharmacological challenge.  
Open arrows represent parent or daughter arteriolar diameter in response to a specific condition; filled arrows 
represent parent or daughter arteriolar erythrocyte velocity in response to a specific challenge.  These data are 
text for additional details. 
 
Figure 2.  Micr
arterioles within in situ cremaster muscle.  Data are presented as mean±SE for LZR under control conditions 
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist 
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric 
oxide synthase inhibitor L-NAME (LN) or combinations of these agents.  Panel A presents data describing 
the magni -2A bifurcation under the specific experimental conditions and Panel B presents 
pharmacological challenge.  Please see text for additional details.   For Panel A, * p<0.05 vs. LZR; † p<0.05 
vs. OZR.   For Panel B, * p<0.05 versus no change. 
 
Figure 3.  
arterioles within in situ cremaster muscle.  Data are presented as mean±SE for LZR under control conditions 
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist 
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric 
oxide synthase inhibitor L-NAME (LN) or combinations of these agents.  Panel A presents data describing 
the ma -3A bifurcation under the specific experimental conditions and Panel B presents 
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pharmacological challenge.  Please see text for additional details.   For Panel A, * p<0.05 vs. LZR; † p<0.05 
vs. OZR.   For Panel B, * p<0.05 versus no change. 
 
Figure 4.  
arterioles within in situ cremaster muscle.  Data are presented as mean±SE for LZR under control conditions 
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist 
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric 
oxide synthase inhibitor L-NAME (LN) or combinations of these agents.  Panel A presents data describing 
-4A bifurcation under the specific experimental conditions and Panel B presents 
the % recovery (to the level deter
pharmacological challenge.  Please see text for additional details.   For Panel A, * p<0.05 vs. LZR; † p<0.05 
vs. OZR.   For Panel B, * p<0.05 versus no change. 
 
Figure 5.  Microvascular per
arterioles within in situ cremaster muscle.  Data are presented as mean±SE for LZR under control conditions 
and in OZR under control conditions and following treatment with the adrenoreceptor antagonist 
phentolamine (P), the antioxidant TEMPOL (T), the PGH2/TxA2 receptor blocker SQ-29548 (SQ), the nitric 
oxide synthase inhibitor L-NAME (LN) or combinations of these agents.  Panel A presents data describing 
the 4A-5A bifurcation under the specific experimental conditions and Panel B presents 
pharmacological challenge.  Please see text for additional details.   For Panel A, * p<0.05 vs. LZR; † p<0.05 
vs. OZR.   For Panel B, * p<0.05 versus no change. 
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Figure 6.  Predicted perfusion distributions in the distal microcirculation of skeletal muscle of LZR and 
OZR under the conditions of the present study.  Frequency distributions are calculated based on an eight 
in 
situ cremaster muscle presented in Figures 2-5.  Individual panels present the distribution of perfusion 
across of 256 (2
8
) parallel arterioles under each experimental condition as a result of the simulation of a 
dichotomous branching network.  Please see text for additional details.   
 
Figure 7.  Data describing the washout of 
125
I-albumin from the in situ gastrocnemius muscle of LZR and 
OZR under the conditions of the present study.  Data are presented as mean±SE for LZR (n=10) under 
control conditions and OZR under control conditions (total n=28) and following intravenous treatment with 
the adrenoreceptor antagonist phentolamine (P; n=10), the antioxidant TEMPOL (T; n=9), the PGH2/TxA2 
receptor blocker SQ-29548 (SQ; n=9), or for combinations of these agents (n=8-10 for each).   
 
Figure 8.  Data (presented as mean±SE) describing the four moments of the washout of 
125
I-albumin from 
the in situ gastrocnemius muscle of LZR and OZR under the conditions of the present study.  Data are shown 
for the mean transit time of the washout (Panel A), the relative dispersion of the washout (RD; Panel B), the 
distribution skewness (Panel C) and kurtosis (Panel D).  Please see text for details.  * p<0.05 vs. LZR; † 
p<0.05 vs. OZR.  
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Conceptual Framework  
The third chapter is entitled “Spatial Heterogeneity in Skeletal Muscle Microvascular Blood Flow 
Distribution is Increased in the Metabolic Syndrome”. It followed from the above paper, and was based 
on the data suggesting that the inability of the OZR skeletal muscle to resist fatigue lies within 
dysfunctional alpha-adrenergic behavior and endothelial dysfunction predominantly driven by oxidant 
stress and altered AA metabolism. However, these mechanisms suggest spatial differences, thus this paper 
uses the in situ cremaster preparation and the in situ blood perfused hindlimb with I
125
 labeled albumin to 
examine an entire microvascular network with intact blood flow. It allowed for the determination of blood 
flow distributions at bifurcations at different levels of resolution. In the OZR it identified an increased 
perfusion distribution compared to the LZR, but revealed that the mechanisms that affect the distribution 
are spatially distinct. The proximal microcirculation perfusion distribution appears largely impacted by 
alpha-adrenergic dysfunction, while the distal microcirculation perfusion distribution is altered by oxidant 
stress and TxA2. The result of these impairments to perfusion is a “low flow” and a “high flow” pathway 
that it iterated at each bifurcation across the entire microvasculature network. The indicator solution 
washout analysis was included to ensure that the results of the high resolution bifurcation study was not a 
result of selection bias, as the I
125
 albumin is an intravascular tracer used for integrated assessment of 
network function. The results indicate significant disparity between the mean transit time, dispersion, 
skewness, and kurtosis of the OZR compared to the LZR, which suggestively confirm the “high/low 
flow” pathways at bifurcations and matches previous predictive models.   
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ABSTRACT 
A key clinical outcome for peripheral vascular disease (PVD) in patients is a progressive decay in skeletal 
muscle performance and its ability to resist fatigue with elevated metabolic demand.  We have 
demonstrated that PVD in obese Zucker rats (OZR) is partially due to increased perfusion distribution 
heterogeneity at successive microvascular bifurcations within skeletal muscle.  As this increased 
heterogeneity () is longitudinally present in the network, its cumulative impact is a more heterogeneous 
distribution of perfusion between terminal arterioles than normal, causing greater regional tissue 
ischemia.  To minimize this negative outcome, a likely compensatory mechanism against an increased  
should be an increased temporal switching at arteriolar bifurcations to minimize downstream perfusion 
deficits.  Using in situ cremaster muscle, we determined that temporal activity (the cumulative sum of 
absolute differences between successive values of , taken every 20 seconds) was lower in OZR than in 
control animals, and this difference was present in both proximal (1A-2A) and distal (3A-4A) arteriolar 
bifurcations.  While adrenoreceptor blockade (phentolamine) improved temporal activity in 1A-2A 
arteriolar bifurcations in OZR, this was without impact in the distal microcirculation, where only 
interventions against oxidant stress (TEMPOL) and thromboxane A2 activity (SQ-29548) were effective.  
Analysis of the attractor for  indicated that it was not only elevated in OZR, but also exhibited severe 
reductions in range, suggesting that the ability of the microcirculation to respond to any challenge is 
highly restricted, and may represent the major contributor to the manifestation of poor muscle 
performance at this age in OZR. 
 
Key Words: rodent models of obesity; microcirculation; skeletal muscle blood flow regulation; models of 
peripheral vascular disease; blood flow heterogeneity; vascular dysfunction 
INTRODUCTION 
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 With ongoing study, there is increasing appreciation that the transition from ‘healthy’ physiology 
to disease states represents a change in the overall system of control from an existing normal structure 
(46).  It is also generally unclear whether this transition represents a failure of the ‘healthy’ system or 
evolving compensations to attempt to optimize the most critical biological outcomes despite progression 
of a challenged environment (38, 57).  For this reason, a detailed understanding of which major 
contributing processes to an outcome are altered with pathology and the extent for which these are 
compensated is critical for developing appropriate therapeutic interventions.  Failure to elucidate both the 
key sites of impairment and the compensatory mechanisms, as well as how these impact functional 
outcomes, has resulted in poorly targeted interventional measures. 
 While the existing literature contains extensive prior interrogation into the effects of 
atherosclerotic peripheral vascular disease on perfusion and performance outcomes in multiple model 
systems as well as the identification of many putative mechanistic contributors to plaque/lesion 
development (1, 9, 20, 27, 30, 39), investigation into the impact of non-atherosclerotic peripheral vascular 
disease (PVD) has received a much more limited investment.  While underrepresented to date, this is an 
exceedingly important area of investigation, as a growing body of evidence suggests that an increasing 
number of human subjects are afflicted with the symptomology of PVD in the absence of overt 
plaque/lesion development (12, 19, 31, 44, 45).   
Based on its origin in a dysfunctional leptin receptor gene, destroying the satiety reflex, the obese 
Zucker rat (OZR) experiences a chronic hyperphagia, developing severe obesity, a progressive worsening 
of glycemic control and plasma lipid profiles and, ultimately, the development of moderate hypertension 
(32, 37).  The importance of the OZR model for studying non-atherosclerotic PVD is considerable, as the 
genesis of the pathological state lies within the leptin resistance-induced hyperphagia, which is found in 
the human population (53, 56).  Further, the severity of the elevated risk factors for a negative 
cardiovascular outcome has repeatedly been demonstrated to be comparable to that determined in 
afflicted patients, and these animals do not develop atherosclerotic lesions. 
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Recent study has provided clear and compelling evidence that impairments to skeletal muscle 
performance that are associated with development of non-atherosclerotic PVD in OZR are not adequately 
predicted by basic indices such as the mechanical responses of resistance arterioles to stimuli or by bulk 
blood flow responses to skeletal muscle (25).   Rather, we have recently demonstrated that a defining 
characteristic of non-atherosclerotic PVD in OZR skeletal muscle is an increasingly asymmetric blood 
flow distribution at successive microvascular bifurcations, resulting in pronounced heterogeneity of 
perfusion across the distal arterioles within the network (24, 59).  While this increased spatial 
heterogeneity of perfusion distribution was improved by interventions against reactive oxygen stress, the 
actions of thromboxane, and altered function within adrenergic vasoconstriction (24, 59), the question of 
the system compensation for this increased perfusion heterogeneity in OZR is entirely unknown.  
Conceptually, a likely compensation for the increased spatial heterogeneity of perfusion in the 
microcirculation of OZR could be via increased temporal switching at arteriolar bifurcations.  As the 
spatial heterogeneity between parallel daughter arterioles would create relative degrees of downstream 
ischemic signals between the parallel perfused regions, a compensation that resulted in increased temporal 
switching between ‘high flow’ and ‘low flow’ daughter arterioles would help to minimize the severity and 
duration of the resulting ischemic regions and could act to maintain muscle performance to the greatest 
possible extent. 
Given this conceptual framework, the purpose of the present study was to determine the degree of 
temporal switching at arteriolar bifurcations within the resting skeletal muscle microcirculation of OZR 
versus LZR, the extent to which this acts as a compensatory physiological mechanism to the increased 
spatial perfusion heterogeneity and to determine the major contributing mechanisms to differences 
between the two conditions.  This study tested the hypothesis that temporal switching at arteriolar 
bifurcations is increased in skeletal muscle of OZR as a means for compensating for the increased spatial 
perfusion heterogeneity and helping to maintain skeletal muscle performance at optimal levels despite the 
evolving pathological state. 
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MATERIALS AND METHODS 
Animals:  Male lean (total n=20; Harlan) and obese Zucker rats (total n=38; fa-/fa-; Harlan) were fed 
standard chow and drinking water ad libitum and were housed in the animal care facility at the West Virginia 
University Health Sciences Center or the Medical College of Wisconsin.  All protocols received prior IACUC 
approval.  At ~17 weeks of age, rats were anesthetized with injections of sodium pentobarbital (50 mg/kg, 
i.p.), and received tracheal intubation to facilitate maintenance of a patent airway.  In all rats, a carotid artery 
and an external jugular vein were cannulated for determination of arterial pressure and for infusion of 
supplemental anesthetic and pharmacological agents, as necessary.  Any animal in which mean arterial 
pressure was found to be below 85 mmHg, or where MAP had decreased by more than 15% from that 
following this initial surgery (without any pharmacological intervention) was not used in the present study.  
Blood samples were drawn from the venous cannula for determination of glucose and insulin concentrations 
(Millipore; Billerica, MA) as well as cholesterol/triglyceride levels (Wako Diagnostics; Richmond, VA), and 
nitrotyrosine (Oxis International; Foster City, CA).  Unless otherwise noted, all drugs and chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Preparation of In Situ Cremaster Muscle:  In each rat (LZR n=20; OZR n=38), an in situ cremaster 
muscle was prepared for intravital microscopy (2, 26, 35), and was continuously superfused with 
physiological salt solution (PSS) equilibrated with a 5% CO2-95% N2 gas mixture, maintained at 35C, as 
it flowed over the muscle.  Volume flow rate was ~3.0 ml/min.  The ionic composition of the PSS was as 
follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 1.18, MgSO4 1.17, NaHCO3 24.0, and 
disodium EDTA 0.03. After a 30 minute period of equilibration following the surgical preparation, 
arterioles and bifurcations within two distinct “bifurcation categories” were selected for investigation: 1) 
~100 m ‘parent’ to ~80 m ‘daughters’ (1A-2A) and 2) ~60 m ‘parent’ to ~40 m ‘daughters’ (3A-
4A).  Arterioles/bifurcations were selected based on the following criteria: 1) distance from any site of 
incision, 2) presence of significant vascular tone (assessed by brisk dilator response to challenge with 10
-3
 
M adenosine), 3) clearly discernible walls, 4) a rapid and stable level of erythrocyte perfusion, and 5) the 
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presence of two clearly defined ‘daughter’ branches that also met criteria 1-4.  Please see Figure 1 for a 
schematic representation (also reference 24). 
 The mechanical (using on-screen videomicroscopy) and perfusion (using optical Doppler 
velocimetry) responses of both the ‘parent’ and ‘daughter’ arterioles within a bifurcation class were 
assessed under resting conditions within the cremaster muscle of each rat.  All procedures were performed 
under control conditions in LZR and OZR, and following treatment of the in situ cremaster muscle with 
the anti-oxidant TEMPOL (10
-3
 M), the TxA2 receptor antagonist SQ-29548 (10
-4
 M), and/or the 1/2 
adrenergic receptor antagonist phentolamine (10
-5
 M); within the superfusate solution.  All treatments to 
the cremaster were of a minimum of 40 minutes duration prior to any subsequent experimental 
manipulation/data collection. 
Interrogation of Arteriolar Bifurcations:  Within each animal, one 1A-2A bifurcation and one 3A-4A 
bifurcation was studied within the arteriolar network.  For an individual measurement, arteriolar diameter 
and erythrocyte velocity were monitored for 5 minutes, with measurements taken every 20 seconds.  All 
arterioles and bifurcations were selected on the basis of the criteria outlined above and were placed into 
their categories by size rather than by strict branch number within the network.     
In order to maintain preparation and collected data quality, no cremaster muscle was exposed to 
all interventions and combinations listed above.  In addition to the collection of responses under control 
conditions, individual cremaster preparations were exposed to a maximum of four interventions, each 
separated by ~30 minutes of washout.  Treatment or washout effectiveness was verified by determining 
abolition or recovery of mechanical responses following challenge with appropriate agonists (e.g., the 1 
adrenergic antagonist phenylephrine, the stable TxA2 mimetic U-46619, and the endothelium-dependent 
dilator agonist acetylcholine for the appropriate initial treatments).  Maximum experimental duration from 
preparation to termination was approximately four hours, after which time all animals were humanely 
euthanized by an intravenous overdose of anesthetic followed by a bilateral pneumothoracotomy, as per 
approved IACUC protocols.   
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Data and Statistical Analyses:  Arteriolar perfusion in both parent and daughter vessels within in situ 
cremaster muscle of LZR and OZR was calculated as: 
  (       )(   )(     ) 
where Q represents arteriolar perfusion (nl•s-1), V represents the measured red cell velocity from the 
optical Doppler velocimeter (mm•s-1; with V/1.6 representing an estimated average velocity assuming a 
parabolic flow profile; Ref. 18), and r represents arteriolar radius (m; Ref. 4).    
 The total volume perfusion in the daughters was determined as the sum of the individual perfusion 
rates, and the proportion of flow within each was determined as the quotient of the individual branch divided 
by the total.   is defined as the ratio of the greater of the two flows in the daughter vessel to the total flow in 
the parent vessel.  As an example, if flow distribution was homogeneous between daughters,  for that 
bifurcation would be 0.5 in both daughter arterioles, while if the proportion of flow in one daughter arteriole 
was 60%, for that bifurcation would be 0.6, with flow distribution being 0.6 in the ‘high perfusion’ arteriole 
and 0.4 in the ‘low perfusion’ arteriole (Figure 1, and Ref. 6).   
 Monitoring  throughout the observation period and analyzing those resulting data used three initial 
approaches.  The first of these was simply to determine the mean±SE of the individual measurements 
throughout the 5 minute observation window, providing the mean value for .  However, this is clearly not 
sufficiently informative in terms of understanding the temporal behavior for  at a bifurcation.  The second 
approach was to determine the cumulative change in  from each of the 15 successive measurements: 
∑( ( )   (   ))
  
   
 
where  represents the perfusion distribution at any given bifurcation and t represents the measurement time 
from 1 (initial) to 15 (final). While these data can provide us with evidence of broader changes in  with 
longer durations, it was apparent that a more sensitive marker is needed to provide sufficient insight into 
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temporal switching at an arteriolar bifurcation.  As such, the final approach is to summate the absolute values 
of the differences in  from one time point to the next to provide for a superior index of total activity: 
∑    ( ( )   (   )) 
  
   
 
This final index (summating absolute difference in ), will provide insight into the total temporal switching at 
any arteriolar bifurcation within the data collection window. 
 In order to determine the effectiveness of any intervention on improving the behavior of  over the 
data collection window in OZR, the values for the  (cumulative, absolute differences) that were collected for 
arteriolar bifurcations in LZR under control conditions (A) were set as the overall control value.  As such, the 
impact of pathology (development of the metabolic syndrome) is determined from the data collected in OZR 
under control conditions (B) and is the absolute difference between these two values:       (   ).  
The extent to which any intervention in OZR can improve normal behavior is given by the value of  
(cumulative, absolute) following the intervention (C), and is represented by:       (   ).  Given this, 
the percent effectiveness of any intervention in restoring the normal behavior of  at a bifurcation in OZR is 
provided by:   (
 
 ⁄ )     . 
 An attractor is generally defined as the set of conditions towards which a given variable evolves over 
time.  To a significant extent, this can be considered as the representation of the behavior of a dynamic 
system over a period of time, and this can be extremely useful in understanding the limits of a system (i.e., 
what behaviors are either not possible, not generally attainable or are extremely unlikely) and the effects on 
system behavior (either beneficial or detrimental) subsequent to an imposed intervention.  The most 
informative manner in presenting an attractor is as an iterated map, where the current state of the parameter 
under study is plotted at a given moment, and then its change in position re-plotted at the next time interval.  
This process is iterated repeatedly, to the conclusion of the data set, and the shape and location of the attractor 
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on the co-ordinate system becomes evident.  This approach also facilitates comparisons between 
experimental conditions and the impact these have on the location and shape of the attractor. 
 All data throughout the manuscript are presented as mean±SE.   Statistically significant differences in 
measured and calculated parameters were determined using a one sample t-test (differences from zero), 
Student’s t-test or analysis of variance (ANOVA) with Student-Newman-Keuls post-hoc test used as needed.  
In all cases, p<0.05 was taken to reflect statistical significance.   
RESULTS 
 Table 1 presents the baseline characteristics of animals used in the present study.  By ~17 weeks 
of age, OZR demonstrated striking obesity and had a significantly higher mass than LZR.  Further, OZR 
exhibited statistically significant elevation in mean arterial pressure, and both plasma insulin and 
nitrotyrosine concentrations.  Data describing the dimension and perfusion characteristics of the 
cremasteric arteriolar bifurcation segments (described above) under the conditions of the present study are 
summarized in Table 2.  These data clearly demonstrate general differences between arteriolar diameter 
and perfusion characteristics that are distributed longitudinally throughout the cremasteric 
microcirculation under the conditions of the present study.   
 Figure 2 presents representative data describing the distribution of the magnitude of  and its 
temporal behavior across 1A-2A (Panels A and B, respectively) and 3A-4A (Panels C and D, 
respectively) arteriolar divisions.  As suggested by these data, in addition to a shift in the frequency 
distribution of  between LZR and OZR at both microvascular divisions, the changes in  (measured 
every 20 seconds over the course of 5 minutes) were less extensive in both proximal and distal 
bifurcations of the resting cremaster muscle microcirculation of OZR as compared to LZR.  
Proximal Resistance Arterioles: The summarized results of the average magnitude of  at 1A-2A 
arteriolar bifurcations over the observation period are presented in Figure 3.  In LZR (Panel A),  was 
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approximately 0.51 under control conditions, and was not altered by acute pharmacological intervention.  
In contrast, average  over the 5 minute period in OZR (Panel B) was much higher, approximately 0.58 
under control conditions.  While interventions containing phentolamine (regardless of the presence of any 
other substance) reduced average to levels determined in LZR, treatment against either the increased 
TxA2 production (SQ-29548) or the elevated vascular oxidant stress (TEMPOL) in OZR were not 
effective, resulting in minimal changes to . 
 Data describing the changes in  in 1A-2A bifurcations between LZR and OZR over the 5 minute 
observation window are summarized in Figure 4.  When presented as the cumulative change in , neither 
LZR (Panel A) nor OZR (Panel B) exhibited a difference between strains or a clear pattern in terms of the 
cumulative change in  within a strain.  However, when the cumulative changes in  are presented as the 
sum of the absolute changes, striking differences are evident.  While a clear reduction in the cumulative 
change in  (absolute) was evidence in OZR (Panel D) as compared to LZR (Panel C), blockade of 
adrenoreceptors (alone or with any other pharmacological intervention) in 1A-2A bifurcations in LZR 
reduced activity at the bifurcation.  In contrast, treatment of elevated oxidant stress with TEMPOL or 
blockade of TxA2 with SQ-29548 has no discernible impact.  In 1A-2A bifurcations from OZR, treatment 
with phentolamine (either alone or with TEMPOL and/or SQ-29548) significantly increased the 
cumulative change in  (absolute) over the data collection window (Panel D).  Similarly to LZR, 
treatment with TEMPOL and/or SQ-29548 in the absence of phentolamine did not have a significant 
impact. 
Distal Resistance Arterioles: Comparable to data presented for proximal resistance arterioles, the average 
 for 3A-4A arteriolar bifurcations over the 5 minute period was ~0.5 in LZR under control conditions 
(Figure 5, Panel A) and this was elevated in OZR (Panel B).  However, while treatment interventions 
were without effect in LZR, application of either TEMPOL or SQ-29548 in OZR significantly reduced 
mean  toward 0.5.  In contrast to the results from more proximal resistance arterioles,  was largely 
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unaffected by phentolamine treatment and interventions targeted at rectifying endothelial dysfunction 
were required in order to cause a significant restoration of . 
 Figure 6 presents the cumulative changes in  over the 5 minute period in 3A-4A arteriolar 
bifurcations from LZR (Panels A and C) and OZR (Panels B and D).   When the changes in  are 
presented as simple accumulation, there were no significant differences between LZR (Panel A) and OZR 
(Panel B) or within a strain as a result of any intervention.  However, when the changes in  are summated 
as absolute differences, clear differences were identified.  In 3A-4A arteriolar bifurcations of LZR (Panel 
C), acute treatment with phentolamine reduced the accumulated changes to , while the presence of 
TEMPOL and/or SQ-29548 resulted in minimal total changes or marginal change (when applied in 
combination with each other or with phentolamine).  In contrast, application of TEMPOL and/or SQ-
29548 significantly improved the cumulative changes to  (absolute) in 3A-4A arteriolar bifurcations of 
OZR, while the effects of phentolamine application were muted (Panel D). 
Effects of Adenosine:  To simulate the impact of elevated metabolic demand on the temporal stability of 
 throughout the cremaster muscle microcirculation, increasing concentrations of adenosine were added to 
the preparation superfusate.  While application of adenosine had minimal impact on average  in LZR, it 
reduced average  in OZR, at both 1A-2A (Panel A) and 3A-4A (Panel C) bifurcations to levels that were 
very similar to that determined in LZR, with the greatest impact being observed with the highest level of 
adenosine (Figure 7).  Adenosine did not impact the cumulative change in  over the 5 minute period in 
summated as absolutes, application of increasing concentrations of adenosine reduced temporal activity in 
LZR at both 1A-2A (Panel B) and 3A-4A (Panel D) bifurcations, although it had minimal impact on 
activity in the bifurcations of OZR (Panels B and D).   
Effectiveness of Interventions in Restoring Normal Behavior:  Figure 8 summarizes the impact of the 
interventions on restoring normal temporal activity at 1A-2A (Panel A) and 3A-4A (Panel B) arteriolar 
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bifurcations in OZR (where the activity at those bifurcation levels in untreated LZR is defined as 
control/normal).  As shown in Panel A, while there is a significant recovery in function with treatment 
with the adrenoreceptor antagonist alone, combined therapy of phentolamine with the agents targeted at 
improving endot
the proximal arteriolar bifurcations of OZR.  Conversely, the reverse pattern was evident for distal 
arteriolar bifurcations of OZR, as treatment with SQ-29548 and/or TEMPOL resulted in significant 
in a further marginal improvement to this outcome. 
Establishment of a New Attractor for PVD:  Figure 9 presents the attractor -2A arteriolar 
bifurcations in cremaster muscle of LZR and OZR (control conditions).  As show in Panel A, the attractor 
tment with phentolamine (Panel B) was effective in restoring the magnitude of 
the attractor in OZR compared to that in LZR, although range remained restricted.  In contrast, treatment 
of the cremasteric network with TEMPOL and/or SQ-29548 was of minimal benefit in restoring the 
attractor in OZR to that in LZR (Panel C).  However, combined treatment with phentolamine and 
TEMPOL/SQ-29548 almost completely restored the magnitude and the shape of the attractor in OZR to 
that in LZR.   This situation was reversed in distal arteriolar bifurcations of OZR and LZR (Figure 10), as 
the shift in the attractor for OZR versus LZR under control conditions (Panel A) was much more strongly 
impacted by treatment with TEMPOL and/or SQ-29548 (Panel C) than with phentolamine (Panel B); 
although combined treatment with phentolamine and TEMPOL/SQ-29548 still resulted in near complete 
restoration of the attractor shape and magnitude determined in LZR (Panel D). 
 The effects of increasing adenosine concentration on the attractor in arteriolar bifurcations of 
OZR are summarized in Figure 11.  In both proximal (Panel A) and distal (Panel B) arteriolar 
bifurcations, treatment with high concentrations of adenosine (10
-3
M) restored the attractor magnitude, 
but not the full extent of the shape.  Lower concentrations of adenosine (10
-7
 or 10
-5
M) were without 
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concentrations of adenosine, there was a less heterogeneous distribution of perfusion at bifurcations, but 
 
DISCUSSION 
 It has long been understood that the development of non-atherosclerotic PVD, with its implicit 
failure of appropriate matching of blood perfusion to meet requisite metabolic demand, is associated with 
a severely compromised ability of the skeletal muscle to maintain performance (i.e., developed tension 
levels; refs. 19, 44).  However, using the OZR model of the metabolic syndrome, it has been clearly 
demonstrated that blood-perfused skeletal muscle rates of fatigue are increased as compared to LZR, and 
that this compromised performance is not simply a function of global ischemia (25).  Rather, treatment 
with an adrenoreceptor antagonist and a substantial restoration of functional hyperemia, muscle fatigue 
rates and oxygen uptake (VO2) remained compromised in OZR as compared to LZR.  It was only after 
combined treatment with both the adrenoreceptor antagonist and interventions ameliorating endothelial 
dysfunction (the anti-oxidant TEMPOL and/or the PGH2/TxA2 receptor antagonist SQ-29548) that muscle 
performance and VO2 were improved.  These results strongly suggest a spatial divergence with regard to 
dysfunction wherein altered adrenoreceptor function primarily impacts bulk perfusion resistance while 
altered endothelial function primarily impairs perfusion:demand matching in the distal microvasculature 
(25).  We have interrogated this spatial divergence in blood flow control in skeletal muscle of OZR and 
have determined that a defining characteristic of PVD in this model is an increasingly heterogeneous 
distribution of blood flow at successive bifurcations within the arteriolar network (defined by the 
strongly predictive of poor muscle performance, it was determined to be longitudinally consistent down 
the arteriolar network, and was demonstrated to lead to severe increases in blood flow distribution at the 
pre-capillary level in OZR as compared to LZR (24, 59).  
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 geneity of perfusion 
distribution represent a deviation from the normal system behavior identified in microvascular networks 
of LZR.  However, as with the majority of biological systems, compensatory mechanisms that can 
minimize the impact of the increased spatial heterogeneity in perfusion should be present.  Logically, the 
most likely compensatory mechanism would be an increased temporal ‘switching’ at the individual 
bifurcations (an increased rate of change with regard to which daughter represents the ‘high’ or ‘low’ 
which signals associated with any developed ischemic signals accumulate within a ‘low flow’ branch.  
While the nature of these signals is not fully clear at this time, with potential contributors stemming from 
the buildup of parenchymal tissue metabolic signals (10, 13, 17, 49), substances released from 
increasingly deoxygenated erythrocytes as they pass through the microcirculation (22, 29, 50, 51), or 
undefined signals that are propagated along myocyte and/or endothelial communication pathways (3, 7, 
21, 55), the general principle appears to be valid regardless of the stimuli involved.   
 The data presented in this study refute our general 
time at both 1A-2A (Figures 3/4) and 3A-4A (Figure 5/6) arteriolar bifurcations in resting skeletal muscle 
of OZR were significant reduced as compared to levels determined in LZR.  This is a particularly striking 
observation, as it clearly suggests that not only does a change in temporal switching at arteriolar 
the reduction in temporal switching actually entrenches the negative outcomes for perfusion distribution 
blunting of temporal activity in arteriolar bifurcations of OZR could be ameliorated.  In proximal 
resistance arterioles, treatment of the resting cremaster muscle with phentolamine, to remove alterations 
to the distribution of adrenergic constriction throughout the network, significantly increased the 
fied in the distal microcirculation, where adrenoreceptor 
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correcting endothelial dysfunction (TEMPOL and/or SQ-29548) had minimal impact on the temporal 
activity of perfusion distribution at proximal arterioles, but significantly improved this response in more 
distal 3A-
very similar to that determined for LZR under control conditions.  It is particularly compelling that these 
interventions, and their sites of greatest impact parallel results in our previous studies with regard to 
ng muscle 
fatigue resistance and VO2 (24).   Specifically, while treatment with either phentolamine or 
TEMPOL/SQ-29548 alone improved select or localized indices of vascular function (with no beneficial 
impact on muscle performance), only combined treatment with phentolamine and TEMPOL/SQ-29548 
resulted in a widely distributed and significant improvement to muscle perfusion, VO2 and performance 
(25).  Taken together, this series of observations suggest that, with a combined intervention designed to 
remove alterations to adrenergic constriction and endothelial dysfunction in the OZR model of metabolic 
syndrome, blood flow hemodynamics at successive arteriolar bifurcations is improved to a condition 
which helps to restore the processes of mass transport and exchange in the microcirculation to a level that 
allows for a significant improvement to muscle performance.  However the extent to which this is 
manifested as a change to the total surface area available for exchange in the muscle or an improvement 
to erythrocyte distribution within the terminal arterioles and capillary networks remains to be elucidated.   
 One of the benefits derived from the increased effort of acquiring temporal data is that it can 
allow for the determination of an attractor.  In essence, an attractor is the set to which a variable will 
adhere over time (36, 58).  Even following perturbation as a result of an imposed challenge, the variable 
will change its behavior over time to return to its attractor if possible (36, 58).  In the present experiments, 
the attractor for both proximal (1A-2A) and distal (3A-4A) arteriolar bifurcations in LZR exhibited a 
both proximal (Figure 9) and distal (Figure 10) arteriolar bifurcations of OZR, where the central region of 
the attractor was shifted to ~0.58, with a narrowed range of achieved values.  Beyond being an intriguing 
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scientific curiosity, this shift in the attractor has critical implications for blood flow control in OZR.  The 
change in both magnitude and range of the attractor with the development of pathology in OZR indicates 
that the ability of arterioles and arteriolar bifurcations to respond to imposed challenges (e.g., changes in 
metabolic demand) will be severely compromised as the potential for perfusion redistribution will be 
constrained to a more limited set of attainable conditions.  Essentially, the development of non-
atherosclerotic PVD in OZR is defined by a loss of flexibility in the control systems contributing to the 
regulation of perfusion distribution in skeletal muscle, thus severely compromising the ability to 
effectively adapt to changing conditions.  This is a particularly striking outcome and it may represent the 
more functionally integrated extension of a similar process identified by Tigno et al. (54) in diabetic 
monkeys, where the randomness of arterial vasomotion was found to be dampened with disease 
progression.  Taken together, it is not simply that we have dysfunction and can identify it in a series of 
reduced preparations.  It is that indices of dysfunction in simplified preparations, when integrated, 
produce an outcome wherein the pathology is partially defined by an impaired ability of the system to 
respond to stressors. 
 Despite numerous attempts, we were unable to acquire a sufficiently robust data set which 
simulator of this condition, we utilized elevated concentrations of adenosine in the preparation 
low (10
-7
M) or moderate (10
-5
or the resulting attractor in arteriolar bifurcations of OZR, while superfusion with high concentrations of 
adenosine (10
-3
restore the range of the attractor (Figure 11).  These observations strongly suggest that the arteriolar 
networks in OZR may be resistant responding to elevated metabolic demand, until a ‘threshold’ is 
reached.  Once a sufficient metabolic intensity (or build-up of the appropriate signal) has been attained, 
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remains blunted).  As we have demonstrated previously (24), this high concentration of adenosine results 
in a maximal relaxation of in situ skeletal muscle arterioles in OZR, meaning that the entire vascular 
reflect only the impact of the architecture and geometric arrangement of the network, as well as the 
intrinsic physical processes associated with blood flow and erythrocyte distribution in vascular networks, 
as has been previously studied by Cokelet (14, 15) and Kiani (33), among others (23, 28).  As presented 
nder these conditions is very similar between LZR and OZR in terms of 
magnitude and shape, but with a restricted range.   
 Given the nature of the data in the present study, attention should be given to the impact of the 
method of anesthesia on outcomes and data interpretation.  Numerous previous studies have demonstrated 
that both inhalational volatile and injectable general anesthetics can impact endothelial function and 
vasomotion (16, 41, 48), as well as baroreflex sensitivity and the sympathetic control of vascular tone 
(48).  As such, either option presents a challenge for data interpretation in the present study, especially 
given the complications associated with altered baroreflex control (40, 47), sympathetic output (11, 47), 
and endothelial function (25) that has been demonstrated in the obese Zucker rat.  While for this research, 
we have elected to utilize a barbiturate anesthetic (owing to the time between exposure and data 
collection, and to avoid the impact on vasomotion), these are issues that become extremely complicated 
and further investigation of the impact of anesthetic regimen on microvascular outomes in models of 
increased PVD risk may be warranted. 
 Obviously, the ultimate outcome for microvascular function, regardless of condition, is the ability 
of the networks to adequately support mass transport and exchange under both resting and challenged 
conditions.  If we assume that the attractors identified for LZR under control conditions are representative 
of ‘health’, for the purposes of the present discussion it may be useful to consider this as ‘optimized’ (i.e., 
these attractors describe microvascular networks functioning optimally).  Assuming this, the attractors for 
OZR would represent the resultant state of the microcirculation under conditions of the metabolic 
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syndrome.  As such, it is important to estimate how these changes to perfusion distribution would impact 
indices such as tissue oxygenation or microvascular hematocrit.  While these measurements are outside of 
the scope of the current study, previous research efforts can provide some potential insight.  In particular, 
the work of Pries et al. (42, 43), has identified a ‘network Fahraeus effect’ that can represent a significant 
contributor to the ultimate reduction in microvascular hematocrit at successive bifurcations owing to a 
disproportionate distribution of flow (and therefore, erythrocytes) at arteriolar bifurcations.  Under 
‘control’ conditions, those authors suggested that this alone could cause a reduction in microvascular 
hematocrit approaching 20%, with direct implications for tissue oxygenation (8, 52).  As the results from 
it would be logical to speculate that this would result in an exacerbation of the ‘network Fahraeus effect’, 
which, when taken in combination with other contributors to hematocrit reduction (e.g., the ‘vessel 
Fahraeus effect’ (15, 43) and other hemo-rheological parameters (5, 23, 34)), would result in a further 
reduction of microvascular hematocrit within the networks.  While specific interventions such as 
adrenoreceptor blockade and inhibiting the actions of TxA2 could provide some amelioration of this 
impairment, based on alterations to the shape of the attractors, only a combined interventional strategy 
would be sufficient to cause an improvement to arteriolar network function that would be sufficient to 
result in alterations to mass transport and exchange that were large enough to improve muscle fatigue 
resistance (25).  Further investigation into the impact of these cumulative perfusion abnormalities in the 
skeletal muscle microcirculation of OZR could provide us with a far more complete understanding of how 
non-atherosclerotic PVD is manifest in this increasingly relevant animal model of the metabolic 
syndrome. 
 
ACKNOWLEDGEMENTS 
  
144 
 This study was supported by grants from the National Institutes of Health (NIH DK R01 64668, 
T32 HL 90610 and RR 2865AR) and the American Heart Association (AHA EIA 0740129N).  The 
authors also wish to express their gratitude for the expert technical assistance from Ms. Milinda James 
from the Department of Physiology and Pharmacology at West Virginia University and for support 
provided through the Translational Research Facility in the Center for Cardiovascular and Respiratory 
Sciences at the West Virginia University HSC.  
  
145 
LITERATURE CITED 
1. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in 
atherosclerosis. Arterioscler Thromb Vasc Biol. 31:969-79, 2011. 
 
2. Bagher P, Segal SS. The mouse cremaster muscle preparation for intravital imaging of the 
microcirculation. J Vis Exp. 2011 Jun 10;(52). pii: 2874. doi: 10.3791/2874.  
 
3. Bagher P, Segal SS. Regulation of blood flow in the microcirculation: role of conducted 
vasodilation. Acta Physiol (Oxf). 202:271-284, 2011. 
 
4. Baker M, Wayland H.  On-line volume-flow rates and velocity profile measurements for blood in 
microvessels.  Microvasc. Res. 7:131-143, 1974. 
 
5. Baskurt OK, Yalcin O, Gungor F, Meiselman HJ. Hemorheological parameters as determinants of 
myocardial tissue hematocrit values. Clin Hemorheol Microcirc. 35:45-50, 2006.  
 
6. Bassingthwaighte JB, Liebovitch LS, West BJ.  “Intraorgan flow heterogeneities.”  In: Fractal 
Physiology.  Oxford University Press, New York, 1994. p. 236-262. 
 
7. Behringer EJ, Segal SS. Spreading the signal for vasodilatation: Implications for skeletal muscle 
blood flow control and the effects of aging. J Physiol. 2012 Aug 13. [Epub ahead of print] PubMed 
PMID: 22890708. 
 
8. Bos C, Hoofd L, Oostendorp T. Mathematical model of erythrocytes as point-like sources. Math 
Biosci. 125:165-189, 1995.  
 
9. Businaro R, Tagliani A, Buttari B, Profumo E, Ippoliti F, Di Cristofano C, Capoano R, Salvati 
B, Riganò R. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad 
Sci. 1262:134-41, 2012.  
 
10. Calbet JA, Joyner MJ. Disparity in regional and systemic circulatory capacities: do they affect the 
regulation of the circulation? Acta Physiol (Oxf). 199:393-406, 2010.  
 
  
146 
11. Carlson SH, Shelton J, White CR, Wyss JM.  Elevated sympathetic activity contributes to 
hypertension and salt sensitivity in diabetic obese Zucker rats.  Hypertension. 35:403-408, 2000. 
 
12. Chandra S, Singh V, Nehra M, Agarwal D, Singh N. ST-segment elevation in non-atherosclerotic 
coronaries: a brief overview. Intern Emerg Med. 6:129-139, 2011.  
 
13. Clifford PS, Hellsten Y. Vasodilatory mechanisms in contracting skeletal muscle. J Appl Physiol. 
97:393-403, 2004.  
 
14. Cokelet GR. Rheology and hemodynamics. Annu Rev Physiol. 42:311-324, 1980. 
 
15. Cokelet GR. Experimental determination of the average hematocrit of blood flowing in a vessel. 
Microvasc Res. 7:382-384, 1974.  
 
16. Colantuoni A, Bertuglia S, Intaglieeta M.  Effects of anesthesia on the spontaneous activity of the 
microvasculature.  Int J Microcirc Clin Exp. 3:13-28, 1984 
 
17. Davis MJ. Perspective: physiological role(s) of the vascular myogenic response. Microcirculation. 
19:99-114, 2012.  
 
18. Davis MJ. Determination of volumetric flow in capillary tubes using an optical Doppler velocimeter.  
Microvasc Res 34:223-30, 1987. 
 
19. Dean SM. Atypical ischemic lower extremity ulcerations: a differential diagnosis. Vasc Med. 13:47-
54, 2008. 
 
20. Demer L, Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-κB 
signaling in atherosclerotic calcification. Circ Res. 108:1482-93, 2011.  
 
21. Diep HK, Vigmond EJ, Segal SS, Welsh DG. Defining electrical communication in skeletal muscle 
resistance arteries: a computational approach. J Physiol. 568:267-81, 2005. 
  
147 
 
22. Ellsworth ML, Sprague RS. Regulation of blood flow distribution in skeletal muscle: role of 
erythrocyte-released ATP. J Physiol. 590:4985-4991, 2012.  
 
23. Fenton BM, Carr RT, Cokelet GR. Nonuniform red cell distribution in 20 to 100 micrometers 
bifurcations. Microvasc Res. 29:103-126, 1985. 
 
24. Frisbee JC, Wu F, Goodwill AG, Butcher JT, Beard DA. Spatial heterogeneity in skeletal muscle 
microvascular blood flow distribution is increased in the metabolic syndrome. Am J Physiol Regul 
Integr Comp Physiol. 301:R975-R986, 2011.  
 
25. Frisbee JC, Goodwill AG, Butcher JT, Olfert IM. Divergence between arterial perfusion and 
fatigue resistance in skeletal muscle in the metabolic syndrome. Exp Physiol. 96:369-383, 2011.  
 
26. Frisbee JC, Sylvester FA, Lombard JH. Contribution of extrinsic factors and intrinsic vascular 
alterations to reduced arteriolar reactivity with high-salt diet and hypertension. Microcirculation. 
7:281-289, 2000.  
 
27. Fuster JJ, Castillo AI, Zaragoza C, Ibáñez B, Andrés V. Animal models of atherosclerosis. Prog 
Mol Biol Transl Sci. 105:1-23, 2012.  
 
28. Gaehtgens P. Distribution of flow and red cell flux in the microcirculation. Scand J Clin Lab Invest 
Suppl. 156:83-87, 1981. 
 
29. Goldman D, Fraser GM, Ellis CG, Sprague RS, Ellsworth ML, Stephenson AH. Toward a 
multiscale description of microvascular flow regulation: O(2)-dependent release of ATP from human 
erythrocytes and the distribution of ATP in capillary networks. Front Physiol. 3:246, 2012. 
 
30. Greenwald SE. Ageing of the conduit arteries. J Pathol. 211:157-172, 2007 
 
31. Hill SF, Sheppard MN. Non-atherosclerotic coronary artery disease associated with sudden cardiac 
death. Heart. 96:1119-1125, 2010.  
 
  
148 
32. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, 
hyperlipidemia, and renal injury. Hypertension. 19(1Suppl):I110-5, 1992.  
 
33. Kiani MF, Pries AR, Hsu LL, Sarelius IH, Cokelet GR. Fluctuations in microvascular blood flow 
parameters caused by hemodynamic mechanisms. Am J Physiol. 266:H1822-H1828, 1994.  
 
34. Lipowsky HH. Microvascular rheology and hemodynamics. Microcirculation. 12:5-15, 2005.  
 
35. Lombard JH, Frisbee JC, Greene AS, Hudetz AG, Roman RJ, Tonellato PJ. Microvascular flow 
and tissue PO(2) in skeletal muscle of chronic reduced renal mass hypertensive rats. Am J Physiol 
Heart Circ Physiol. 279:H2295-H2302, 2000.  
 
36. Mandelbrot BB, “Fractal attractors and fractal (“chaotic’) evolutions.”  In: The Fractal Geometry of 
Nature.  pp. 193-199, 1983.  W.H. Freeman and Company, New York, USA.  
 
37. Mathé D. Dyslipidemia and diabetes: animal models. Diabete Metab. 21:106-11, 1995.  
 
38. Menolascina F,  Siciliano V, di Bernardo D. Engineering and control of biological systems: A new 
way to tackle complex diseases FEBS Lett. 586:2122–2128, 2012. 
 
39. Meru AV, Mittra S, Thyagarajan B, Chugh A. Intermittent claudication: an overview. 
Atherosclerosis. 187:221-37, 2006. 
 
40. Pamidimukkala J, Jandhyala BS. Evaluation of hemodynamics, vascular reactivity and 
baroreceptor compensation in the insulin resistance Zucker obese rats.  Clin Exp Hypertens. 18:1089-
1104, 1996. 
 
41. Park, KW, Dai HB, Lowenstein E, Sellke FW.  Effect of sevoflurane and desflurane on the 
myogenic constriction and flow-induced dilation in rat coronary arterioles.  Anesthesiology. 90:1422-
1427, 1999. 
 
42. Pries AR, Secomb TW, Gaehtgens P, Gross JF. Blood flow in microvascular networks. 
Experiments and simulation. Circ Res. 67:826-834, 1990. 
  
149 
 
43. Pries AR, Ley K, Gaehtgens P. Generalization of the Fahraeus principle for microvessel networks. 
Am J Physiol. 251:H1324-H1332, 1986.  
 
44. Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol. 
181:1-10, 2004.  
 
45. Rioufol G, Finet G. Non-atherosclerotic mild anterior myocardial ischaemia. Arch Cardiovasc Dis. 
103:135-136, 2010.  
 
46. Rollie´ S, Mangold M, Sundmacher K. Designing biological systems: Systems Engineering meets 
Synthetic Biology. Chem Engineer Sci. 69:1–29, 2012. 
 
47. Schreihofer AM, Mandel DA, Mobley SC, Stepp DW.  Impairment of sympathetic baroreceptor 
reflexes in obese Zucker rats.  Am J Physiol Heart Circ Physiol. 293:H2543-H2549, 2007. 
 
48. Seagard JL, Bosnjak ZJ, Hopp Jr. FA, Kotrly KJ, Ebert TJ, Kampine JP.  Cardiovascular 
effects of general anesthesia.  p. 149-170.  In: “Effects of Anesthesia”, Eds: Covino BR, Fozzard HA, 
Rehder K, Strichartz H., Waverly Press, Inc., Baltimore, MD, 1985. 
 
49. Segal SS. Regulation of blood flow in the microcirculation. Microcirculation. 12:33-45, 2005.  
 
50. Sprague RS, Ellsworth ML. Erythrocyte-derived ATP and perfusion distribution: role of 
intracellular and intercellular communication. Microcirculation. 19:430-439, 2012.  
 
51. Sprague RS, Bowles EA, Achilleus D, Stephenson AH, Ellis CG, Ellsworth ML. A selective 
phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans 
with type 2 diabetes: implication for vascular control. Am J Physiol Heart Circ Physiol. 301:H2466-
H272, 2011. 
 
52. Stainsby WN, Snyder B, Welch HG. A pictographic essay on blood and tissue oxygen transport. 
Med Sci Sports Exerc. 20:213-221, 1988. 
  
150 
 
53. Tanofsky-Kraff M, Yanovski SZ. Eating disorder or disordered eating? Non-normative eating 
patterns in obese individuals. Obes Res. 12:1361-1366, 2004. 
 
54. Tigno XT, Hansen BC, Nawang S, Shamekh R, Albano AM. Vasomotion becomes less random as 
diabetes progresses in monkeys. Microcirculation. 18:429-439, 2011.  
 
55. Tran CH, Vigmond EJ, Plane F, Welsh DG. Mechanistic basis of differential conduction in skeletal 
muscle arteries. J Physiol. 587:1301-1318, 2009. 
 
56. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. 
Trends Endocrinol Metab. 21:345-352, 2010.  
 
57. van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and 
personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics. 7:1087-1094, 2006. 
 
58. Wagner CD, Nafz B, Persson PB. Chaos in blood pressure control. Cardiovasc Res. 31:380-387, 
1996.  
 
59. Wu F, Beard DA, Frisbee JC. Computational analyses of intravascular tracer washout reveal altered 
capillary-level flow distributions in obese Zucker rats. J Physiol. 589:4527-4543, 2011. 
 
 
 
 
  
  
151 
Table 1.  Baseline characteristics of ~17 week-old LZR and OZR used in the present study.  * p<0.05 
versus LZR.  Data are presented as mean±SE. 
 
 LZR (n=20) OZR (n=38) 
Mass (g) 3579 67610* 
MAP (mmHg) 104±4 135±6* 
[Glucose]plasma (mg/dl) 106±9 188±12* 
[Insulin]plasma (ng/ml) 1.7±0.2 8.8±1.3* 
[Nitrotyrosine]plasma (ng/ml) 17±4 53±7* 
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Table 2.  ity (VRBC; 
mm/s), and volume perfusion within the arteriole (Q; nl/s).  * p<0.05 versus LZR; † p<0.05 versus OZR.  Data are presented as mean±SE; -P 
represents treatment with phentolamine, -T represents treatment with TEMPOL, -SQ represents treatment with SQ-29548; with combinations 
representing treatment with multiple agents. 
  LZR OZR O-P O-T O-SQ O-PT O-PSQ O-TSQ O-PTSQ 
 ID 95±4 81±5 93±4 83±5 84±6 93±4 94±4 85±5 94±4 
1A VRBC 56±6 42±6 53±6 46±5 44±5 53±5 53±6 47±4 54±5 
 Q 248±12 135±15* 225±16† 156±13 152±11 225±9† 230±15† 167±11 234±12† 
 ID 70±5 60±6 67±5 64±4 63±5 68±4 68±5 64±4 69±4 
2A VRBC 50±4 34±6 47±6 38±6 36±4 46±5 48±4 41±5 49±5 
 Q 120±12 60±7* 104±11† 76±10 70±6 104±6† 109±7† 82±12 115±7† 
 ID 54±5 46±6 50±5 51±6 49±4 53±4 52±4 51±5 53±5 
3A VRBC 35±6 24±4 34±6 25±5 27±4 35±4 36±4 27±4 36±4 
 Q 50±5 25±4* 42±4† 32±6 32±4 48±5† 48±5† 33±5 50±6† 
 ID 37±5 32±4 33±5 38±5 37±4 38±4 38±4 37±5 38±4 
4A VRBC 35±5 20±5 30±5 24±4 23±3 32±4 33±5 24±5 36±5 
 Q 24±3 10±3* 16±3 17±3 15±3 23±3† 23±4† 16±4 26±4† 
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FIGURE LEGENDS 
Figure 1.  Schematic representation of an arteriolar bifurcation used for study.  Presented are the key 
measured parameters of arteriolar diameter and erythrocyte velocity, which are used to calculate blood flow 
-
two daughter arterioles arising from a parent.  Please see text for additional details. 
 
Figure 2.  -2A (Panels 
A and B, respectively) and 3A-4A (Panels C and D, respectively) arteriolar bifurcations in LZR and OZR 
u
minute collection window.  Please see text for additional details. 
 
Figure 3.  -2A arteriolar bifurcations of LZR (Panel A) and OZR (Panel B) over the 5 
minute collection period.  Data (presented as mean±SE) are presented for LZR and OZR under control 
conditions and in OZR following treatment of the cremaster muscle with phentolamine (Phent), TEMPOL 
(TEM), SQ-29548, or combinations of these agents.  * p<0.05 versus control in that strain.  † p<0.05 
versus LZR Control. 
 
Figure 4.  -2A 
arteriolar bifurcations in LZR and OZR.  Data (presented as mean±SE) are presented for LZR and OZR 
under control conditions and in OZR following treatment of the cremaster muscle with phentolamine 
(Phent), TEMPOL (TEM), SQ-
summated either as differences between successive time points (Panels A and B) or as the absolute 
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differences between successive time points (Panels C and D).  * p<0.05 versus control in that strain. † 
p<0.05 versus LZR control.   Please see text for additional details. 
 
Figure 5.  The averag -4A arteriolar bifurcations of LZR (Panel A) and OZR (Panel B) over the 5 
minute collection period.  Data (presented as mean±SE) are presented for LZR and OZR under control 
conditions and in OZR following treatment of the cremaster muscle with phentolamine (Phent), TEMPOL 
(TEM), SQ-29548, or combinations of these agents.  * p<0.05 versus control in that strain.  † p<0.05 
versus LZR Control. 
 
Figure 6.  -4A 
arteriolar bifurcations in LZR and OZR.  Data (presented as mean±SE) are presented for LZR and OZR 
under control conditions and in OZR following treatment of the cremaster muscle with phentolamine 
(Phent), TEMPOL (TEM), SQ-29548, or combinations of these agents.  
summated either as differences between successive time points (Panels A and B) or as the absolute 
differences between successive time points (Panels C and D).  * p<0.05 versus control in that strain. † 
p<0.05 versus LZR control.   Please see text for additional details. 
 
Figure 7.  
arteriolar bifurcations of LZR and OZR in response to increasing concentrations of adenosine.  Data 
(presented as mean±SE) are presented for 1A-
ata for 3A-4A 
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as absolute differences (Panel D). * p<0.05 versus LZR under that condition.  † p<0.05 versus LZR 
control. 
  
Figure 8.  tive, 
absolute) at 1A-2A (Panel A) and 3A-4A (Panel B) bifurcations in OZR.  Normal activity is defined as that 
determined in arteriolar bifurcations at those two sites in LZR.  Data (presented as mean±SE) are presented 
for OZR following treatment of the cremaster muscle with phentolamine (Phent), TEMPOL (TEM), SQ-
29548, or combinations of these agents.  * p<0.05 versus no change under that condition. 
 
Figure 9.  Presentation of the attractor describing the overall spatial- -2A 
arteriolar bifurcations in LZR (blue) and OZR (red) under control conditions (Panel A).  The attractors are 
points within that condition.  In subsequent panels, the control data is greyed (light for LZR, dark for 
OZR) and the effects of the interventions on the attractor are presented in black.  This is done for 
treatment with phentolamine (Panel B), TEMPOL and/or SQ-29548 (Panel C) and phentolamine and 
TEMPOL and/or SQ-29548 (Panel D). 
 
Figure 10.  Presentation of the attractor describing the overall spatial- -4A 
arteriolar bifurcations in LZR (blue) and OZR (red) under control conditions (Panel A).  The attractors are 
presented as 
points within that condition.  In subsequent panels, the control data is greyed (light for LZR, dark for 
OZR) and the effects of the interventions on the attractor are presented in black.  This is done for 
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treatment with phentolamine (Panel B), TEMPOL and/or SQ-29548 (Panel C) and phentolamine and 
TEMPOL and/or SQ-29548 (Panel D). 
   
Figure 11.  Presentation of the attractor describing the overall spatial-temporal behav -2A 
(Panel A) and 3A-4A (Panel B) arteriolar bifurcations in LZR and OZR under control conditions and in 
response to treatment with 10
-3
M adenosine.  As described in Figures 9 and 10, the control data is greyed 
(light for LZR, dark for OZR) a
OZR are presented in black.   
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Conceptual Framework  
The fourth chapter is entitled “Blunted Temporal Activity of Microvascular Perfusion 
Heterogeneity in Metabolic Syndrome: A New Attractor for Peripheral Vascular Disease?”. It addresses 
what we hypothesized would be the logical compensation for the increase in perfusion heterogeneity at 
bifurcations seen in the previous paper, what is known as “temporal switching”.  The perfusion 
heterogeneity at bifurcations is iterated longitudinally across the entire microvascular network and should 
lead to local regions of tissue with an accelerated buildup of metabolic dilators, thus increasing the 
temporal switching at bifurcations to meet that demand. Interestingly, the temporal activity was blunted in 
both the proximal and distal microcirculation. This suggests that the poor muscle performance in the OZR 
is the cumulative response of spatial and temporal impairments to blood flow regulation.  
Of special relevance is the identification of an attractor for PVD, which is elucidated by the 
presentation of the temporal data as an iterated map. Beyond a scientific curiosity, an attractor is 
significant because it describes how a dynamic system will evolve toward a set of conditions over time. 
The attractor generated for a system demonstrates the ability of the system to respond to perturbations, 
and can infer the flexibility of a network as the system will seek to return to its attractor upon being 
disturbed. The attractor for the LZR, representing health, has a wide range and is centered on 0.5. This 
remains constant for both the proximal and distal microcirculation. The attractor for the OZR is not only 
elevated throughout the entire microcirculation, but also significantly limited in its range, suggesting that 
the system is limited in its ability to respond to perturbations.  This compromised network flexibility 
could be a major contributor to the development of poor vascular outcomes in MetSyn subjects.  
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Altered Hemodynamics within the Skeletal Muscle Microvasculature in the Obese Zucker Rats  
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ABSTRACT  
 Increasing evidence has indicated that a key contributor to the development, maintenance, and 
progression of peripheral vascular disease (PVD) is altered microvascular structure, function, and 
reactivity. Recent research has observed an increasingly heterogeneous perfusion distribution within the 
skeletal muscle microvasculature of the obese Zucker rat, a model of PVD. This heterogeneous perfusion 
distribution is iterated throughout the microvascular network and dominated by spatially distinct 
mechanisms; driven by alpha-adrenergic dysfunction in proximal microvessels and oxidant stress based 
increases in vascular thromboxane A2 in distal microvessels. Additional research demonstrated that a 
temporal compensation for the increased heterogeneous perfusion distribution was also blunted. Taken 
together, the spatial and temporal alterations to microvascular blood flow will serve to entrench a 
physiological state of inadequate blood flow regulation throughout skeletal muscle. One of the hallmark 
characteristics of PVD is an inability to resist the development of fatigue. The heterogeneous perfusion 
distribution within the microvasculature suggests that the OZR’s inability to resist fatigue may be the 
result of a dysfunctional distribution of erythrocytes in the skeletal muscle microcirculation. To determine 
erythrocyte distribution with the capillaries and arterioles we utilized the in situ cremaster preparation 
with video microscopy to obtain a representative sample of capillary tube hematocrit and the blood 
perfused isolated hindlimb preparation with I
125
 labeled albumin and Cr
51
 labeled RBCs to obtain 
microvascular hematocrit. The analysis indicates that the cumulative sum of altered spatial and temporal 
regulation of microvascular perfusion distribution results in a lowered microvascular hematocrit and a 
large variation in capillary hematocrit in the OZR compared to the LZR. This altered erythrocyte 
distribution represents a significant contributor to the poor muscle performance observed in the OZR.  
Key Words: microcirculation; microvascular hematocrit; obese zucker rat; peripheral vascular disease; 
microvascular dysfunction; network hemodynamics  
INTRODUCTION  
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PVD is an insidious pathologic state that ultimately deprives organs of adequate blood flow and afflicts 
between 8-13 million Americans. The prevalence of PVD increases with age, afflicting 10-20% of the 
population over 60 years of age. Once diagnosed, PVD is largely irreversible barring surgery, and 
possesses a high direct and indirect cost burden to society
29, 30
 . A growing subset of the population 
presents with the overt signs of PVD, but without the classically demonstrated atherosclerotic lesions, 
suggesting that a significant contributor to the development of PVD is microvascular dysfunction. 
Human subjects diagnosed with the Metabolic Syndrome (MetSyn) possess a significantly greater 
risk of developing PVD. The significance of this cannot be understated, as ~34% of the U.S. meet the 
diagnosable criteria for MetSyn today
29, 31-34
. The rate of the overweight, obese, and extremely obese 
adults within the U.S. population is over 75%
35
. Given that obesity is generally understood to be the 
initiating condition for the development of MetSyn, there is concern that a significant portion of the 
population is at risk for developing MetSyn and the associated pathologies at a much younger age.  
The obese Zucker rat (OZR) is a rodent model for studying the development of MetSyn. Owing 
to its dysfunctional leptin receptor the OZR possesses an impaired satiety reflex, which results in chronic 
hyperphagia. Thus, by ≈17 weeks of age, the OZR experiences significant increases in mass, moderate 
hypertension, insulin resistance, loss of glycemic control, and a pro-inflammatory and pro-thrombotic 
state. The OZR is an appropriate model for examining the development of MetSyn and non-
atherosclerotic PVD. Recent studies have demonstrated that MetSyn in the OZR results in a progressive 
decay of skeletal muscle performance
36, 37
. There appears to be dual contributors to this inability of 
skeletal muscle to resist fatigue.  One of the contributors appears to be alpha-adrenergic in origin and 
restricts bulk blood flow delivery to the skeletal muscle. Another contributor is impaired oxygen uptake, 
resulting from an increase in oxidant stress, which reduces NO bioavailability as well as altering 
arachidonic acid metabolism to increase vascular production of  thromboxane A2 (TxA2). The 
simultaneous treatment of both altered systems results in improved performance outcomes in the OZR. 
Additional studies concluded that the above mentioned contributors to impaired skeletal muscle 
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performance impact the microcirculatory system in a spatially distinct manner.  The dysfunction in the 
proximal microcirculation is dominated by altered alpha-adrenergic based elements to vascular tone, 
while the dysfunction within the distal microcirculation is characterized by endothelial dysfunction, 
specifically via altered metabolism of arachidonic acid (AA)
38, 39
. However, both serve to increase 
perfusion heterogeneity at bifurcations in the microvasculature.  The interpretation of the above work 
suggests PVD promotes perfusion heterogeneity at microvascular bifurcations through spatially distinct 
mechanisms
40, 41
. Further research postulated that, due to the increased perfusion heterogeneity at 
bifurcations, temporal switching between the low flow and high flow branch would increase due to 
accelerated buildup of metabolites, or other regulatory signals, downstream within the low flow pathway. 
However, our most recent data suggested that temporal switching is actually blunted at bifurcations in the 
OZR
40, 41
. The cumulative outcome of increased perfusion heterogeneity across a microvascular network, 
along with simultaneous blunting of the temporal switching, will entrench the impairments to perfusion 
distribution and mass transport/exchange, ultimately contributing to negative outcomes for skeletal 
muscle performance. Our hypothesis, building on the above work, is that the Metabolic Syndrome 
entrenches alterations to blood flow distribution and negatively impacts erythrocyte distribution 
throughout the microvasculature. Specifically, we hypothesize that the alterations to perfusion distribution 
in the OZR, when iterated throughout the entire skeletal muscle network, will serve to lower average 
microvascular hematocrit and thus result in impaired oxygen delivery within the capillaries.  
We predict that hematocrit in the skeletal muscle microcirculation of the OZR will be 
significantly lower across the whole organ compared to the LZR. This overall reduction of hematocrit 
would occur in the OZR due to a heterogeneous perfusion distribution that would skew the hematocrit 
disproportionally low compared to flow distribution. The primary goal of the experiment is to obtain 
microvascular hematocrit (Hmv) using the Overholser model, as previously described
42
. Additionally, 
capillary tube hematocrit will be obtained in a representative sample to determine the impact of an altered 
flow distribution on oxygen exchange vessels. The inability of the skeletal muscle microcirculation to 
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adequately regulate perfusion distribution becomes progressively more relevant as increased metabolic 
demand cannot be matched with increased perfusion. At rest, the lowered average hematocrit may have 
little impact on tissue oxygenation, but with increased metabolic demand this would result in an 
inadequate supply of oxygen to tissue.  This would offer insight into the acceleration in fatigue resistance, 
and also into the increased inflammatory state often observed in the MetSyn, which may be due to the 
tissue hypoxia.  
MATERIALS AND METHODS  
Approximately 17 week old male lean and obese Zucker rats (Harlan) were used. All protocols 
have prior approval of the IACUC, the rats will be housed within the animal quarters of WVU, and 
provided with sterilized food and water ad libitum. All animals were anesthetized with sodium 
pentobarbital (390mg/mL), and a patent airway maintained with tracheal intubation. At the conclusion of 
the experiment, all animals are humanely euthanized with excess sodium pentobarbital and a bilateral 
pneumothoractomy. 
Isolated Hind Limb preparation and Tracer Washout Curves - In a set of age matched animals, the self-
perfused left hindlimb of each animal will be isolated in situ, as demonstrated previously
43
. The carotid 
artery will be cannulated for monitoring of mean arterial pressure and the jugular vein cannulated for 
infusion of heparin (500IU/kg) to prevent coagulation of the blood. An angiocatheter will be inserted into 
the femoral artery for insertion of each bolus tracer.  A Transonic probe (0.5-0.7 PS) of the appropriate 
size will be placed on the femoral artery to monitor perfusion. A small shunt will be placed in the femoral 
vein of the gastrocnemius muscle to facilitate sampling of the venous effluent. The above referenced 
interventions, phentolamine (10 mg/kg), TEMPOL (50 mg/kg) and/or SQ-29548 (10 mg/kg), will be 
intravenously introduced to the animal and tested for efficacy using phenylephrine (10 μg/kg), 
methacholine (10 μg/kg) or U-46619 (10 μg/kg), respectively. Two radionuclides will be utilized, I125 
labeled albumin and Cr
51
 bound to red blood cells. Upon bolus injection, the venous effluent will be 
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collected at a rate of 1/s for the subsequent 35 seconds. The subsequent injection, after each intervention, 
did not occur until 30 minutes of perfusion with an injection of homologous erythrocytes used to replace 
the lost hematocrit. They were examined for estimated microvascular hematocrit (Hmv). All were prepared 
using published protocols
42, 44-48
.  
Preparation of In Situ Cremaster Muscle: In a separate set of age matched animals the cremaster muscle 
was separated from surrounding tissues and isolated for viewing with intravital microscopy. During the 
entire experiment the cremaster was maintained at 35
o
C, superfused with a physiological salt solution and 
bubbled with a 5% CO2/balance N2 gas. Capillaries with red blood cell flow were identified using on 
screen video microscopy and hematocrit was quantified at 10 vessels per animal. All procedures were 
performed under control conditions in LZR and OZR, and the following interventions were added to the 
superfusate; the anti-oxidant TEMPOL (10
-3
 M), the TxA2 receptor antagonist SQ-29548 (10
-4
 M), and/or 
the alpha1/alpha2 adrenergic receptor antagonist phentolamine (10
-5
 M). 
Data Analysis  
For the tracer washout analysis, the following equations were used from Overholser et al. to 
obtain the hematocrit reduction ratio (hr)
42
.  The hematocrit reduction ratio is the ratio of the 
microvascular hematocrit to the large vessel hematocrit and is calculated from the equation below.  
C l.organ (t-T) = hr C R.organ [(t-T)hr)  
where C l.organ is the albumin tracer curve, C R.organ is the red cell tracer curve, t is time, and T is the mean 
transit time. This will allow deduction of the microvascular hematocrit reduction ratio. The hr can be 
entered into the following equation to calculate microvascular hematocrit.  
Hr = Hmv/ Hlv where Hmv is microvascular hematocrit and Hlv is large vessel hematocrit.  
Capillary tube hematocrit was calculated from video stills utilizing the in situ cremaster 
preparation, as described previously
40, 41
. It was calculated by counting the number of red blood cells in a 
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known length and diameter of vasculature. All data is presented as mean ± SEM with statistically 
significant differences represented by p<0.05. Student’s t-test or analysis of variance (ANOVA) with 
Student-Newman-Keuls post-hoc test was used as needed.   
RESULTS  
Table 1 contains baseline characteristics of the lean and obese Zucker rats used in the indicator 
dilution washout study. Compared to the LZR controls, at ≈17 weeks of age the OZR model exhibits 
significantly increased mass, moderate increases in mean arterial pressure, insulin resistance, 
dyslipidemia, and elevated plasma glucose levels.  
Table 1: Indicator Dilution 
Washout 
LZR OZR 
Mass (grams) 361 ± 9  688 ± 12 
MAP 102 ± 4  138 ± 10  
 
Figure 1 is a representative figure containing the washout data for I
-125
 labeled albumin and Cr
-51
 
labeled RBCs in both the OZR and LZR. The solid red and black lines are the LZR albumin and RBC 
tracers respectively. The dotted red and black lines are the OZR albumin and RBC tracers respectively. It 
is evident that the OZR RBC’s initially washout more rapidly than the LZR RBC’s, but then slow at the 
end of the time period. The OZR albumin curve has a smaller height but a much higher tail than the LZR 
control.  
Figure 2 presents the microvascular hematocrit as calculated from the ratio between the animal’s 
respective albumin and RBC tracer washout curves. It shows that the LZR (n=5) microvascular 
hematocrit remains similar to the average large vessel hematocrit of 45. The OZR (n=8) microvascular 
hematocrit is significantly lower than the LZR control. The microvascular hematocrits of the OZR with 
interventions of phentolamine or TEMPOL/SQ-29548 appear lower but have very large SEM. The 
microvascular hematocrit of the OZR with all treatments is significantly elevated above the OZR 
baseline. * p < 0.05 vs. LZR. † p < 0.05 vs. OZR.  
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Figure 3 is the capillary tube hematocrit as calculated from video microscopy. There were no 
significant differences between LZR, OZR, and OZR with treatments. * p < 0.05 vs. LZR. † < 0.05 OZR.  
Discussion  
The culmination of recent work has shown that alterations within the skeletal muscle 
microcirculation of the obese Zucker rat result in increasingly heterogeneous perfusion distributions at 
bifurcations. Specifically, there is an increased perfusion distribution in the OZR with spatially distinct 
mechanisms that is unable to be compensated for temporally. This results in a ‘low flow” and “high flow” 
pathway at bifurcations that is iterated across the microcirculatory network. This inability to adequately 
distribute blood flow will have a negative impact on erythrocyte distribution, with the bulk of RBC’s 
flowing down the “high flow” pathway and being unable to redistribute to the “low flow” pathway with 
increased metabolic demand.  The importance of distribution of erythrocytes lies within three basic 
concepts of erythrocyte distribution within blood flow. The first is the Fahraeus effect, which is a lowered 
tube hematocrit caused by the differential velocities of RBC’s and plasma.  The second is the Fahraeus 
network effect, which describes how an unequal hematocrit distribution at a proximal bifurcation will 
lead to increasingly heterogeneous hematocrit distribution further downstream and result in an averaged 
lower hematocrit. The final concept is phase separation, which describes how low flow branches or side 
branches may “skim” the RBC poor areas of the blood, again leading to lowered hematocrit in those side 
branches relative to the high flow
49
. The integration of all three concepts, when combined with the 
evidence of increased perfusion distribution heterogeneity in the OZR, suggests that this will lead to an 
overall reduction in microvascular hematocrit as well as capillary tube hematocrit.  
 The results of the indicator dilution tracer washout experiment show that there is a 
reduction in OZR microvascular hematocrit compared to the LZR. The treatments of phentolamine and 
TEMPOL/SQ-29548 by themselves demonstrate not necessarily a significant increase in hematocrit 
distribution, but certainly a large increase in the variance that removes any significance compared to the 
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LZR. However, treatment with all of the interventions in the OZR does significantly improve 
microvascular hematocrit compared to the LZR.  
The capillary tube hematocrit does not show a significant difference between the LZR and OZR, 
or with any of the OZR interventional groups. However, what is readily apparent is the large variance 
observed in the OZR compared to any other group, LZR, OZR, or OZR + intervention. This indicates that 
there is indeed significant high and low hematocrit levels within the gas exchange vessels of the OZR, 
heterogeneity not observed in the LZR. The inability of this technique to obtain the lower hematocrit 
levels hypothesized may in fact be a limitation of the preparation itself, whereby vessels are chosen that 
have steady visible RBC flow, resulting in an inadequate sample size representative of the population.  
The conclusion of the above research is that there is a lowered average hematocrit within the 
OZR microcirculation. It is a result of the entrenched heterogeneous perfusion distribution observed at 
bifurcations within the OZR, and not only serves as a significant contributor to the impaired performance 
of skeletal muscle, but most likely would result in development of ischemic or pro-inflammatory regions 
of tissue where the low distribution of erythrocytes exists. While the hematocrit within the capillaries 
does not initially show the differences hypothesized, the increased variance would indicate areas of 
significantly elevated and lowered hematocrit compared to the LZR, suggesting that perhaps our sample 
population is not representative of the whole tissue bed.  
Taken together with our previous research, the outcome of this lowered microvascular hematocrit 
and increase in variance within the capillaries allows for a better understanding of the progressive decay 
of skeletal muscle function within MetSyn. Increasing evidence points toward altered regulation of 
microvascular control, largely influenced by alpha adrenergic dysfunction and oxidant stress based 
increases in thromboxane A2, as a significant contributor to this dysfunction. This results in an inability of 
the peripheral vascular system to adequately deliver oxygen to the appropriate local tissue region. 
Speculatively, this has tremendous impact on the human population of MetSyn, including those already 
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diagnosed with PVD. Those diagnosed with PVD will be best served with not just exercise, but also 
treatment of the underlying microvascular problems. Further, as the epidemic of MetSyn and PVD 
increases within developed countries, the subpopulation of subject presenting without atherosclerotic 
plagues and lesions will require alternative diagnostic exams, as well as treatment of the microvascular 
disease.  
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Figure Legends  
Figure 1: Representative figure of tracer washout curves. Presented are the I
-125
 labeled albumin (red 
lines) and the Cr
-51
 red blood cells (black lines). The LZR lines are solid and the OZR lines are dashed. 
The microvascular hematocrit is calculated as the ratio between the two lines using Overholser et al.  
Figure 2: Bar chart showing the microvascular hematocrit as calculated from tracer washout curves of 
LZR, OZR, and OZR + interventions. Data is resented as mean ± SEM. * p < 0.05 vs. LZR. † p < 0.05 vs. 
OZR.  
Figure 3: Bar chart showing capillary tube hematocrit as calculated from video stills for the LZR, OZR, 
and OZR ± interventions. Data is presented as mean ± SEM. * p < 0.05 vs. LZR. † p < 0.05 vs. OZR. 
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Conceptual Framework  
The fifth and final chapter focused on the hemodynamics within a microvasculature network, and whether 
the spatial and temporal alterations to vascular tone in the Obese Zucker rat have an impact on 
microvascular hematocrit. It sought to integrate the previous work and determine whether there is an 
altered erythrocyte distribution throughout the microvascular and capillary networks. We found a 
significantly lowered microvascular hematocrit in the OZR and a large variation in capillary hematocrit 
compared to the healthy LZR.  These results suggest that MetSyn induced alterations to vascular tone 
ultimately lead to a lowered erythrocyte distribution, and provide insight into the perfusion:demand 
mismatch and lowered performance outcomes observed in the OZR. 
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Discussion 
 The purpose of this dissertation is to investigate network control of blood flow to determine the 
extent to which Metabolic Syndrome-induced microvascular dysfunction alters hemodynamics within 
skeletal muscle. We first sought to determine if MetSyn impacts the ability of isolated microvessels to 
integrate multiple inputs and subsequently change overall diameter compared to a healthy animal. Myogenic 
activity is a significant contributor to vascular tone and significantly elevated vasoconstriction in response to 
elevated intraluminal pressure is observed in the OZR in compared to the LZR. The first chapter emphasized 
that MetSyn alters myogenic activity largely through increases in oxidant stress, which has the combined 
effect of reducing nitric oxide bioavailability and altering AA metabolism to increase production of vascular 
TxA2. The data demonstrated that the oxidant stress derived changes to myogenic activation has a significant 
effect in blunting the responses of dilator stimuli. The blunted dilator response occurs in hypoxia, a dilation 
derived from endothelial dependent NO production, and dilation to a mimic of metabolic stimulation. 
Interestingly, the skeletal muscle microvasculature in the OZR shows an equal impact of an antioxidant or 
TxA2 receptor antagonist at alleviating the blunted dilator response to hypoxia. In contrast, while there is a 
comparable blunted dilator response to acetylcholine, TEMPOL proved to be a far more effective 
intervention than SQ-29548. While treatment with adenosine (mimic for metabolic demand) showed a less 
severe blunting of dilation when integrated with pressure induced constriction, it still was lower, suggesting 
that the increased myogenic activation could play a role in altering blood flow despite increases in metabolic 
demand. Taken together, these data implicate oxidant stress and vascular production of TxA2 as significant 
contributors to the increased myogenic activation seen in the OZR and serves to alter basal vascular tone and 
hemodynamics within the confines of MetSyn. This is part of the foundational work that illustrates ex vivo 
that MetSyn does not just alter point sources for reactivity in blood vessels, but fundamentally alters the 
ability of the network to appropriately integrate dilator and constrictor signals.  
 Building on this work, the second chapter demonstrates a functional performance inhibition within 
the OZR skeletal muscle. The OZR has significantly blunted blood flow, higher resistance, decreased oxygen 
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uptake, and decreased oxygen exchange compared to the LZR. These combined factors serve to significantly 
impair the OZR’s ability to resist fatigue development at all levels of metabolic stimulus and are present even 
at rest.  It was determined that the restricted bulk blood flow and increased resistance present in the OZR are 
alleviated with treatment of phentolamine, an alpha-adrenergic antagonist. The blunted oxygen extraction and 
oxygen uptake were alleviated with TEMPOL or SQ-29548. There were two key observations about these 
data. The first is that no treatment by itself improved tension development in the OZR compared to the LZR. 
This suggests a dual component of dysfunction that will equally serve to limit OZR skeletal muscle 
performance, and both components must be addressed for an effective outcome in terms of functional 
performance. The second observation is the decreased oxygen extraction and oxygen uptake in the OZR 
skeletal muscle. Classically it would be expected that by repairing the blunted bulk blood flow delivery 
within the muscle this would allow for adequate oxygen delivery throughout the skeletal muscle. 
Additionally, it would be expected that there would be an increased oxygen extraction as a compensatory 
mechanism for the decreased blood flow and previously identified rarefaction present in the OZR. This 
implies two spatially distinct mechanisms within the vasculature, an alpha-adrenergic constraint prohibiting 
bulk blood flow and dysfunction in the gas exchange regions of the vasculature dominated by increasing 
oxidant stress. This would provide the impetus for Chapter 3, where we begin to examine the perfusion 
distributions throughout the microvascular network.  
 Chapter 3 begins by changing the preparation to the in situ cremaster preparation, a preparation that 
allows us to examine an intact skeletal muscle microvascular network. The preparation allowed us to 
combine video microscopy with an optical Doppler velocimeter, thus enabling calculation of the blood 
flow distribution at bifurcations of varying sizes. A heterogeneous blood flow distribution was observed 
in the OZR microvascular network, meaning that a “high flow” and “low flow” pathway at each 
bifurcation was iterated throughout the entire network. Interestingly, the data revealed spatially distinct 
mechanisms, with alpha-adrenergic dysfunction dominating the proximal microcirculation and oxidant 
stress based increases in vascular TxA2 playing a greater role in the distal microcirculation. The 
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respective interventions were able to restore perfusion distributions back to levels of control at each 
spatially distinct location. This was further supported by an I
125
 labeled albumin washout curve, which 
utilized the isolated gastrocnemius preparation. It is representative of whole network flow distribution, 
and the OZR washout kinetics clearly revealed altered intravascular flow patterns compared to the LZR, 
which was further confirmed with a computation model demonstrating the expected heterogeneous flow 
distribution throughout the OZR microvasculature and predicting a large number of very low flow 
ischemic pathways with only a few high throughput pathways.  
 The results of the previous study indicating a heterogeneous perfusion distribution with spatially 
distinct mechanisms in the skeletal muscle microvasculature of the OZR lead us to ask how the body 
would normally compensate for such dysfunction. When one examines the functional impact of a 
“high/low” flow pathway in microvascular skeletal muscle, one would expect to a see buildup of waste 
products and ischemic metabolites downstream of the low flow pathway, as predicted computationally. 
This would occur naturally even in health, as even the LZR does not have a perfect 50/50 flow 
distribution pattern. Due to the increase in perfusion distribution heterogeneity in the OZR, one would 
expect a more severe ischemia within the low flow pathway, thus providing an elevated rate of buildup of 
metabolically active waste products that would have a dilatory effect upon the low flow pathway. Thus 
the “high/low” flow pathway would switch, and we hypothesized that in the OZR there would be a 
significantly increased temporal switching compared to the LZR. However, the temporal switching was 
blunted in the OZR in both the proximal and distal microcirculation. The importance of blunted temporal 
switching cannot be understated. Not only is there no temporal compensation for the perfusion 
heterogeneity in skeletal muscle, but it is actually blunted. This implies that it will exacerbate the 
perfusion heterogeneity, locking in a high and low flow pathway, resulting in chronic ischemic regions of 
tissue at rest and permanently inhibiting blood flow regulation. Additionally, the temporal aspect of the 
data allowed for the generation of an attractor for the OZR and LZR. An attractor is a set of conditions 
that a dynamic system will adhere to over time. In the LZR, attractor centers on 0.5, but has a broad and 
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diverse range. This illustrates the constant flux that persists at homeostasis. Systems must be perturbed at 
multiple levels to alter attractors, and this is clearly illustrated in the OZR. The attractor for the OZR was 
elevated and reduced in range compared to the LZR. This suggests a limited ability of the OZR 
microvascular network to respond adequately to perturbations. The cumulative outcome of spatial and 
temporal alterations to skeletal muscle microvasculature is to produce an inability of the system to 
adequately regulate blood flow. This evidence, combined with previously referenced papers, suggest that 
this altered perfusion distribution will have an effect on erythrocyte distribution throughout the system, 
and brought us to Chapter 5.  
 Chapter 5 hypothesizes that the altered perfusion distribution iterated across the microvascular 
network, combined with an inability to temporally compensate, will result in a lowered microvascular 
hematocrit as well as a lowered capillary hematocrit. It utilizes indicator dilution washout curves to obtain 
a “snapshot” of microvascular hematocrit as well as video microscopy to obtain a representative sample 
of capillary hematocrit. The results showed that the OZR showed a significant decrease in microvascular 
hematocrit. Treatment with either an alpha-adrenergic blocker, antioxidant, or TxA2 receptor antagonist 
improved the variance of the OZR, but only with all three was there a significant improvement of 
hematocrit with equal variance to even above levels of control. The capillary hematocrit proved slightly 
troublesome, as it indicated no significant differences between any groups, LZR or OZR. However, the 
variance of the OZR indicates very high and low flow hematocrits, which when averaged are not 
significantly different. This would indicate that our hypothesis is correct, and perhaps our sample is not 
representative of the true population.  
 To summarize the above dissertation, the evidence presented suggests that MetSyn contributes to 
dysfunctional vascular control through increased myogenic activation, which is brought on by oxidant 
stress based increases in vascular production of TxA2. This, combined with adrenergic dysfunction, 
results in significant impairments to the ability of skeletal muscle to resist fatigue. Subsequent research 
demonstrates that a primary consequence of alterations to vascular tone is increased perfusion 
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heterogeneity at bifurcations, and that this perfusion heterogeneity exists at both the proximal and distal 
microcirculation. The mechanisms of this dysfunction are spatially distinct, with adrenergic dysfunction 
dominating at the proximal microcirculation and increases in oxidant stress and alterations to arachidonic 
acid metabolism dominating in the distal microcirculation. Further, MetSyn blunts the temporal switching 
that potentially could alleviate the increased perfusion distribution. The cumulative outcome of spatial 
and temporal alterations to vascular tone is a lower microvascular hematocrit, which could serve as a 
influential contributor to the inability of the OZR skeletal muscle to resist fatigue development.   
MetSyn entrenches a pathological condition whereby the skeletal muscle circulation is limited not 
only in matching perfusion with demand, but also restricts the logical compensation through temporal 
switching. This inevitably leads to the condition whereby a subject is unable to reverse the decreased 
performance outcome, and we argue that it is at this point where PVD, CVD, and the other pathologies 
intrinsically indicated by MetSyn begin to present. Further studies are needed to examine the impact of 
common interventions on microvascular function. These include but are not limited to exercise, weight 
loss, surgery, lifestyle alterations, and pharmaceutical drugs. Each needs to be evaluated for its impact on 
the underlying microvascular dysfunction. Taken together, this dissertation hopefully sheds light on the 
mechanisms within the microcirculation that MetSyn and PVD impact, and allows for novel and relevant 
treatment for the human population.  
